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F O R E W O R D
The National Institute on Drug Abuse is pleased to publish as a
NIDA Research Monograph this updated state-of-the-art review of the
procedures utilized for testing drugs for their physical dependence
potential and abuse liability. NIDA has a long history of working
with the Committee on Problems of Drug Dependence (CPDD) to attain
our mutual objective in broadening the knowledge base in this area.
It has been 11 years since the previous review by the Committee on
Problems of Drug Dependence, and 9 years since the publication by
WHO of Evaluation of Dependence Liability and Dependence Potential
of Drugs. During this period, the field has advanced
significantly, particularly as new classes of compounds have been
included within the range of those known to result in human
dependence. In addition, this review represents a major conceptual
clarification in distinguishing between testing of physical
dependence potential and abuse liability. The rationale this
distinction is well described in Chapter II.
The ultimate objective is to develop and refine methods that will
allow for the prediction of the human dependence or addiction
potential of a compound. Too often, the problems of human drug
dependence have been attributed to the physical dependence
potential of a drug. The use of the word dependence in two very
different senses has contributed its share of confusion.
effort to maintain clarity, the authors of the manuscript have
consistently referred to measurement of physical dependence
liability so as not to confuse that concept with the clinical
syndrome of drug dependence. This is particularly important since
increasingly the evidence supports the view that the problems of
human drug dependence are more closely related to the abuse
liability of a drug than to its physical dependence potential.
In the Prefatory note that follows, the importance of these 
procedures in making national and international regulatory
decisions has been emphasized.  Not to be over looked is the fact 
that the laboratory work necessary for the development of these
testing procedures has also contributed to the identification and
characterization of novel compounds and the elucidation of   
fundamental biobehaviorial mechanisms of drug action.  The recent Text
v
growth of knowledge of the neural mechanisms involved in drug abuse
has been explosive. Along with this has come a rapidly developing
ability to synthesize new drugs with markedly greater, specificity,
increasing the requirement for refined methods of assessing abuse
liability. Future development in the area may be expected to focus
on the role of drug interactions, the role of environmental and
social factors and, perhaps most importantly, the role of
individual genetic differences in the liability to abuse of drugs.
The CPDD can be expected to continue to play an important
leadership role in providing a forum for the integration of the
many scientific, social and legal issues involved in coping with
the problems of human drug dependence.
Jean Paul Smith, Ph.D.
Acting Associate Director for Science
National Institute on Drug Abuse
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P R E F A C E
For many years, the Department of Health and Human Services (DHHS)
has had a special interest in developing methodologies for
assessing abuse liability of drugs, irrespective of their known or
potential therapeutic usefulness. More recently, additional
interest in this area has grown as a result of the authorities
granted to the Secretary of DHHS in the Comprehensive Drug Abuse
Prevention and Control Act (P.L. 91-513) and the Psychotropic
Substances Act of 1978 (P.L. 95-633). These statutes provide the
Secretary with the authority to determine the abuse liability of
drugs and make scheduling recommendations with regard to the need
for domestic and international controls in an effort to prevent or
reduce the abuse. Thus, efforts to expand our knowledge to make
informed scheduling decisions has received support as part of the
overall drug abuse prevention effort.
Within the DHHS, the National Institute on Drug Abuse (NIDA) is
authorized by the Secretary to conduct the necessary studies for
the proper evaluation of the abuse liability of drugs and other
substances and to evaluate the nature and extent of associated
health risks. Pursuant to these responsibilities, NIDA supports
various intramural and extramural research efforts both to
determine the abuse liability of new drugs and to develop methods
for making more specific determinations about new classes of
compounds. These efforts have been significantly enhanced by close
collaboration with the Committee on Problems of Drug Dependence
and the National Institute of Arthritis, Diabetes, and Digestive
and Kidney Diseases.
It is hoped that this scholarly and comprehensive review of the
existing methodologies will be of benefit to both the public and
private sector domestically, as well as internationally. In
addition to being a unique reference, it can serve as a guide for
future drug abuse liability screening initiatives and a foundation
on which newer and more specific methodologies can be developed.
The monograph may be of assistance to other countries interested in
incorporating some abuse liability testing as a requisite for drug
registration and assist the World Health Organization (WHO) in its
efforts to identify the range of existing parameters available for
assessing the abuse liability of drugs required of them by
international treaties.
James R. Cooper, M.D.
Associate Director for Medical
and International Affairs
National Institute on Drug Abuse
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I. Introduction
The Committee on Problems of Drug Dependence. (CPDD) has been in
existence since 1929 and is the longest standing group in the
United States concerned with drug dependence and abuse. Its history
from 1929 until the early 1970s was summarized by the late Nathan
B. Eddy (1973). From 1929 until 1976, the CPDD was associated with
the National Academy of Sciences - National Research Council. Since
1976, it has existed as an independent body presently affiliated
with ten national societies representing various disciplines
concerned with problems of drug dependence and abuse.
A major thrust of the CPDD has been to facilitate the development of
safer and more effective therapeutic agents while reducing the risks
of dependence and/or abuse. Most of the drugs evaluated by the CPDD
are drugs with well-defined current or potential clinical use.
Knowledge of the dependence potential and/or abuse liability of a
drug proposed for marketing is of obvious importance with respect to
its scheduling both within the United States and internationally.
By appropriate screening prior to marketing, it should be possible
to avoid cases of iatrogenic dependence and/or self-generated abuse
that would have occurred and formed the basis for later scheduling
of the drug after post-marketing experience.
In some cases, discovery of dependence potential and/or abuse
liability might be grounds for a decision not to manufacture a drug.
Dependence and abuse are among the costs, along with other adverse
side effects, that must be weighed against a drug's potential
therapeutic efficacy. Ordinarily, a drug will not be tested for
dependence potential and/or abuse liability until other aspects of
efficacy and safety have been demonstrated in a scientifically sound
and systematic manner employing appropriate standards of measurement
and controls to avoid bias. At this point, a serious level of
dependence potential and/or abuse liability can counterbalance the
prospect for a modest therapeutic advance. Thus screening for
dependence potential and/or abuse liability may prevent the
marketing of an undesirable new product.
The drug assessment activities of the CPDD. then, have come to serve
three general purposes. In the first instance, they have provided
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information to the pharmaceutical industry and the public to assist
in evaluating the dependence potential and/or abuse liability of new
drugs. Secondly, they have advanced the basic scientific purpose of
identifying and characterizing truly novel compounds, and
stimulating their synthesis. In this regard, the CPDD has
collaborated closely with the National Institutes of Health. And
thirdly, the CPDD has implemented and supported the assessment of
dependence potential and abuse liability in both animal laboratory
and human clinical settings. In 1947, the CPDD initiated and
supported an animal testing facility at the University of Michigan.
In the early 1970s. a similar unit was formed at the Medical College
of Virginia. The focus of activity at both facilities has been upon
testing opioids, although in recent years other types of drugs have
been studied more often. In 1980, the CPDD awarded, on a
competitive basis, starter grants to laboratories for the
development of clinical procedures for evaluating drug dependence
potential and abuse liability in man. And, in 1982, initiatives
were undertaken to broaden the scope of CPDD's testing activities to
encompass CNS stimulants and depressants.
The CPDD has twice before, in 1966 and 1973, published position
papers on the testing of drugs for "dependence liability" in animals
and humans (CPDD 1966; 1973). The present paper represents a
continuation of these state-of-the-art reviews. A revision is
timely now because there have been several new and important
developments over the past decade. First, a growing number of
opioids of the mixed agonist-antagonist type are in various stages
of development as anesthetics and analgesics. Reports indicate that
the analgesic effects of these new compounds are not accompanied by
the subjective mood changes associated with abuse liability, but the
evidence in this regard is inconclusive. Second, considerable
public concern has been generated by reports of physical dependence
involving commonly used sedatives and anxiolytics even at
therapeutic doses. Third, a number of cannabinoids and their
homologs are under evaluation as potential therapeutic agents.
Fourth, expanded development of anorectic agents and antidepressants
has emphasized the importance of abuse liability assessment of the
centrally active stimulants. And fifth, the verification of the
street-use of dissociative anesthetics (e.g., phencyclidine and its
congeners) has added another group of substances with high abuse
liability. These substances produce a constellation of effects
including sedation, stimulation, and hallucinosis.
References
Committee on Problems of Drug Dependence, Addendum I: Testing for
dependence liability in animals and man. Bulletin, Problems of
Drug Dependence. Washington, D.C.: National Academy of
Sciences -- National Research Council, 1966. pp. 1-10.
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Problem: 1928-1971. Washington, D.C.: National Academy of
Sciences, 1973.
2
II. Concepts and Definitions
Traditional concepts and definitions of drug dependence and drug
abuse are in need of re-evaluation and revision. Advances in
knowledge about drug actions, and particularly in research
technology, have made possible an operational approach to
pharmacological assessment of the risks of dependence on, and abuse
of, psychoactive drugs of various categories, yet non-operational
terminology still persists. The distinction between "physical" and
"psychic" or "psychological" dependence, for example, has long since
outlived its theoretical basis. Even the dichotomy between
"physical" and "behavioral" factors has not provided a particularly
useful framework for analyzing the essential dimensions of
drug-related problems. And while the terms "dependence" and "abuse"
are generally considered preferable to the word "addiction" as a
basis for the development of an operational language in this field,
persistent terminological ambiguities must be acknowledged.
One such problem derives from the continued use of the word
"dependence" in at least two quite different ways. In the first
instance, "physical dependence" is used with reference to the
biochemical, physiological, and behavioral consequences of repeated
exposure to a drug resulting in tolerance, and an abstinence
syndrome when the drug is withdrawn. A second, less technical, use
of the term "dependence" (or, more commonly, the phrase "drug
dependence") refers to a complex of behavioral phenomena often
described by such terms as "loss of voluntary control over drug
taking," "compulsive drug use," 'and "reduced range of behavioral
options." In this second case, the obvious overlap with the term
"abuse" (or more commonly, the phrase "drug abuse") further
complicates both technical and non-technical language usage.
In response to these problems, a recently published World Health
Organization Memorandum on Nomenclature and Classification (Bull.
WHO 1981) recommended substitution of the word "neuroadaptation" for
physical dependence, and deletion of the term "abuse" from the drug
lexicon on the grounds that it is essentially a value-judgmental
term rather than an operational one. In addition, the WHO
Memorandum further proposes use of the term "drug dependence
syndrome" to encompass virtually all the phenomena currently
3
described by the two terms "dependence" (i.e., "neuroadaptation"
plus "drug dependence") and "abuse." The main advantages of the
terminology suggested in the WHO Memorandum lay in its clear
differentiation between the primary process (drug self-
administration) and secondary consequences (neuroadaptation), and
its emphasis on experimentally or clinically operational terms
devoid of value judgments.
From a scientific and technical perspective, the phrase "drug
dependence syndrome," as defined in the WHO Memorandum, is
conceptually indistinguishable from the older term "addiction" when
the latter is used to designate the complex of persistent behavioral
and physiological changes associated with chronic self-
administration of drugs. However, the WHO Memorandum was not
designed as an operational guide to the testing of those properties
of drugs that might be related to the risk of dependence and/or
abuse. In contrast, the present document is intended specifically
for that purpose. Since the testing procedures to be described are
largely based on concepts and terminology that had evolved before
the publication of the WHO document, and that still enjoy wide
acceptance, we will not at this time attempt to revise the
operational terms that are in general use.
The final resolution of these differences in terminology has not
been achieved. Many workers in the field as well as the lay public
are still unaware of the new terminology proposed by WHO.
Accordingly, for purposes of this discussion we shall continue to
use the terms "physical dependence" and "abuse" as conventionally
defined. These familiar terms are encoded in the laws and
regulations which control the scheduling of drugs and the
determination of manufacturing quotas. Should the proposed WHO
terminology come into general use, future revisions of the present
document will provide for the necessary changes.
"Physical dependence," as used in the following sections of this
review. refers to physiological and behavioral alterations that
become- increasingly manifest when drug administration is stopped
after repeated exposure to a pharmacologic agent. Changes
associated with (but not limited to) the development of tolerance
and the physiological effects of drug withdrawal are expressed as an
abstinence syndrome (Cochin 1970; Kalant et al. 1971; Eddy 1973;
Clouet and Iwatsubo 1975). "Abuse" is used with reference to events
that precede or accompany strong drug-seeking, drug discrimination,
and drug-taking behaviors in association with self-administration of
a pharmacological agent, often in a social context (Brady and
Griffiths 1977; Griffiths et al. 1980; Brady 1981; Woods et al.
1982). The abuse concept clearly encompasses toxicity' as well,
1 . e., adverse physiological and/or behavioral consequences (Schuster
and Fischman 1975).
The relevance and importance of this distinction between "physical
dependence" and "abuse," for drug evaluation purposes, resides in
the fact that while both these processes are of obvious public
health concern, their defining properties are not coextensive and
they do not invariably occur together. The assessment of "physical
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dependence potential" in terms of tolerance and withdrawal, while
obviously an important aspect of drug evaluation, does not by itself
predict the drug-seeking and drug self-administration which are
essential features of abuse, and which one attempts to predict by
assessment of "abuse liability." Drug-seeking and drug-taking
behaviors can be maintained in strength by doses of cocaine or
morphine, for example, which produce no significant degree of
tolerance or withdrawal (Schuster and Woods 1967; Johanson et al.
1976; Jones and Prada 1977). Conversely, some compounds such as
propranolol have clear dependence potential (i.e., development of
tolerance after repeated dosing, and an abstinence syndrome after
drug withdrawal) at doses which have little or no attendant abuse
liability, i.e., do not give rise to drug-seeking or drug-taking
(Myers and Austin 1929; Crandall et al. 1931; Ambrus et al. 1951;
Rector et al. 1955; Jaffe 1980).
In summary, from the perspective of drug testing, to which this
review is addressed, pharmacologic assessment can most conveniently
be related to the changes or events antecedent to repeated drug-
taking, on the one hand, or consequent to it, on the other. It is
primarily the reactive biochemical, physiological, and behavioral
consequences, of drug administration, both acute and chronic (in
terms of tolerance and withdrawal), which define a pharmacologic
agent's physical dependence potential. The proactive drug-seeking,
and drug discrimination which occur as antecedents to habitual drug
use, on the other hand, together with the adverse effects of such
use (i.e., a combination of the drug's reinforcing properties and
its toxicity), define a drug's abuse liability.
Physical dependence and abuse, as defined, do of course frequently
occur together. Changes in drug-seeking and drug-taking often occur
as sequelae to both the acute effects of a drug and to tolerance and
withdrawal after chronic drug exposure (Musto 1973). Conversely,
the biochemical, physiological, and/or behavioral changes which
define physical dependence can be sequelae of abuse-related drug
self-administration (Jaffe 1980). But the relative contributions of
these distinguishable processes to drug-related problems can vary
widely with different pharmacologic agents as a function of such
factors as dose level, environmental interactions, and previous drug
history (Mendelson and Mello 1982). Moreover, the methods used to
assess physical dependence potential and abuse liability, both in
humans and in laboratory animals, are quite distinct. Therefore
these terms are retained throughout the following description of the
methods by which they are assessed.
Beyond the problem of terminology, of course, fundamental issues
concerning the validity of biochemical, physiological, and
behavioral methods for assessing dependence potential and abuse
liability continue to be debated (Martin 1966; Jasinski 1977). The
ultimate test animal, and the most precious, is of course, the
human. Situations have arisen in which drugs were passed through
the animal screens only to show abuse liability in humans. And
street users have been able to discover abusable drugs or their
combinations which were never tested in animals and were never
suspected of abuse liability even after extensive clinical use.
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Other drugs, such as the benzodiazepines, may be abused more often
by humans than might have been expected on the basis of animal
screening studies.
Such considerations notwithstanding, the focus developed in this
document on formal changes and their temporal ordering in
relationship to the drug intake event does provide an operational
basis for characterizing the full range of a drug's functional
properties and for evaluating all available measures of its
structure (i.e., physico-chemical) and activity (i.e.,
physiological-behavioral) in comparison to known standards. In the
final analysis, such "pharmacological equivalence" remains our most
reliable approach to the assessment of physical dependence potential
and abuse liability.
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III. General Methodological Considerations
The profile of a specific drug's physical dependence potential and
abuse liability is defined by a number of its pharmacologic effects
observed over a wide range of doses. Assessment of these effects
involves a range of procedures that quantify the responses after
acute administration (e.g., analgesia, behavioral performances, EEG
patterns) and after chronic administration (e.g., tolerance
spontaneous and/or precipitated withdrawal). Furthermore
behavioral paradigms for assessing drug-seeking and drug-taking
(e-g., drug self-administration procedures), for determining the
stimulus properties of drugs (e.g., drug discrimination procedures),
and for assessing behavioral toxicity (e.g., sensorimotor
psychophysical procedures) have been employed with increasing
frequency in systematic drug evaluations. The standardization of
such assessment techniques thus makes it possible to provide a
comparative analysis of relative dependence potential and/or abuse
liability in both animals and humans across a number of drug doses
and drug classes with increasing confidence.
Evaluating the acute effects of a drug is a necessary antecedent to
the subsequent study of tolerance, and ultimately, physical
dependence potential. In this regard, numerous pharmacological
assays are employed that serve not only as the comparison response
for tolerance studies, but as the basis for screening unknown
compounds for physical dependence potential and/or abuse liability,
as well. These assessments are made by comparing the effects of the
unknown drug to a standard compound (e.g., morphine, pentobarbital,
amphetamine, etc.). Once the acute effects of a drug are well
characterized, the development of tolerance to these effects can be
adequately quantified. While the fact that tolerance develops after
chronic administration of a drug does not necessarily mean that the
drug possesses significant dependence potential and/or abuse
liability, it may serve as a partial explanation for gradual changes
in intake over time as observed in drug self-administration studies.
Under any circumstances, judicious interpretation of the results of
tolerance studies serves an important function in the ultimate
assessment of a drug's dependence and/or abuse profile.
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Procedures for assessing the relative dependence potential of a drug
have historically relied upon either substitution or  primary
dependence methods. The discovery of specific antagonists has added
an important dimension to the study of physical dependence potential
by providing a means of precipitating withdrawal signs. Another
critical consideration in comparing the physical dependence
potential of two or more drugs is the degree to which the effects of
the drugs during chronic dosing are equivalent. Procedures for
assessing the abuse liability of a drug have focused predominantly
upon drug self-administration and drug discrimination paradigms. In
the former case, methods have been developed for determining not
only whether a drug will be self-injected (e.g., substitution
procedures), but for determining the relative reinforcing efficacy
of a given drug as compared to standard drugs of abuse (e.g.,
progressive ratio and choice procedures). Drug discrimination in
animals, which approximates measures of subjective reports in
humans, has been utilized to measure and compare the discriminative
stimulus properties of drugs both within and between .pharmacologic
classes.
Most importantly, laboratory animal methodologies have provided an
applied technology for quantifying the acute and chronic effects of
a drug in relationship to known standards of dependence potential
and abuse liability. By and large, these methods complement, and in
some cases extend, those employed in human research. Testing in
human beings is complicated by the fact that there is great inter-
individual variability in reactivity to and tolerance for various
substances and that this initial tolerance level can be drastically
modified by prior drug experience. Therefore, it is necessary not
only to require of volunteers a drug-free period of several weeks to
be certain that any drugs taken either therapeutically or
recreationally have been eliminated, but control and experimental
groups should be matched with respect to drug-taking histories,
baseline reactivity, and tolerance. Simple random assignment to
drug or control group is usually not sufficient to assure equivalent
groups because most drug trials are based on small samples.
In addition to matching experimental and control groups, attention
should be paid to obtaining subjects who will represent the
population likely to be administered the drug clinically. This
means that tests should not be restricted to persons with extensive
prior drug experience, and that subjects should come from the age
and sex groups likely to be given the drug. And since attrition
rates may be high for human drug studies that require weeks or
months of administration and follow-up, rewards for participation
should be increased in proportion to the length of the study to
reduce dropouts. Additionally, attention to methods for endpoint
analysis to avoid loss of data for those who do not complete the
test period is essential, since those compliant with long and
difficult studies are unlikely to be representative of the general
population of potential users.
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IV. Specific Drugs and Drug Classes
A. General Considerations
Many, though not all, of the substances under consideration are
drugs with well-defined clinical uses, and for some, there are
currently no good therapeutic alternatives. These facts must be
given due consideration in the overall evaluation of drugs with
physical dependence potential and/or abuse liability. New compounds
in these classes should, however, be expected to have either unique
therapeutic properties or fewer adverse side effects than currently
available drugs.
B. Opioids
The opioids (opiates) are a heterogeneous set of compounds widely
utilized in suppressing the symptoms of pain, in the treatment of
cough, dyspnea, and diarrhea, and, in certain circumstances, in the
production of anesthesia, either as a primary agent or in
combination with non-opiate anesthetics. Certain opioids are also
utilized in maintenance programs for the management of opioid
dependence and abuse. Morphine remains the major reference
compound, though many other agents in this class produce comparable
acute and chronic effects. In general, there are three types of
opioids: pure agonists, pure antagonists, and those with mixed
agonist/antagonist actions. Distinctions between pure agonists and
mixed agonist/antagonists can be made on the basis of their effects
on any one or all four distinct opioid receptor populations: mu,
kappa, sigma, and delta, of which the prototypes are morphine,
ethylketazocine, N-allylnormetazocine (SKF 10,047), and enkephalin,
respectively. There is now considerable debate over whether the
sigma opioid receptors are not, in fact, the same as the
phencyclidine receptors or binding sites. This area remains to be
clarified. Most of the compounds are structurally related to the
naturally occurring 4,5-epoxymorphinans (morphine, codeine, and
thebaine). While morphine was formerly difficult to make in the
laboratory, many semisynthetic analogues (e.g., diacetylmorphine or
heroin, hydromorphone, oxymorphone, hydrocodone, and oxycodone)
could be relatively easily synthesized from morphine, codeine, or
thebaine. These latter three key compounds can now be synthesized
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from readily available simple compounds in good overall yield by a
process which can be adapted to large scale synthesis.
Phenylpiperidines and related compounds such as meperidine,
alphaprodine, loperamide, diphenoxylate, and fentanyl are purely
synthetic drugs. Diphenoxylate and loperamide are particularly
useful in treating diarrhea. Meperidine and alphaprodine are useful
analgesics with a relatively short duration of action. Fentanyl is
used as an anesthetic and in combination with droperidol used to
produce neuroleptic analgesia. Propoxyphene, methadone and its
congeners, and levo-alpha-acetylmethadol (LAAM) are also
efficacious analgesics, but both methadone and LAAM are used
primarily in the management of opioid dependence and abuse.
Relatively pure antagonists such as naloxone, naltrexone, and
nalmefene are essentially free of morphine-like effects, and can
block the effects of morphine and other opioids. The efficacy of
these antagonists varies with the type of opioid receptor acted upon
by the agonist. The opioid agonist/antagonist analgesics represent
a unique class of compounds with very different pharmacological
profiles. Nalorphine
dysphoric effects.
and cyclazocine both possess pronounced
Pentazocine, butorphanol, and nalbuphine are all
effective analgesics, produce physical dependence, and
precipitate
may
withdrawal signs in opioid-dependent subjects.
Buprenorphine, a semisynthetic oripavine derivative, is a highly
lipophilic compound that is a potent analgesic but can precipitate
opioid withdrawal. Because it exhibits a "ceiling" effect to both
its analgesic and side effects,
agonist of the morphine type.
it has been classified as a partial
A recent new use of opiates and opioids has been as the sole agents
in anesthesia. Morphine,. as well as fentanyl, and mixed agonist/
antagonist analgesics have been used in very large doses. Since
respiration is maintained artificially during surgery, the
depressant effect on respiration is obviated. The opioid effects
are then terminated by administering large doses of naloxone.
With the discovery of endogenous ligands (e.g., enkephalins and
endorphins) for the opioid receptor, attempts have been made to
synthesize longer acting peptides (e.g., D-ala2-D-leu5-enkephalin)
with the hope of finding a compound that is selective for
subpopulations of opioid receptors.
C.  CNS Depressants Sedative/Hypnotics, Anesthetics,
Anxiolytics, and Antihistamines
CNS depressants that are employed as sedative/hypnotics or as
anxiolytics comprise a wide range of chemically different compounds.
While few qualitative differences exist between these compounds,
they possess marked quantitative differences with respect to the
degree of CNS depression. The older hypnotics include the inorganic
bromides, chloral hydrate, and paraldehyde, while the barbiturates
(e.g., pentobarbital) are currently more widely used. More
recently, the use of nonbarbiturate sedative/hypnotics belonging to
various distinct chemical classes has increased steadily. These
include the acylureas (e.g., carbromal and bromvaletone), carbamates
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(e-g, ethinamate and meprobamate), piperidinediones (e.g.,
gluthethimide and methyprylon), acetylenic carbinols (e.g.,
methaqualone), benzodiazepines (e.g., diazepam and nitrazepam), and
the aliphatic alcohols (e.g., ethanol).
Another class of compounds that exerts generalized CNS depression is
the volatile anesthetics. Abuse of such licit compounds as various
halogenated anesthetic gases including halothane, methoxyflurane,
and enflurane, is relatively rare. The anesthetic nitrous oxide,
however, is currently enjoying a revival of illicit use. Obsolete
compounds include the ethers, cyclopropane, fluroxene, and ethylene.
Illicit use of compounds typically employed as propellants in
commercial spray cans (e.g., fluorocarbons), and various solvents
and glues such as aliphatic hydrocarbons (e.g., hexane and naphtha),
aromatic hydrocarbons (e.g., toluene, xylene, and benzene), ketones
(e.g., acetone and cyclohexanone), esters (e.g., amyl acetate),
alcohols (e.g., butyl, ethyl, methyl, and isopropyl alcohols),
glycols (e.g., ethylene glycol), and gasoline is more common.
The older antihistaminics (H1 blocking agents) are classified into
three chemical. groups:
tripelennamine),
ethylenediamines (e.g., pyrilamine and
doxylamine), and
aminoalkylethers  (e.g., diphenhydramine
alkylamines e. g., chlorpheniramine and
pheniramine). Most of the H1 blockers produce some degree of
sedation and drowsiness at therapeutic doses. There are some
exceptions (phenendamine). Further, at higher doses the H1 blockers
have been observed to produce hallucinosis. The primary actions of
the H1 blockers are to block the histamine-induced contractions of
the bronchiolar .and gastrointestinal smooth muscle with partial
effects on the cardiovascular system and no effect on histamine-
induced gastric secretions. The latter action is postulated to be
another receptor - H2. The prototypic H2 blocking agent,
cimetidine, has been reported to have CNS activity especially in the
elderly.
D. CNS Stimulants: Anorectics, Local Anesthetics, and
Antidepressants
Compounds that stimulate the CNS and/or elevate mood are represented
by numerous pharmacological classes. The xanthines (e.g., caffeine,
theobromine), phenylethylamines (e.g., amphetamine, pemoline), and
diphenylmethanes (e.g., methylphenidate, deanol) all increase;
wakefulness, talkativeness, and random motor activity.
often elevated, sometimes with euphoria, and respiration is
occasionally stimulated. Anorexia is a common effect as well. In
addition to CNS stimulation, compounds like cocaine (which is a
benzoic acid ester extracted from the leaves of Erythroxylon coca),
as well as its analogues (e.g., procaine, benzocaine) possess marked
local anesthetic action. While the tricyclic antidepressants such
as imipramine and amitriptyline elevate mood in depressed patients,
they are generally without effect in normal individuals. Newer
antidepressants of different chemical classes, however, may have
such potential.
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E. Hallucinogens and Anticholinergics
Many compounds, when taken in sufficient doses, can cause
hallucinations that may be secondary to delirium, sedation, or
stimulation. The compounds appropriately classified as
hallucinogens produce. visual and/or auditory hallucinations not
necessarily associated with delirium, sedation, or stimulation.
Many compounds are derivatives or analogues of endogenous amino
acids. Compounds in this class include the substituted
indolealkylamines (e.g., lysergic acid diethylamide or LSD,
dimethyltryptamine or DMT, psilocybin. harmine, and ibogaine). and
the substituted phenylalkylamines (e.g., mescaline, 2,5-dimethoxy-
4-methylamphetamine or DOM). The 3-N-substituted piperidyl
benzilates (e.g. ditran) and the classical anticholinergics atropine
and scopalamine, when taken in sufficient doses, also produce
hallucinosis.
F. Cannabinoids
Residues from Cannabis sativa include a number of chemically
distinct compounds with the cannabinoids the
pharmacologically active group.
being major
At least 20 different naturally
occurring cannabinoids have been identified and include delta-g-
tetrahydrocannabinol (THC), delta-8-THC, cannabinol, and
cannabidiol. The most potent compound, delta-9-THC, has been shown
to be a potentially useful agent in the management of emesis,
glaucoma, and muscle spasm. Many congeners of delta-9-THC have been
synthesized, of which synhexyl (a delta-6a-lOa, n-hexyl derivative
of THC) and DMHP (a dimethylheptyl side chain congener of synhexyl)
were the first to be studied. Significant undesired side effects
precluded further studies with these compounds, but other synthetic
analogues such as nabilone, SP 106, and CP 44,001 may be potentially
useful therapeutic agents in man.
The cannabinoids, unlike other compounds reviewed, present a 'range
of problems which have hindered the understanding of their
pharmacology. The identification and standardization of the active
constituents in these preparations has been difficult. The
compounds are relatively unstable, insoluble in aqueous solutions,
and have many metabolites, including some that are pharmacologically
active. Clearly, the development and refinement of methods for the
isolation and purification of the natural alkaloids of the plant
Cannabis sativa have been instrumental in the progress that is
reviewed here. In addition, a number of synthetic cannabinoids have
demonstrated some specificity in their actions, and, as such, may
prove to be more useful as potential therapeutic agents. The
assessment of the cannabinoids as a class, however, must necessarily
involve procedures sensitive to all known actions of these
compounds; the standard for comparison is the major active agent,
delta-9-tetrahydrocannabinol.
G. Dissociative Anesthetics
The prototypic compound, 1-(1-phenylcyclohexyl) piperidine or PCP
produces a wide spectrum of effects, from stimulation and
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hallucinations to depression and analgesia. One analogue, ketamine,
enjoys a widespread use in veterinary medicine and some special uses
as a short-acting anesthetic in man. Other analogues have been
synthesized which are essentially based on substitutions of one of
three functional groups of the PCP nucleus: phenyl ring, cyclohexyl
ring, or the amino group. The latter analogues are not legitimately
manufactured or marketed, but widespread illicit synthesis has been
documented.
While most studies on the structure-activity relationships of PCP
analogues have used compounds with substitutions on the phenyl or
cyclohexyl ring, the majority of illicitly synthesized compounds are
N-substituted.
been the
Small chain alkyl groups (e.g., ethyl, propyl) have
most common substitutions which N-ethyl-l-
phenylcyclohexylamine (PCE) and 1-(n-propyl)-1-phenylcyclohexylamine
(NPPCA), respectively. The former compound, PCE,is currently under
Schedule I control as is 1-(1-phenylcyclohexyl) pyrrolidine or PCPY.
Toxicological manifestations of PCP analogue abuse have also been a
major cause for concern with respect particularly to the compound
l-piperidinocyclohexanecarbonitrile or PCC which, upon entering a
biological system, releases hydrogen cyanide. While PCC itself is
currently under Schedule II control (like PCP), it is a precursor to
PCP synthesis and thus tends to be a common contaminant in illicitly
synthesized PCP and other analogues. PCP analogue abuse is a
complex problem which essentially stems from the fact that the
identity of the compound is rarely confirmed and very little
information is available about the many easily synthesized
analogues.
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V. Animal Testing Procedures
A. General Methods
1. Procedures for Characterization of Drug Effects
a. Acute Drug Effects
i) Spontaneous locomotor activity
The jiggle cage method of Harned et al. (1952) determines the
effects of test compounds on spontaneous motor activity.
rats are placed in a cage suspended in air by a spring.
Usually,
Movements
of the rat are recorded kymographically on chart paper and can be
quantified with respect to control animals given vehicle. An
additional measure of locomotor activity is obtained using an open-
field grid (Brimblecombe 1963). An observer (blind to the
treatment) counts the number of squares entered over a set period of
time. The photo-cell annular cage is also employed to determine
motor activity. Typically, mice or rats are treated with either
vehicle or the test compound and the number of times an animal
interrupts the light beam over a given interval is recorded.
Time-course data are easily obtained with this method using
cumulative recorders.
ii) Forced motor activity
A measure of motor impairment (ability of rats or mice to remain on
a rotating rod) can be obtained using a variety of procedures, one
example being the rotorod assay (Dunham and Miya 1957; Kinnard and
Carr 1957). The device consists of a motor-driven, aluminum rod
(6-8 cm diameter) which is divided into several segments by circular
aluminum plates which serve to limit lateral movements of the
animals on the rod. Once the rodent is placed on the rod, it is set
in motion and the time until the animal falls off is recorded.
Typically, a maximum cut-off of 1-2 minutes is used. Animals can be
tested numerous times after a single injection to generate
time-course data.
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iii) Electroencephalographic (EEG) activity
This procedure employs the brain's electrical activity as a measure
of a drug's effect (Klemm 1969). Recently developed computer-
assisted analysis (e.g., power spectrum) has permitted not only
qualitative but quantitative measures of drug-induced changes in EEG
activity. The EEG has been used to quantify acute and chronic drug
effects in various species including the mouse (Morley and Bradley
1977), rat (Lukas et al. 1980). cat (Schallek et al. 1967), dog
(Wikler and Altschul 1950), and monkey (Gehrmann and Killam 1976).
This technique is most often employed in chronic animals which have
been implanted with cerebrocortical EEG electrodes, although sub-
cortical electrodes have also been employed. The animals are
typically allowed to acclimate to the surroundings and control EEG
activity is recorded. Once the EEG recording is stable, a drug is
administered and' the resultant EEG activity is monitored on a
polygraph and stored on magnetic tape for subsequent computerized
power spectral analysis. This analysis consists of measuring the
amount of energy (or power) as a function of frequency.
Another component of the analysis of the EEG effects of drugs of
abuse relates to the quantification of various stages in the
sleep-wakefulness continuum. In all mammals, at least three stages
are readily distinguished - a waking stage, a slow-wave stage of
sleep, and a rapid-eye-movement (REM) stage of sleep. The EEG from
mammals can be scored for the onset, duration, and cyclicity of the
stages. Transitions between stages are also noted. These form the
basis for the evaluation of drug-induced alterations (van Twyver
1969).
In recent years, there has been increasing use of evoked potentials
in the EEG to define and quantify the actions of drugs. A constant-
intensity stimulus, such as a light flash, a signal tone, or a mild
electric shock, is administered repeatedly to the subject, and the
EEG activity is recorded during a fixed sweep of the last 500 msec
of each stimulus. Summation of these recordings in a computer
results in averaging-out of the random background activity, but
progressive augmentation of the specific wave pattern of response to
the stimuli. Drug effects on the latency and amplitude of each
component of the response can then be expressed in precise
quantitative terms (Kalant 1978a).
iv) Behavioral performance
Numerous drugs have been reported to modify a wide range of
performances including food and water consumption, exploratory and
aggressive behaviors, punishment, escape, avoidance, and conditioned
suppression responses. With the exception of the conflict procedure
(Geller and Seifter 1960), which is relatively selective for
anxiolytics, few behavioral paradigms are employed routinely in
animal models of abuse liability and/or dependence potential.
Consummatory behavior (e.g., food or water intake) has been shown to
increase after acute administration of opioid antagonists, but
benzodiazepines induce hyperphagia as well. In addition, procedures
which employ response rates as a measure of performance appear to be
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affected by drugs belonging to a wide range of pharmacological
classes. This relationship is also dependent upon the response rate
prevailing at the time of drug administration (e.g., law of initial
effect); thus, procedures that maintain low response rates are
typically increased by many compounds while high response rate
performance is typically suppressed. This phenomenon has been
elegantly demonstrated using a multiple schedule technique (e.g.,
mult. FR/FI). Drug-induced changes of response rates in the same
animal can be demonstrated to be directly related to the schedule of
reinforcement (Dews 1955; Kelleher and Morse 1968).
The contributions of behavioral pharmacology to the assessment of
drug abuse liability and physical dependence potential have had
their greatest impact in the areas of tolerance and withdrawal. At
least three different behavioral factors have been shown to have
important effects upon the rate of development of tolerance, and
upon the degree of tolerance developed. The first is the presence
or absence of a requirement for task performance while the subject
is under the influence of a drug. Animals receiving the drug just
prior to the start of each training session acquire tolerance more
rapidly than animals receiving the same dose of the same drug
immediately after each training session (Kalant et al. 1971; LeBlanc
et al. 1973). The second factor is the effect of the drug upon the
relationship between the performance and its consequences. For
example, rats were trained to bar-press for food rewards on a
schedule of alternating periods of FI and DRL. Under the influence
of the first dose of amphetamine, their response rates increased
during both components of the schedule, but this caused loss of
rewards only in the DRL component and not during the FI. With
repeated amphetamine tests on the same schedule, the rats rapidly
developed tolerance to the rate-increasing effect during the DRL
portions, while showing no tolerance during the FI portions of the
schedule (Schuster et al. 1966). The same phenomenon has been
observed subsequently with other drugs (Krasnegor 1978). The third
factor is the presence or absence of environmental stimuli linked by
Pavlovian conditioning to the administration' of a drug. If an
animal receives a dose of a given drug repeatedly in the same
environment, it shows more tolerance when tested in the same
environment than when tested with the same dose in a new environment
(Siegel 1976; Le et al. 1979).
All three sets of observations mentioned in the preceding paragraph
have given rise to the concept of behavioral tolerance as distinct
from classical or pharmacological tolerance (Krasnegor 1978).
However, it has been argued that these are not separate forms of
tolerance, and that the behavioral factors simply alter the rate or
extent of development of an intrinsic biological adaptation (Kalant
et al. 1971; Kalant 1978b). The extent to which behavioral
variables contribute to the tolerance will vary according to the
specific circumstances. It is important, however, in testing drugs
for physical dependence liability, to ensure that the same test
paradigm is employed throughout, so that the behavioral influences
are kept constant for all the drugs under comparison.
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Behavioral procedures for determining the appetitive and/or aversive
properties of drugs have as well extended the application of
classical conditioning methods to the assessment of drug abuse
liability. Conditioned taste aversion paradigms have been employed,
for example, in which the consumption of a saccharin solution to
which an animal has been previously exposed in association with
psychoactive drug injection is subsequently compared with water.
Saccharin preference under such conditions indicates appetitive drug
effects whereas saccharin rejection suggests aversive properties
even though drug self-administration tests may reflect reinforcement
effect (Cappell and LeBlanc 1975). A similar "place preference"
procedure involves a comparison of the time spent in each of two
distinctive environments (i.e., differing in visual, auditory,
olfactory, and/or tactile cues) as a function of different drug,
drug dose, or vehicle injections under such clearly discriminable
conditions. The appetitive effects of cocaine or morphine, for
example, are reflected in the increased time spent in the
environment associated with such drug injection, while aversive
effects produce avoidance of the drug injection site (Mucha et al.
1982).
v) Binding assays
With the discovery of specific receptors to which opioids,
stimulants, neuroleptics, and benzodiazepines bind, quantitative
study of structure-activity relationships (QSAR) has emerged as a
major pharmacological method which has provided extensive
information regarding the basic mechanism of action of drugs of
abuse. Binding sites in brain tissue have as well been reported for
both PCP and its analogues, and the good correlation between binding
affinity and potency in clinical use has served not only to enhance
understanding of drug/receptor interactions, but to validate the use
of this technique as a predictor of drug effects as well. While
binding to CNS tissue is normally associated with a drug's
physiological/behavioral effects, binding assays involving other
tissues (e.g., smooth muscle) have proven equally useful. In fact,
guinea pig ileum and mouse vas deferens have been used extensively
to characterize the binding characteristics of the opioids and
endogenous, opiate-like peptides (Kosterlitz et al. 1973; Woods et
al. 1981).
The basic concept in binding studies involves the use of a
radiolabelled (e.g, 3H, or less frequently, l4C) ligand (e.g.,
dihydromorphine, flunitrazepam) which is first incubated with the
tissue to which nonlabelled test drug is then added. By measuring
the remaining radioactivity on the tissue, the degree of
displacement of the labelled ligand can be determined, and thus a
measure of relative affinity for the binding site is obtained for
the test compound. Additional information regarding the binding
characteristics of drugs of abuse is obtained by determining the
effects of adding receptor antagonists or electrolytes (e.g., Na+)
to the incubation (Pert and Snyder 1974). Differential and
incomplete displacement of binding has been interpreted to mean that
there are multiple receptor populations for a specific drug class.
In many instances, a high correlation between the results of binding
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studies and the observed physiological and behavioral effects with
certain drugs has been found. This has led to the inclusion of
binding characteristics in the pharmacological profile of some
drugs.
2. Procedures for Assessing Physical Dependence Potential
a. Tolerance to Drug Effects
The development of tolerance to a drug is reflected by an
attenuation of the original response with subsequent exposures to
the drug. Thus, the dose must be increased in order to re-establish
the original response. By quantifying the acute effects of a drug,
it is possible to track the development of tolerance to any one
effect. This is particularly important because tolerance does not
necessarily develop equally, that is, to the same degree or at the
same rate, to all of a drug's effects. Tolerance may be
dispositional or functional; the former is primarily due to an
increased rate of biotransformation and/or drug elimination from the
body, while the latter refers to a diminished sensitivity of the CNS
(Kalant et al. 1971). An additional dimension to tolerance which
has become evident as a result of refinements in the development of
performance procedures is behavioral tolerance. This phenomenon may
be apparent only with respect to some specific aspect of the
behavioral repertoire which has previously been "learned" under the
influence of the drug (see above "Behavioral Performance" section).
The development of tolerance is most apparent when exposure to the
drug is continual. Various techniques have been employed to
maximize drug exposure, including continual infusions, multiple
parenteral injections, addition of a compound to food or drinking
water, and implantation of subcutaneous pellets or miniature osmotic
pumps.
b. Withdrawal from Chronic Drug Administration
The abstinence syndrome is defined by the physiological and
behavioral consequences of terminating chronic administration of a
drug (also called abrupt withdrawal). Both the dose and duration of
exposure determine the dependence potential of a drug, and the
degree of dependence potential differs among drugs from different
classes. The basic procedures for assessing these effects, however,
are similar in format, and involve two basic techniques: direct or
primary (dependence), and single dose substitution (Fraser and
Jasinski 1977). In the former, the test compound is administered on
a chronic basis to drug-naive animals; the initial dose is usually
low, and as tolerance to toxic effects develops, the dose is
increased. At the end of the dosing schedule the drug is withheld,
and the animals are observed for physical signs and symptoms of
withdrawal. Single dose substitution procedures involve rendering
animals dependent on a standard drug (e.g., morphine, barbital) for
a specified period of time. The drug is then withheld, and the
animals are observed for withdrawal signs. Once the withdrawal
syndrome appears, a single dose of the test compound is administered
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to determine whether the withdrawal signs can be reversed or
attenuated.
A recent development in the study of relative dependence potential
has been the use of a functionally equivalent dosing regimen for the
drugs being compared (Boisse and Okamoto 1978). This procedure
takes into account the physicochemical properties of a drug which
determine metabolic and elimination rates (and thus, the amount of
drug in the body) as a factor influencing dependence potential. The
most common procedures for accomplishing functional equivalence are
behavior rating scales (for degree of CNS depression) and devices
for measuring ataxia (e.g., rotating rod). Doses are adjusted in
order to maintain equal degrees of sedation.
Most dependence studies are conducted using spontaneous withdrawal
techniques (i.e., the drug is simply discontinued). Techniques for
assessing opioid dependence potential, however, have been extended
by the development of an opioid receptor antagonist, naloxone.
Thus, precipitated withdrawal is possible and the need to wait 12-24
hours for withdrawal signs is obviated. The recent discovery of a
benzodiazepine receptor antagonist (Ro 15-1788) has also provided
for a similar extension of dependence assessment procedures with
this increasingly more prominent class of clinically useful
compounds (Lukas and Griffiths 1982).
3. Procedures for Assessing Abuse Liability
a. Drug Self-Administration
Drug self-administration procedures represent the most widely used
method for assessing relative abuse liability with drugs belonging
to various classes. With the development of a chronic intravenous
catheter (Clark et al. 1961; Weitzman et al. 1961) and methods for
automated delivery of drugs, studies of drug self-administration
were first undertaken in rats over two decades ago (Weeks 1962;
Weeks and Davis 1964). Procedures for implanting i.v. catheters in
non-human primates have since been refined and detailed (Deneau et
al. 1969; Lukas et al. 1982). Chronic intragastric catheters have
also been developed for rats (Gotestam 1973; Lukas and Moreton 1979)
and primates (Altshuler et al. 1975; Lukas et al. 1982)) and
automated drinking systems have been described in reports of oral
drug self-administration studies (Meisch and Henningfield 1977; Ator
and Griffiths 1982).
Two basic types of drug self-administration procedure are commonly
used: 1) continuous or direct, and 2) substitution. In the former,
the animal is allowed access to the test compound without prior
experience. This procedure is useful in assessing whether an animal
will initiate self-injections of the test compound, and if so,
whether responding for the compound will change over time. In the
substitution procedure, drug self-administration is first
established with a standard compound (e.g., cocaine, morphine) known
to be reinforcing, that is, animals will work to obtain access to
the compound. Once performance and drug intake have stabilized, the
test compound is substituted for the standard. The abuse liability
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pattern is defined by numerous characteristics including intake,
time course, and stability of responding. Once self-administration
behavior is established with a compound (e.g., dose-response
functions are generated, relative potencies are determined), the
next step in characterizing abuse liability is to determine relative
degree of reinforcing efficacy. Numerous procedures including
progressive ratio, response rate analysis, discrete-trial choice,
and concurrent schedule control, have been utilized to address this
question.
i) Progressive Ratio Procedures
Progressive ratio procedures involve a two-step operation in which
stable operant performance (typically maintained on a fixed-ratio
schedule) is first obtained with the reinforcer. Subsequently, the
number of responses required for delivery of reinforcement is
systematically increased until responding falls below some criterion
level. The highest ratio at which performance remained above
criterion is referred to as the "breaking point"; Hodos and Kalman
(1963) demonstrated that the higher the concentration or volume of
liquid reinforcer the greater the breaking point. Because of this
relationship the breaking point is taken to represent a measure of
relative reinforcer strength.
The extent to which a progressive ratio procedure can provide useful
data regarding the reinforcing efficacy of a drug is dependent upon
the fulfillment of certain criteria. First, since the actual
procedure followed varies substantially between laboratories, it is
important to recognize that the measures obtained are not absolute,
but rather are relative to some standard. Therefore, it is crucial
that all interpretations of reinforcing strength be made on the
basis of relation to a standard compound (e.g., morphine,
pentobarbital, cocaine, etc.). Second, since the reinforcing
properties of drugs are dose related, there is every reason to
suspect that the breaking point may also be dose related. Thus,
complete dose-effect curves must be evaluated in order to determine
not only whether different drugs maintain higher breaking points,
but also whether different doses maintain this performance as well.
ii) Response Rate Analysis
Interpretations of relative reinforcing strength can sometimes be
measured in terms of the rate of responding prior to the drug
injection. The degree to which this applies, however, is dependent'
upon the schedule of reinforcement employed. Historically, a
negative correlation has been shown to exist between drug dose and
response rate (Downs and Woods 1974; Goldberg et al. 1972; Pickens
and Thompson 1968). The response requirement for these studies was
typically a continuous reinforcement or a low fixed ratio, and thus,
the direct effect of the self-injected drug was most likely
responsible for the decreases' in response rate. Using schedules
that employ either a fixed-interval schedule (Balster and Schuster
1973) combined with a time-out (15 minute) period after each self-
injection or a fixed ratio schedule with a long time-out period
(Griffiths et al. 1981), however, it is possible to observe a
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positive relationship between increasing drug dose and higher rates
of responding. This relationship does nonetheless have the
limitation that, as the direct effects of higher doses of the drug
persist for, longer periods of time, response rates will decrease.
iii) Choice Procedures
An obvious extension of procedures that assess the reinforcing
strength of a single drug is one which permits an animal to select a
preferred drug dose, or to choose between two different drugs.
Typically, different colored lights are used to signal the
availability of different reinforcers. After initial exposure with
various doses of a single drug (Brady and Griffiths 1977) or two
different drugs (Johanson and Schuster 1977), the animal is given
the opportunity to choose between the doses or drugs by operating a
third lever which switches the color of a viewing light indicating
which reinforcer is available. Only one reinforcer is available at
a time. Completion of the response requirement on the appropriate
lever results in delivery of drug previously associated with that
1 color. The percentage of choices of one drug or dose over another
and the response rates maintained by the injection are determined to
reflect the relative degree of reinforcing strength. Attempts to
eliminate possible confounding effects of drug interactions have
resulted in procedures which offer choices between drug and food
(Griffiths et al. 1975).
iv) Concurrent Schedules
The procedures for assessing concurrent drug availability differ
from choice procedures in that concurrent schedules make both drugs
(or different doses of the same drug) available simultaneously.
Using variable interval schedules, higher rates were generally
associated with the response alternative which delivered higher
cocaine doses (Iglauer et al. 1975). As with other procedures, this
relationship became asymptotic as higher doses were studied.
b. Drug Discrimination Procedures
Assessment of the discriminative stimulus properties of drugs has
been recently demonstrated to provide a useful adjunct to self-
injection techniques for the evaluation of a pharmacological agent's
abuse liability. The value of drug discrimination procedures in
this regard relates to the fact that these procedures are designed
to utilize the physiological or interoceptive alterations induced by
many psychoactive drugs as the "cue" for an appropriate response to
obtain food or avoid shock (Overton 1971). Thus, these procedures
can provide information analogous to a human testing situation in
which subjects categorize drugs with respect to their subjective
effects.
The basic procedure involves training animals to respond
differentially (depending upon the nature of drug pretreatment) in
either a T-maze (e.g., go left if drugged; go right if nondrugged)
or a two-lever choice situation (e.g., left lever produces food or
avoids shock if drugged; right lever produces food or avoids shock
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if nondrugged). Training time can be decreased by introducing
differential drug conditions on the first exposure rather than
pretraining on both levers or arms of a T-maze (Overton 1979). Once
stable responding has been established and the percent of correct
responding is high (e.g., ›)85%) then test sessions are initiated in
which novel drug conditions are presented in order to assess
generalization. Within the context of abuse liability testing,
three basic procedures can then be followed. First, generalization
of the training dose can be demonstrated for other doses of the
training drug (Schuster and Balster 1977). This ensures that the
discriminative stimulus of the drug is in fact controlling the
responding. Secondly, once an appropriate training drug and dose
are chosen, generalization to other compounds within the same
pharmacologic class can be assessed to provide evidence for the
pharmacological specificity of drug stimulus control. All results
must be interpreted in relation to the training drug dose, however,
since this can markedly affect the results of such testing (Waters
et al. 1972). Thirdly, cross-generalization to drugs belonging to
other pharmacologic classes can be assessed in a similar manner.
Generally, drugs belonging to the same or similar classes tend to
produce training-drug-appropriate responding while drugs from
different classes do not (Colpaert and Rosecrans 1978).
c. Behavioral Toxicity
A broad range of performance procedures has been used to assess both
the acute and chronic decrements which define the behavioral
toxicity of abused drugs. Progress in this area of pharmacology has
closely paralleled laboratory developments in the experimental
analysis of behavior, and has focused most recently upon
psychophysical methods for sensorimotor assessment. The role of
behavioral toxicology has become increasingly important in such drug
evaluation because substances with only minimal (if any) disruptive
behavioral or physiological effects are not generally regarded as
having significant abuse liability even though self-administration
may be widespread (e.g., caffeine in tea or coffee). In contrast,
compounds self-administered even sparingly which produce disruptive
physiological/behavioral changes are considered to have high abuse
liability (e.g., lysergic acid diethylamide). Drugs may fall
anywhere on the continua defined by these parameters and relative
abuse liability is most effectively determined by a comprehensive
assessment of these interactive behavioral/physiological dimensions.
Most procedures employed are based on standard behavioral paradigms
(Weiss and Laties 1975), and,as such, are distinguished from the
more traditional assessment of teratology. Performance decrements
are usually assessed in terms of motor impairment as an index of
behavioral toxicity (e.g., changes in lever pressing to obtain food
or avoid shock), although recent developments in the application of
classical psychophysical procedures have broadened the scope of
sensorimotor evaluation techniques. These refinements in animal
psychophysical methodologies have made available valid and reliable
experimental procedures for precise measurement of sensory functions
in non-human primates, birds, rodents, and carnivores (Masterton et
al. 1969; Stebbins 1973; Fay 1974; Dolling 1980). In general, these
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advances can be seen to have resulted from a marriage of two
technologies--classical human psychophysics on the one hand, and
animal learning and conditioning on the other. Further, the
training and testing procedures for obtaining valid and reliable
measures of sensory function in such animals have been thoroughly
documented (Blough 1966; Stebbins 1970). providing convincing
demonstrations of their sensitivity and specificity in more general
behavioral pharmacology applications.
Most recently, for example, applications of these psychophysical
procedures to the evaluation of auditory and visual threshold and
reaction time changes in baboons have been reported following
pharmacological treatments involving several drugs of abuse (Brady
et al. 1979; Hienz and Brady 1980; Hienz et al. 1981). Baboons
housed in individual cages and maintained on a 22-hour restricted
feeding schedule were trained to press a lever and hold it depressed
for varying intervals until presentation of a light flash or tone
burst. Correct responding (defined by release of the lever within
1.5 seconds of stimulus presentation) was rewarded with banana-
flavored food pellets. A 1-second intertrial interval (ITI) was
then imposed during which no stimuli were presented and any lever
press reinstated the ITI. Experimental sessions were conducted
daily over a Z-hour period with auditory and visual thresholds
determined by randomly varying the intensity of the test stimuli
from trial to trial and examining the number of correct lever
'releases. Four to five separate measures of thresholds and reaction
times were obtained, each based on blocks of 140 trials, thus
providing a measure of the time course of drug effects.
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6. Procedures for Assessing Opioids
1. Characterization of Opioid Effects
a. Acute Drug Effects
i) Analgesia
Numerous methods are currently available that provide reliable
assessments of the analgesic potency of an opioid. Traditionally,
methods have been segregrated into two classes depending on the
degree to which a non-opioid (e.g., salicylate) can be distinguished
from an opioid analgesic. In the case of the former, Randall and
Selitto (1957) have described a technique in which brewer's yeast
(0.1 ml of a 20% suspension) is injected into a rat's foot. The
ensuing pain and swelling are determined by applying increasing
pressure to the foot. Salicylates elevate the pain threshold in the
inflamed foot only, while opioids elevate pain thresholds in both
hind legs.
Procedures for assessing the analgesic properties of opioids are
mainly conducted with rodents and assess the degree of pain from
heat (e.g., tail flick, hotplate), pressure (tail compression), or
electric shock (e.g., shock titration, stimulation). With the
exception of electric shock, the basic procedures are similar and
 are usually characterized by a group study design, appropriate
controls (e.g., for habituation), operationally defined end-point
responses (e.g., paw lick, vocalization), and a maximal cut-off time
to prevent tissue damage. The tail flick (D'Amour and Smith 1941),
hotplate (Eddy and Leimbach 1953), hot water (Janssen et al. 1963),
electric stimulation (Knowlton and Cross 1943), flinch jump (Evans
1961)) and tail compression (Dandiya and Menon 1963; Geller et al.
1979) methods all include these features. Typically, animals are
first tested for their sensitivity to the system under non-drug
conditions. Then, groups of 8-10 rodents receive either the test
drug or vehicle and are retested at various intervals (e.g., 10
minutes). The "index of analgesia" can then be obtained by
employing the method of Cox et al. (1968) which normalizes the
results from different compounds. Analgesia (as measured by an
increased latency to respond) is characterized not only by the time
to peak effect, but by onset and offset as well. The use of a
maximal cut-off time would generally preclude the quantitation of
analgesic efficacy. However, calculation of a percent of "maximal
analgesia" according to the formula (test)-(control)/(maximum)-
(control) X 100 can circumvent the problem. Collins et al. (1964)
attempted to obviate the problems associated with the artificial
"ceiling" of analgesic effect with opioids by using a rectal
electrode method for delivery of electrical stimulation of
increasing intensity in the range of 0 to 24 V, at a rate of 1 V/set
with rats. Reaction thresholds were measured as a function of the
time from the onset of stimulation until vocalization. Drugs were
given S.C. or i.p. and animals were tested at 15 and 30 minutes, and
then at 30 minute intervals for 3 hours after drug administration.
Weak analgesics such as acetylsalicylic acid were inactive, while
barbiturates were active only at doses that induced deep CNS
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depression. Using the increase in threshold in volts (rather than %
of control), the dose-effect curve for morphine increased
exponentially with increasing dose while codeine possessed a much
shallower, linear curve.
ii) Spontaneous Locomotor activity
These procedures described above in general methods are commonly
used to assess the pharmacological activity of opioids. While the
measure of locomotor activity does not provide information relevant
to the prediction of dependence potential, it does provide a baseline
for the study of tolerance and cross-tolerance to other drugs.
Opioid-induced changes in locomotor activity are characterized by
both depressant and stimulant actions. In general, the biphasic
response consists of an initial depressant phase which typically
precedes the delayed stimulated phase. Since the overall effect is
species-, dose-, and time-dependent, however, it is important to
obtain frequent measures of locomotor activity after drug
administration rather than single, fixed-time measures (e.g., 30
minutes post injection).
iii) Electroencephalographic (EEG) activity
Visual analysis of the direct EEG has revealed that morphine and its
surrogates slow the predominant frequency and increase high-voltage
delta activity (Khazan 1975); some analogues such as methadone
induce spike-and-dome activity after high doses.. On the basis of
EEG and behavioral profiles and naloxone sensitivities, it is
possible to distinguish between opioids acting at different
receptors (Tortella et al. 1980). While the effect of opioids on
the EEG are readily discernible, the need to quantify the changes in
both voltage and frequency components has resulted in the emergence
of numerous computer-assisted techniques. Currently, power spectral
analysis is used to quantify not only the acute effects of opioids,
but the development of tolerance, cross-tolerance, and drug-seeking
behavior as well (Young et al. 1978).
In the application of EEG procedures for assessing the acute effects
of opioids, as described in general methods above, opioid effects
may appear in biphasic form. In characterizing the EEG profiles of
morphine, methadone, l-alpha-acetylmethadol (LAAM) and its two
demethylated metabolites (NLAAM and DNLAAM), for example, an 8-hour
post-injection evaluation revealed the appearance of distinct EEG
changes 1-2 hours after LAAM which matched those observed
immediately after NLAAM (Lukas et al. 1980). Cross-tolerance has
also been quantified using power spectral analysis (Lukas et al.
1982) with opioid challenges in LAAM-maintained rats producing
attenuation of the EEG voltage and a shift to a higher predominant
frequency. The technique also distinguished between high and low
maintenance doses of LAAM and, in addition, demonstrated that the
development of cross-tolerance to morphine was more complete than
that developed to methadone.
Shifts in the predominant EEG frequency during rapid-eye-movement
(REM) sleep have as well been used to track drug-seeking behavior in
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dependent rats (Young et al. 1978). The REM sleep predominant
frequency gradually slows during the 2-hour interinjection interval
until the next self-injection of morphine when "reset" to the faster
frequency (i.e., about 1 Hz) is observed. Power spectral analysis
has also been utilized to characterize the EEG profile of the
prototypic mu, kappa, and sigma agonists (Young et al. 1981). The
different compounds are defined by a unique fingerprint-like array
based on the voltage and frequency components of the power spectrum.
Thus, the mu agonist morphine produces a large increase in voltage
over the O-10 Hz band while ketocyclazocine (a kappa agonist)
produces a definite peak in the 5-8 Hz band with lower activity in
the O-4 Hz band. (N-allyl-normetazocine, the putative sigma agonist,
produced .a power spectrum characterized by relatively much lower
voltage in the O-10 Hz band, and a small, sharp peak at 7.5 Hz.
iv) Behavioral performance
Although behavioral methods have been utilized to assess analgesic
activity (e.g., shock titration), conditioning techniques have not
generally been used to identify opioids or distinguish them from
other drug classes. Behavioral paradigms for the assessment of
opioid activity have focused mainly on the measurement of tolerance
and, more recently, in the classification of opioids based upon the
subclasses of opiate receptor activity. Antagonist-induced (i.e.,
naloxone, naltrexone) differential shifts in the dose-response
curves of opioid effects upon lever-pressing in rats on a fixed
interval food reinforcement schedule, for example, have been related
to the several presumed subpopulations of opioids (Harris 1980).
The agonist morphine was completely antagonized by naloxone or
naltrexone while butorphanol, ketocyclazocine, ethylketocyclazocine,
and low doses of cyclazocine were only partially antagonized. The
rate-decreasing effects of SKF-10,047 and high doses of cyclazocine
were not blocked by the opioid antagonists.
v) Seizure threshold
Using the flurothyl-induced seizure assay in rats, opioids have been
shown to either decrease, increase, or have no effect upon seizure
thresholds. On the basis of these differential effects, opioids
have been classified into four distinct subclasses based upon the
observed dose-response. relationships, stereospecificity, naloxone
sensitivity, and development of tolerance-cross-tolerance (Cowan et
al. 1979). The technique for flurothyl administration has been
detailed by Truitt et al. (1960) and Adler (1975). Animals are
placed in a large volume (e.g., 3-4 1) glass jar. A screen holds a
gauze pad inside the jar which is fed by plastic tubing connected to
a syringe containing a 10% v/v solution of flurothyl in ethanol.
Controlled continuous infusion of flurothyl onto the gauze is
maintained by an infusion pump at a rate of 0.103 ml/min. A full-
blown generalized seizure usually occurs about 320-350 seconds after
the onset of the infusion.
The profile of flurothyl-induced seizures has been described for
rats as containing four components. The rat's typical exploratory
behavior is interrupted by short periods of "freezing" or
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immobility. Between 150 and 200 seconds after infusion onset,
jerky, tremor-like movements prevail which are replaced by preclonic
or myoclonic jerks occurring 50-100 seconds later. Clonic movements
of the forelimbs signal the onset of the full seizure involving
both forelimbs and hindlimbs. Test compounds are administered
subcutaneously to individual rats 30 minutes before exposure to
flurothyl. The time interval between the start of the infusion and
the onset of a clonic convulsion is used as the seizure threshold.
vi) Spinal dog preparation
The chronic spinal dog assay (Martin et al. 1976) has been used to
assess the pharmacologic effects of many opioids, determine relative
potencies, and provide a means of establishing pharmacological
equivalence. The technique allows simultaneous measurement of
pupillary diameter, pulse rate, pain reflexes, touch reflexes, and
body temperature among other physiological processes. The
preparation is also capable of differentiating between naive and
opioid-tolerant animals and the measures obtained are sufficiently
sensitive to allow detection of an opiate abstinence syndrome, even
after relatively low doses. Results obtained with this technique
contributed to the formulation of opiate receptor subspecies
accounting for the effects of any given opiate by its action on one
or a combination of three receptors (Gilbert and Martin 1976; Martin
et al. 1976).
The preparation involves transection of the spinal cord at either a
high (e.g., 5th-6th cervical) or a low (e.g., lOth-11th thoracic)
level. Standard measurement of pupillary diameter, pulse rate,
respiratory rate, and body temperature follows recovery from surgery
(Martin and Eades 1964). Somatic reflexes elicited below the level
of spinal cord transection are recorded isotonically (Wikler and
Frank 1948) in the following order: patellar reflex, crossed
extensor reflex, ipsilateral extension thrust, and the ipsilateral
flexor reflex (Martin et al. 1964). The patellar reflex is evoked
using a reflex hammer applied at a rate of about once every 3
seconds. Dorgen forceps are applied across the first and fourth
toes of a hindlimb for 3 seconds in order to evoke the crossed
extensor and ipsilateral flexor reflex. Rapid extension of the toes
or pressure applied to the base of the toe pad elicits the
ipsilateral extensor thrust.
Control observations of all measures and reflexes are made 30
minutes before acute drug administration, and repeated at 15 and 30
minutes post drug and then hourly for 5-7 hours. Total scores are
obtained for each measure by summing the differences between the
before and after drug responses. In this manner, the overall
pharmacologic profile of a compound is obtained and compared to
standard compounds.
vii) Gastrointestinal motility
Acute administration of opioids causes a marked reduction in the
propulsive action of the entire gastrointestinal (G.I.) tract. This
is associated with an increase in tone, the net effect being to
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delay gastric emptying and slow passage of the contents through the
intestines. The movement of gastric contents through the G.I. tract
can be measured fairly accurately using the charcoal meal method in
rodents (Green 1959; Cowan et al. 1977). Groups of rats are food
deprived for 18 hours, but water is available up until 1 hour before
testing. Twenty minutes after subcutaneous injection or 50 minutes
after oral administration of the test compound or vehicle control,
the rats are given a charcoal meal (5 ml/kg) via gavage. After a
standard time interval (usually 10 minutes) the rats are killed by
cervical dislocation and the distance travelled by the charcoal meal
along the small intestine from the pyloric sphincter is measured.
This distance is then converted to a percentage of the total length.
Opioids significantly slow the passage of the charcoal meal along
the intestines. Furthermore, this effect is dose-related for
morphine with a maximal effect (i.e., no distance traveled) observed
after 3 mg/kg, S.C. (Cowan et al. 1977). Buprenorphine, in doses of
0.01-1.0 mg/kg, s.c., similarly decreases the passage of the
charcoal meal, but higher doses (i.e., 10-30 mg/kg) result in a
reversal of this effect until the distance traveled is the same as
after vehicle control (Cowan et al. 1977). The procedure thus
appears to be sufficiently sensitive to detect both agonist and
antagonist effects of the opioids.
viii) Body temperature
Opiates produce marked changes in body temperature in many species.
The specific effect, however, depends on a number of factors
including species, strain, sex, and age of subject, housing
conditions, ambient temperature, degree of restraint, the particular
drug used, its dose and route of administration. (See reviews by
Burks and Rosenfeld 1979; Clark and Clark 1980; Lotti 1973).
Body temperature is commonly measured by means of a rectal
thermistor probe at regular time intervals after drug administration
(e-g., every 30 minutes for 4-6 hours). Mean changes from pre-drug
baseline and areas under the time-response curves are calculated.
Opioids thought to act on different receptor types have been studied
using variations on this basic technique in several species (e.g.,
mouse, Rosow et al. 1980, 1982a,b; rat, Geller et al. 1983; cat,
Clark and Cumby 1978, Clark and Ponder 1980, Clark et al. 1981).
For continuous measurement, either surgical implantation of a
thermistor or restraint of the animal is generally required. The
latter condition, however, has been shown to influence the
thermoregulatory effects of opiates (Holtzman and Villarreal 1969;
Martin et al. 1977). Whole-body calorimetry is a more sophisticated
technique that allows continuous measurement of several
thermoregulatory-related responses (e.g., oxygen consumption,
respiratory water loss) in addition to simple body temperature (Lin
et al. 1979).
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ix) Pupillary effects
Change in pupil size is a well-known effect of opiate
administration. As with body temperature, the direction of change
is species-dependent. Man, rabbit, and dog respond to morphine with
miosis (constriction); cat, rat, mouse, and monkey exhibit mydriasis
(dilation). Until recently, pupil size was commonly measured
several times after drug administration by direct observation, with
calipers, or by means of still photographs (Nomof et al. 1968;
Janssen and Jageneau 1956; Gerald et al. 1976; Jasinski and Martin
1967). More precise, almost continuous measurement can now be
achieved through cinematography and infra-red videopupillometry
(Tallarida et al. 1977; Murray and Loughnane 1981; Adler et al.
1981). Frequent sampling methods are highly recommended because of
the fluctuations in pupil size induced by opioids (Henderson and
Graham 1925; Oono 1965; Klemfuss et al. 1979; Tallarida et al.
1977). The entire subject of the pupillary effects of opioids and
the methodology for studying such effects have recently been
reviewed (Murray et al. 1983).
x) In vitro procedures
These procedures deal mainly with the effects of opioids on smooth
muscle tissues such as guinea pig ileum and mouse vas deferens
(Kosterlitz and Waterfield 1975). Tissues from naive, untreated
animals are used to assess the acute effects of opioids. The animal
is sacrificed and the smooth muscle is dissected, washed, suspended
in Tyrode's solution, and affixed to an isotonic gravity lever.
Contractions are recorded kymographically or via a force transducer.
Once stable, the tissue's normal response to electrical stimulation
is determined. The procedure is then repeated in the presence of
various concentrations of opioid agonists and mixed agonists/
antagonists in order to determine relative potencies and efficacies.
The opioid-induced attenuation of the electrically produced
contraction or twitch is blocked by naloxone and serves as the basis
for the determinations of "PA2" values (Takemori et al. 1969).
xi) Binding assays
The affinity of opioids for binding sites in the CNS can be
determined in numerous species including rat, cat, pig, and monkey.
Current procedures, based on the original work by Pert and Snyder
radiobeled (e.g, 3H) agonist 'such as etorphine (Simon et al.
(19973) Simon et al. (1973) and Terenius (1973) utilize a
or antagonist nalaxone (Pert and Snyder 1973) which is incubated
with a suspension of whole brain synaptosomes. Alternatively,
regional binding can be determined using only selected areas of the
brain in the incubation medium, or by photoaffinity labeling (Kuhar
and Uhl 1979).
For determination of relative binding affinity, the test compound is
incubated in the medium and its affinity for the binding site is
reflected by the amount of radiolabeled etorphine that is displaced.
The test compound is also studied in the presence and absence of
sodium chloride during the incubation. Sodium ions enhance the
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binding of agonists while decreasing the binding of antagonists
(Pert and Snyder 1973). This technique has been validated by the
demonstration that extreme values of a ratio of binding affinity in
the presence versus absence of sodium chloride predicts the
characteristics of pharmacologic action in the whole animal (Simon
et al. 1975; Woods et al. 1979).
2. Opioid Physical Dependence Potential
a. Tolerance to Drug Effects
The opioids exert a wide range of effects on numerous organs and
physiological systems. In theory, tolerance to morphine can be
assessed for any of its measurable actions; however, tolerance
develops to the many different effects of morphine, to different
degrees, and at different rates. Furthermore, it is not known
whether the mechanisms of tolerance development for each morphine
effect have a common basis, although this is often tacitly assumed.
Tolerance to morphine after repeated administration can be evaluated
by graded assay methods where a decrease in sensitivity to a given
dose of morphine can be measured, or by quanta1 assays that
determine the increase in the dose of morphine required to produce
an all-or-none effect. In general, chronic administration of
opioids leads to tolerance to both the depressant effects (e.g.,
analgesia, behavioral suppression, EEG effects) and the stimulant
effects (e.g., pupillary diameter, gastrointestinal motility).
However, the stimulant effects are less sensitive to the development
of tolerance. Since it appears that the degree of tolerance
developed is directly proportional to the duration of exposure to
the compound (both dose- and time-related), methods for maintaining
optimal exposure have followed two basic strategies: multiple
injections and continuous exposure.
Multiple injections of morphine have been given intraperitoneally,
subcutaneously, intravenously, and intracerebrally to produce
tolerance, although under certain conditions it is possible to
demonstrate tolerance after a single injection. In general,
however, a high degree of tolerance is attainable only after
frequent repeated injections of high doses of morphine over several
weeks. In recent years, the morphine pellet implantation procedure
(Way et al. 1969) has been widely used to produce a high degree of
tolerance and physical dependence, as well, in the mouse, rat, and
guinea pig within three days. One or more specially formulated
pellets containing 75 mg morphine base (Gibson and Tingstad 1970)
are inserted subcutaneously in the back of the animal after making a
small incision.
After implantation of the morphine pellet(s), animals exhibit the
characteristic signs of acute morphine effects. In mice this
consists of the typical Straub tail and increased motor activity
within 30 minutes after implantation of a single pellet. By 24
hours, the acute effects have subsided and the general behavior of
the morphine-implanted mice resembles that of placebo -implanted
controls. In rats, the typical acute narcotic effects are also
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observed shortly after implantation of 1 or 2 pellets. These signs
include a cataleptic state, exophthalmos, and shallow respiratory
movements (Wei and Way 1975). In the guinea pig, after implantation
of 4 morphine pellets, the animals become sedated for 24 hours and
have a decreased reaction time to a thermal stimulus when tested by
the hot-plate method. Reaction times return to normal 14 hours
after implantation. A biphasic change in body temperature and some
body weight loss were also observed during the first 2 days after
implantations (Goldstein and Schulz 1973). In all three species,
tolerance and physical dependence are maximal on the third day after
pellet implantation.
In vitro procedures are also available for studying opioid
tolerance. Tolerance development in the ilea of guinea pigs can be
induced by implanting morphine pellets subcutaneously (Goldstein and
Schulz 1973; Huidobro-Toro et al. 1978). A supplementary amount of
agonist should be added to the media to prevent abstinence when the
preparation is washed. Tolerance in vitro can also be produced in
this preparation by incubating segments of excised ileum from naive
animals with the agonist at 37OC for 1 to 4 hours (Rezvani et al.
1983); the effect is stereospecific for the active l-isomers and can
be prevented by naloxone. Development of tolerance to one opioid is
accompanied by cross-tolerance to other opioids of the same
subclass.
b. Withdrawal from Chronic Drug Administration
An abstinence syndrome is represented by a 'constellation of
behavioral signs that is peculiar to a given species. Not all the
signs will appear in one subject and certain of the signs may be
exhibited by a nondependent one. In any assessment, therefore, the
selection of the signs to be observed and their relative rank
ordering of importance are sometimes made arbitrarily. Several
dimensions can be considered, including the frequency of occurrence,
the intensity of each event, and the probability that such a sign
would occur in a given population. For example, withdrawal jumping
is a characteristic abstinence sign in the mouse (Collier et al.
1972). The mean number of jumps per mouse, the height of each jump,
and the incidence of jumping may all be used to quantify the
withdrawal behavior.
In choosing a particular sign of withdrawal for judging dependence
intensity, the possibility that experimental manipulation of the
dependent state might selectively affect only the withdrawal sign
and not the total syndrome must always be kept in mind. This
criticism can be met by using several withdrawal signs. However,
the rates of development of withdrawal signs are not always parallel
and certain intense abstinence signs may suppress the appearance of
other signs (Blasig et al. 1973).
The abrupt withdrawal syndrome is difficult to quantify because the
protracted course of abstinence requires extended observation for
several days. The slow onset and prolonged course of abrupt
morphine withdrawal have led to the increasing use of antagonist-
precipitated withdrawal for evaluating physical dependence. The
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syndrome produced by opiate antagonists, in contrast to abrupt
withdrawal, is a rapid, explosive event that condenses in a short
time period the abstinence signs of abrupt withdrawal.
Withdrawal signs that appear upon termination of chronic exposure to
an opioid fall into three basic classes: autonomic (e.g., blood
pressure, pulse, diarrhea, respiratory rate, pupil diameter, body
temperature), somatomotor (e.g., nociception, various neuromuscular
reflexes, Straub tail, convulsions), and behavioral (e.g.,
irritability, eating and drinking, sleep, degree of alertness). In
general, the autonomic signs appear first and, in the absence of
other signs, suggest a mild abstinence syndrome. The appearance of
somatomotor effects constitutes a more intense syndrome. Behavioral
Changes are observed throughout the course of withdrawal, though
they may make their initial appearance after the early autonomic
signs.
The dependence potential of opioids has been quantified in numerous
species including mice, rats, dogs, and monkeys. The procedures
most commonly used to assess withdrawal effects with opioids involve
rating autonomic signs, seizure threshold, reflexes, body weight,
body temperature, and EEG activity. Body weight in rats falls
following either abrupt or precipitated withdrawal and often amounts
to as much as 10% of the pre-withdrawal weight. Maximum changes are
noted about 1-2 hours after precipitated and 48 hours after abrupt
withdrawal (depending on half-life of the opioid). Other species
show different time courses of effect depending on pharmacokinetic
factors (Akera and Brody 1968; Wei and Way 1975). The antagonist-
induced jumping that occurs in opioid-dependent rodents can be
utilized to provide a sensitive, precise measure of one sign of
physical dependence. Utilizing as an index the dose of naloxone
(ED50) to precipitate withdrawal jumping in dependent mice, a
decrease in the naloxone ED50 over time by 70-fold has been
demonstrated as animals become increasingly dependent on morphine
after pellet implantation (Way et al. 1969).
Numerous methods have been used to maximize the animal's exposure to
opioids, and thus induce dependence. Oral administration remains a
favored route because of its ease and minimal maintenance. This is
accomplished either by gavage (Stolerman and Kumar 1970),
intragastric catheter (Lukas et al.1982), or in the drinking water
(McMillan et al. 1974). Continuous exposure to opioids has also
been accomplished by programmed intravenous injection (Weeks 1962),
intraperitoneal injection using a chronic i.p. catheter (Teiger
1974), reservoir implantation (Goode 1971), and pellet implantation
(Wei et al. 1973), with the development of miniature osmotic pumps
(e.g., Alzet) adding to the sophistication of such implantation
procedures (Wei and Loh 1976).
i) Primary physical dependence
Methods for assessing the dependence potential of morphine in rats
were developed by Akera and Brody (1968). While the procedure for
other species varies, the basic method is as follows:
evenly spaced injections should be used, but dependence can also
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easily be produced with two injections per day: 1 in the morning
and 1 in the late afternoon or evening. As tolerance to the
sedative and depressant effects develops, the maintenance dose is
increased. Once the desired dose and duration of exposure are
reached, the withdrawal syndrome can be observed either by stopping
the injections (abrupt or spontaneous withdrawal) or by injecting a
small dose of the opioid receptor antagonist, naloxone (precipitated
withdrawal). In general, spontaneous withdrawal is characterized by
slow onset (hours), relatively moderate intensity, and long duration
(hours-days) while precipitated withdrawal has a rapid onset
(minutes), relatively severe intensity, and a relatively short
duration (1-2 hours).
ii) Single dose substitution
This method was first described for opiates by Seevers (1936) and
has been modified by a number of laboratories (Yanagita 1973).
Rhesus monkeys are treated with morphine at a dose of 3.0 mg/kg,
subcutaneously four times a day. These animals are maintained on
this regimen for long periods of time and thus acquire a relatively
stable dependence upon morphine. Minimum exposure duration is 60
days. On a test day, the regularly scheduled morphine injection is
withheld until morphine abstinence signs of intermediate intensity
are present. This is typically 14 hours after injection. Then a
dose of test compound or morphine is 'given S.C. and the abstinence
scores are rated on the degree of change from pre-injection. A drug
with morphine-like dependence potential will suppress the withdrawal
signs while a drug with little or no opioid agonist activity will
not affect the progressively more intense abstinence signs. The
animals are evaluated l/2, 1, 2, and 3 hours after administration or
until they have returned to the pre-injection level. When a lower
maintenance dose of morphine (e.g., 0.3 mg/kg, s.c.) is used,
specific differences between pure agonists and mixed agonist/
antagonist analgesics can often be detected. Low-dose morphine-
induced dependence is maintained by mixed agonist antagonists, while
these compounds actually precipitate withdrawal in high-dose
morphine-maintained animals. Martin and co-workers (1974) have
established a standardized bioassay procedure for assessing the
relative potencies for suppressing morphine-abstinence signs.
3. Opioid Abuse Liability
a. Drug self-administration
Procedures for assessing self-administration of opioids have been
described using rats (Weeks 1962; Khazan et al. 1967; Moreton et al.
1976). dogs (Jones and Prada 1973), and non-human primates (Thompson
and Schuster 1964; Deneau et al. 1969; Woods 1980). Most studies
have been conducted using animals that have been prepared with an
indwelling intravenous catheter. The animals are given an injection
which is contingent upon completing a required number of lever
responses (i.e., fixed ratio) or following a single response after a
preset time interval (i.e., fixed interval). Two basic procedures
are employed: continuous or direct, and substitution. A factor
relevant to the conduct of both types of studies is whether opioid
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dependence must first be present before morphine or its surrogates
will be self-administered.
i) Continuous self-administration
In this procedure (Woods and Schuster 1968) rhesus monkeys are first
prepared with an indwelling intravenous catheter and then restrained
within a cage using an extension arm and harness system (Yanagita et
al. 1965). The availability of morphine for self-injection by lever
pressing is indicated by illuminating a small light above the lever.
The schedule is then changed to a variable interval 2.5 minutes (the
first response after an average interval of 2.5 minutes results in
drug delivery). After a period of 15 days, the drug solution is
replaced by physiologic saline. Another dose of morphine is then
tested in a similar manner. In some instances, to avoid overdose,
the maximal number of self-injections allowed is limited to four.
Using this procedure, the unit dose of 10 mg/kg/inj was observed to
maintain self-injection performance though no signs of abstinence
were observed during saline exposure. In contrast, self-injection
of higher doses resulted in a distinct abstinence syndrome when
saline was substituted for morphine.
An alternative to this procedure permits access to relatively low
doses of an opioid to determine whether drug intake increases with
duration of exposure in the self-administration paradigm. This
procedure is useful in determining whether tolerance develops to the
appetitive or aversive properties of the drug.
ii) Substitution
In this procedure, drug self-administration is initially maintained
by a standard compound (usually cocaine, morphine, or codeine), and
test doses of experimental compounds are substituted upon attainment
of stable baseline performance. As a control, the drug's vehicle or
saline is also substituted for the same duration of time in order to
monitor the extinction of drug-reinforced responding. Comparisons
can then be made between the response rates maintained by the
standard compound, saline, and the test compound (Woods 1980).
Availability of drug for self-injection is usually indicated by
illumination of a light or activation of a tone or buzzer. Upon
completion of the response requirement (usually fixed ratios of 30
or 160 responses), the standard drug is delivered via a peristaltic
or syringe pump. After stable responding for the standard drug has
been maintained, a dose of the test drug is substituted for varying
periods from 1 to 15 days. The number of self-injections and the
response rates for injection are quantified and serve as the basis
for determining abuse liability. Additional doses and test drugs
are evaluated in a similar manner.
iii) Reinforcing efficacy analysis
Extensions of the substitution procedure for evaluating the relative
abuse liability of opioids have included only a few procedures.
Response rate analysis (Woods 1980; Aigner and Balster 1979) and
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injection patterns remain the major criteria for rank-ordering
compounds with respect to their reinforcing efficacy. Yanagita et
al. (1982) using a progressive ratio procedure demonstrated that
buprenorphine maintained lower break points than pentazocine.
Choice procedures have been used to determine the relative
reinforcing efficacy of various doses of heroin (Griffiths et al.
1981). and a recent report (Mello et al. 1981) has described the use
of second order schedules to demonstrate the reinforcing properties
of buprenorphine.
iv) Tolerance and physical dependence
The relative potency of an opioid is decreased with tolerance
development (i.e., higher doses are necessary to maintain
self-injection performance), but it is not clear whether the
reinforcing properties of the drug have changed, or, alternatively,
the animals must titrate their level of dependence. Two types of
procedures are available to avoid such problems. First, drugs can
be tested in prevously opioid-dependent (but presently non-
dependent) animals to minimize any differences which may be due to
the animal's drug history (Steinfels et al. 1982). Secondly,
cocaine can be used as the standard drug so that the opioid
tolerance and/or dependence normally associated with codeine or
morphine does not develop. This consideration is important when
mixed agonist/antagonist analgesics are the test compounds, since
withdrawal may be precipitated upon substitution in an opioid-
dependent animal.
b. Drug discrimination
Procedures for assessing the discriminitive stimulus properties of
opioids have, for the most part, been developed for the rat and
monkey, but the pigeon and gerbil have also been utilized (see
reviews Holtzman 1982, 1983). Two basic methods have been employed:
shock avoidance (Shannon and Holtzman 1976) and food presentation
(Herling and Woods 1981).
In the shock avoidance procedure, animals typically must first press
a "starting" lever after which they must press the appropriate lever
on the other side of the cage in order to prevent shock delivery.
The appropriate lever is determined by whether the animal has
received a saline injection (e.g., left lever appropriate) or an
injection of the training drug - usually morphine (e.g., right lever
appropriate). The similarities in the stimulus properties of other
opioids are then tested over a wide dose range, with 90% drug-
appropriate responding usually being the accepted criterion for
discrimination.
In the food presentation paradigm, monkeys are usually maintained at
80-9096 of their free-feeding weight and then trained to press one of
two levers in order to receive a food pellet (Herling and Woods
1981; Woods et al. 1982). The response requirement is usually 20 to
30 lever presses (i.e., FR 20-30) and the appropriate lever is
determined by whether the animal has received an injection of an
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opioid (e.g., either etorphine or morphine) or saline. Training is
continued until 90% or better appropriate responding is maintained.
Using these procedures, a large number of opioids have been
characterized with respect to their discriminative stimulus
properties (Holtzman 1982; Woods et al. 1982). In order to fully
characterize the conglomerate opioid class of drugs (viz a viz, mu,
kappa, and sigma agonists and mixed agonists/antagonists), however,
it is important that the protocol includes animals that have been
trained on drugs other than the pure agonists morphine and etorphine
(e-g., cyclazocine, ethylketocyclazocine, N-allylnormetazocine). In
addition, different doses of these compounds should be used in order
to be able to characterize the full spectrum of a drug's effects
(Holtzman 1982). It is also useful to determine to what extent the
discriminative stimulus properties of these compounds can be blocked
by opioid antagonists such as naloxone or naltrexone. Finally, the
animal species utilized must be taken into account, since distinct
differences have been observed particularly between the rat, pigeon,
and monkey. Drug discrimination procedures have nonetheless been
used effectively to differentiate a number of opioids in three
classes: opioids that generalize to morphine and are antagonized by
naltrexone or naloxone; opioids that generalize to cyclazocine and
are not easily antagonized; and opioids that generalize to
cyclazocine and phencyclidine and are not antagonized (Holtzman
1982).
c. Behavioral Toxicity
To date, no procedures such as those outlined in the general
methodological section have been employed to systematically
investigate the adverse sensory or motor effects of various opioids
in animals. One study, using size selection discrimination of a
visual stimulus, showed that morphine in doses of 1-10 mg/kg
decreased reaction times in rhesus monkeys (Brown and Bass 1967).
This finding is consistent with other reports that morphine
possesses both depressant and stimulant effects which may be
dose related.
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C. Procedures for Assessing CNS Depressants: Sedative/
Hypnotics, Anesthetics, Aaxiolytics, and Antihistamines
1. Characterization of CNS Depressant Effects
a. Acute Drug Effects
i) Sleep Induction
This procedure determines the hypnotic potency of a compound in
addition to characterizing the nature of the sleep state (e.g.,
light, intermediate, deep). Typically, the fasted mouse is used and
the compound is administered orally, although other species and
routes may be employed. The procedure described by Gruber et al.
(1944) initially begins testing with a dose empirically derived
during pilot studies. If sleep is produced, as evidenced by loss of
righting reflex, a series of decreasing doses is given (ten
different mice per dose) and the ED50 is determined. Additional
data obtained include the onset and duration of sleep (from the loss
to return of the righting reflex) and the duration of symptoms
following hypnosis.
An extension of this procedure may be used to identify compounds
that prolong or potentiate the sleep time of a test compound. Two
groups of fasted mice are used; one group receives 10% of the ED50
dose (determined as above) of a compound identified as a sedative
and the other group receives vehicle. Thirty minutes later both
groups receive pentobarbital sodium at a dose of 6 mg/kg i.p.,and
the onset and duration of hypnosis are observed and comparisons are
made between the two groups.
ii) Spontaneous Locomotor Activity
The procedures described in the general methods section above are
most commonly used to assess the pharmacological activity of these
compounds which decrease spontaneous locomotor activity in a
dose-related manner. No distinction between compounds within the
depressant class can be made using this test, though differences in
duration of action can be detected.
iii) Electroencephalographic (EEG) Activity
Using the procedures outlined in the general methods section above,
CNS depressants have been shown to induce characteristic shifts in
the power of various frequency bands. These shifts have basically
consisted of an increase in the overall power, with the greatest
increase occurring in the 8-13 and 13-25 Hz bands (Gehrmann and
Killam 1976). This contrasts with the narcotics which typically
increase power in the O-4 Hz band (Lukas et al. 1980). Using this
procedure, various compounds including barbiturates,
benzodiazepines, and other depressants have been classified and
compared with respect to the particular shifts in power and
predominant frequency after their administration (Gehrmann and
Killam 1976, 1978; Joy et al. 1971; Schallek and Johnson 1976;
Schallek et al. 1967). Benzodiazepines have a characteristic EEG
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effect and change the sleep-wakefulness cycles and continuum.
Further, one can couple behavioral effects with EEG changes
(Gehrmann and Killam 1975).
iv) Behavioral Performance
While numerous operant paradigms have been employed to study the
depressant effects of these compounds (e.g., ratio or interval
schedule responding for a reinforcer such as food or water), the
most widely used method for studying the anxiolytic effects of CNS
depressants, particularly the sedative/hypnotics, is the conflict
procedure. First introduced by Geller and Seifter (1960), the model
was further developed and refined (Cook and Davidson 1973) and
subsequently validated by Cook and Sepinwall (1975) as a predictor
of anxiolytic effects. This validation was based upon the good
correlation between the relative potencies of numerous clinically
effective anxiolytic agents (e.g., diazepam, oxazepam,
chlordiazepoxide, phenobarbital, amobarbital, and meprobamate) and
their attenuation of punishment effects upon operant responding.
Basically, the procedure involves imposing a punishment (usually
electric foot shock) contingency upon a stable performance baseline
(usually a variable interval schedule for food). The schedules can
be either alternating or concurrent, with better separation of
performance obtained using the latter. The introduction of shock
suppresses responding for food, and the administration of a minor
tranquilizer attenuates the suppressive effects of the shock. Thus,
responding during shock is actually increased after treatment with a
benzodiazepine or a barbiturate; this selective effect is typically
observed at doses which have little or no effect on non-punished
responding (e.g., Cook and Sepinwall 1975). This procedure appears
to be relatively specific for sedative/hypnotics, while major
tranquilizers (e.g., chlorpromazine), stimulants (e.g.,
amphetamine), antihistamines (e.g., diphenhydramine).
anticonvulsants (e.g., phenytoin), and opioid analgesics (e.g.,
morphine) lack significant effect. The procedure does not, however,
discriminate between the barbiturates, ethanol, and the
benzodiazepines.
v) Binding Assays
While the specific mechanism of action of CNS depressants has not
been completely elucidated, one common feature is that they appear
to interact with gamma-aminobutyric acid (GABA). Currently, no
specific neuronal sites have been shown to bind selectively to
barbiturates. However, they have been shown to increase GABA
activity in a number of in vitro preparations (Eccles et. al. 1971;
Nicoll 1978) and more recently, both anesthetic and convulsant
barbiturates enhance GABA binding to rat brain synaptosomes (Willow
and Johnston 1981).
In contrast, a receptor that specifically binds' benzodiazepines has
been identified (Squires and Braestrup 1977; Mohler and Okada 1977)
and it has been shown that the binding of GABA to its receptor is
enhanced in the presence of benzodiazepines (Haefely 1977).
Furthermore, validation of the benzodiazepine binding assay has been
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provided by a number of studies (Braestrup and Squires 1978; Mohler
et. al. 1978) in which the affinities of benzodiazepines for the
binding site correlate well with their pharmacological activities
and clinical potencies.
Essentially, the procedure for assessing the affinity of test
substances for the benzodiazepine receptor is conducted using
tritiated diazepam or flurazepam. Appropriate neuronal tissues are
incubated with the radiolabeled ligand, and various concentrations of
the test compound are added. The relative binding affinity of the
test compound is directly related to the amount of labeled diazepam
(or flurazepam) that is displaced. Displacement of the labeled
compound is indicated by a decrease in the disintegrations per unit
time emitted from the tissue after washing.
The discovery of these specific binding sites has led to the search
for an endogenous anxiolytic ligand. Historically, numerous
compounds (e.g., the beta carbolines) have been suggested as likely
candidates, but no convincing evidence exists to date as to the
existence or identity of this substance. A more recent finding that
the benzodiazepine derivative, ethyl-8-fluoro-5,6-dihydro-5-methyl-
6-oxo-4H-imidazo[1,5a][l,4]benzodiazepine-3-carboxylate (Ro 15-1788)
can bind to the receptor and block numerous pharmacological effects
of benzodiazepines (Hunkeler et al. 1981; Darragh et al. 1981;
Mohler et al. 1981; Polc et al. 1981), however, 'provides a unique
and potentially powerful tool for investigating the acute effects of
benzodiazepines and, ultimately, for characterizing the withdrawal
syndrome (Lukas and Griffiths 1982).
2. CNS Depressant Physical Dependence Potential
a. Tolerance to Drug Effects
Sedation is the, primary pharmacological effect of this class of
compounds. Upon repeated exposure to a standard dose, tolerance
develops as seen by an attenuation of the degree and duration of CNS
depression. According to Kalant et al. (1971), tolerance may be
dispositional or functional. The former is primarily due to an
increased rate of drug metabolism and elimination from the body
while the latter refers to a diminished sensitivity of the CNS. The
extent to which each mechanism contributes to the overall observed
degree of tolerance is unclear. For some drugs, at least,
information on the relative contribution of these factors can be
obtained by conducting pharmacokinetic studies in conjunction with
the pharmacological assays. Thus, drug disappearance curves could
be constructed that would match (or in some cases, not match) the
time-effect curves. While dispositional tolerance may be relatively
important when assessing pentobarbital (see review, Conney 1967), it
cannot account for both the tolerance developed to barbital (which
is only slightly metabolized) and the development of tolerance after
intraventricular administration (Stolman and Loh 1975; Lyness et al.
1979). By employing a "maximally tolerable dose" technique, Okamoto
and co-workers (1975) have been able to separate the two components
of barbiturate tolerance. Essentially, they demonstrated that
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dispositional tolerance develops very quickly while functional
tolerance develops more gradually.
The degree of tolerance that can be attained is directly related to
the time intervals between exposures to the drug (Gruber and Keyser
1946). Numerous techniques have been employed to maximize the
exposure of the CNS to depressant drug, including: continual
parenteral administration of barbiturates (Kato et al. l964), adding
barbiturates to the drinking water (Crossland and Leonard 1963) or
to food (Belknap et al. 1973). implantation of a barbiturate pellet
(Ho et al. 1975), or delivery of a barbiturate via a subcutaneously
implanted miniature osmotic pump (Siew and Goldstein 1978).
Whichever method is used, it is apparent that tolerance develops to
the mild behavioral effects (e.g., loss of fine motor control, mild
ataxia) of barbiturates but not to the lethal effects (see Okamoto
and Boisse 1981). Thus, as tolerance develops to a CNS depressant,
the therapeutic index decreases.
Numerous animal species have been used to study barbiturate
tolerance and graded rating scales for CNS depression have been
developed and utilized in the rhesus monkey (Yanagita and Takahashi
1970) and the cat (Okamoto et al. 1975). The effects most often
studied include: ataxia. decreased locomotion, decreased
respiratory rate, impaired righting reflex, and changes in cornea1
and linguomandibular reflexes and nictitating membrane tone.
Regardless of the response -studied. it is important that studies of
tolerance include: appropriate dosing schedules and route of
administration, full dose-response evaluations, and appropriate
controls to account for order effects. In addition, measures of
cross-tolerance to another drug within the same class as well as in
a different class are extremely important in characterizing the
overall profile of a drug.
b. Withdrawal from Chronic Drug Administration
Withdrawal from chronic administration of numerous sedative/
hypnotics has been assessed in various animal species including mice
(Ho 1976), cats (Okamoto et al. 1975), dogs (Deneau and Weiss 1968).
and monkeys (Yanagita and Takahashi 1973). While. species
variability generally exists, the sedative/hypnotic abstinence
syndrome is basically characterized by gross behavioral
manifestations which include anorexia, hyperirritability, tremors,
and convulsions. These signs have been grouped into three levels of
withdrawal: Mild - hyperirritability, mild tremor, anorexia,
piloerection; Intermediate - aggravated tremor, muscle rigidity,
impaired motor activities, retching or vomiting, weight loss (10%);
Severe - convulsions, hallucinatory behavior, nystagmus,
unresponsiveness to environmental stimulation, hyperthermia,
morbidity, and mortality.
Another technique that has been utilized to quantify barbiturate
dependence potential is seizure susceptibility. During barbiturate
withdrawal a decrease in seizure threshold has been observed after
the administration of pentylenetetrazol (Jaffe and Sharpless 1965).
and bemegride and picrotoxin (Crossland and Turnbull 1972).
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Barbiturate withdrawal has also been assessed using audiogenic
seizures (Crossland and Turnbull 1972; Gates and Chen 1974) and
flurothyl-induced seizures (Greer and Alpern 1976). Kindled
seizures can also be used for this purpose. Alcohol withdrawal has
been shown to increase the susceptibility to seizures in animals
with previously kindled epileptic foci in the amygdala (Pine1 et al.
1975, 1978).
i) Primary Physical Dependence
Nethods for assessing the dependence potential of barbital in naive
dogs were developed by Seevers and Tatum (1931) and later extended
by Fraser and Isbell (1954). The production of primary dependence
on sedative-hypnotic drugs is directly related to the dose, dosing
interval, duration of treatment, and the route of administration.
Typically, 100 mg/kg of barbital sodium in 4 divided doses is given
orally for 60-90 days. It is sometimes necessary to initiate
treatment with lower doses and gradually increase the dose as
tolerance develops. When comparisons between different drugs are to
be made, it is important that the dosing schedules are adjusted such
that the pharmacological effects of the drugs are equivalent' (e.g.,
see Okamoto et al. 1975). Quantitative measures of withdrawal signs
are equally important when attempting to compare the dependence
potential of numerous compounds. In this regard, the method of
Jones and co-workers (1976), which describes a bioassay for sedative
dependence potential, appears to be the most sophisticated and
perhaps the best validated system to date.
In general, comparative studies indicate that the use of monkeys and
carnivores provides clearer and more profound withdrawal effects,
but that rodents offer the advantage of being cost effective. This
is especially true during preliminary screening procedures where a
large number of experimental subjects is required. Historically,
the assessment of the dependence potential of a compound required
that exposure to the drug be terminated. The recent discovery of
the specific benzodiazepine receptor antagonist (Ro 15-1788), that
can block numeruds pharmacological effects of the benzodiazepines
(Hunkeler et al. 1981; Darragh et al. 1981; Mohler et al. 1981; Pole
et al. 1981), has provided a unique and potentially powerful tool for
studying the benzodiazepine withdrawal syndrome.
Administration of Ro 15-1788 to baboons that had been treated with
diazepam (20 mg/kg/day) via an intragastric catheter for only 7 days
produced numerous signs of withdrawal including bruxism, nose
rubbing, retching and vomiting, abnormal body postures, tremors and
convulsions (Lukas and Griffiths 1982). The withdrawal signs were
more frequent and of greater intensity when the duration of diazepam
exposure was increased to 35 days. Furthermore, when compared with
spontaneous withdrawal from diazepam, the Ro 15-1788 precipitated
abstinence syndrome was characterized by a relatively rapid onset
(i.e., 7-10 minutes), intense signs, and short duration (i.e., 4-8
hours). In contrast, spontaneous withdrawal (obtained by simply
stopping the diazepam) was characterized by a slow onset (i.e., 5-7
days), relatively milder signs, and a long duration (i.e., 8-13
days). Ro 15-1788 has also been used to precipitate withdrawal
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signs in benzodiazepine-treated mice, rats, cats, and squirrel
monkeys (Rosenberg and Chiu 1982; Cumin et al. 1982; McNicholas and
Martin 1982).
ii) Single Dose Substitution
This method was first described by Deneau and Weiss (1968) and
involved the administration of barbital sodium (100 mg/kg/day) to
dogs for periods of up to 2 years. The termination of drug resulted
in the appearance of withdrawal signs, the severity of which was
assessed using an objective point-scoring system. A test compound
was then administered (at a dose previously determined during pilot,
acute studies) for 5 consecutive days and its effectiveness in
reversing the withdrawal signs was determined. A total of twelve
compounds were evaluated in this manner and all except glutethimide
were found to completely substitute for barbital. After the 5-day
substitution period, the test compound was withheld and the
abstinence signs were  quantified. Similar methods have been
developed for the monkey (Yanagita and Takahashi 1973), cat (Okamoto
et al. 1975), and rat (Essig 1966). More recently, Jones et al.
(1976) have developed a quantitative bioassay for comparing the
dependence potential of various CNS depressants in the dog. In
order to effectively compare the dependence potential of various
compounds, it is necessary to incorporate procedures which ensure
that the drugs are functionally equivalent; two drugs are
functionally equivalent only if they produce the same peak,
residual, and total degree of CNS depression.
3. CNS Depressant Abuse Liability
a. Drug Self-Administration
Procedures for assessing self-administration of sedative/hypnotics
have been described using rats (Walton and Deutsch 1978), and
non-human primates (Yanagita and Takahashi 1970, 1973; Griffiths et
al. 1981). While the intravenous route has been employed most
often, the development of other methods including intragastric
(Yanagita and Takahashi 1973) and oral (Ator and Griffiths 1983)
self-administration has recently been reported. Drug injections are
usually contingent upon completion of a fixed number of responses on
a lever (i.e., fixed ratio schedules), but interval and second-order
schedules have also been used effectively. Two basic procedures are
employed: continuous or direct, and substitution.
i) Continuous self-administration
In this procedure (e.g., Yanagita 1976) the intravenous route is
preferred as long as solubility characteristics permit. The
subjects (usually monkeys) are first given the opportunity to
self-inject the drug vehicle alone, and once low and stable response
rates are achieved, a dose of the compound to be tested replaces the
vehicle at one-quarter to one-half the minimal effective dose (as
determined during the acute studies) for 2 to 4 weeks. If, at the
end of this period, the animal still has not increased its rate of
responding, then an automatic injection schedule is superimposed on
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the self-injection schedule for 2 more weeks. Response rates and
daily self-injections are monitored during this period. Then the
automatic injections are terminated and the self-injection unit dose
is decreased by one-half to one-fourth to determine whether response
rates increase. Finally, the subject is again exposed to 'the
vehicle alone while response extinction is characterized and the
subject is observed for possible withdrawal signs. Using this
procedure, pentobarbital and alcohol were reported to be self-
administered at moderate rates while diazepam, chlordiazepoxide, and
oxazepam were self-injected at lower rates (Deneau et al. 1969;
Yanagita and Takahashi 1973; Yanagita 1976).
ii) Substitution
In this procedure, drug self-administration is initially maintained
by a compound known to reinforce self-injections (e.g., cocaine,
codeine) and test doses of experimental compounds are substituted
upon a stable baseline performance. As another control, saline or
the drug vehicle is also substituted in order to assess extinction
as well as to serve as a measure of the animal's operant level of
responding. Comparisons are then made between self-injection rates
following saline substitution and substitution of an appropriate
range of doses of the test compound.
While the number of responses required for drug- delivery in the
continuous procedure is usually only one, larger numbers (e.g., 30,
160) are typically employed in substitution procedures. In
addition, the opportunity to self-inject a compound is usually
limited either by programming brief sessions (Schuster and Thompson
1969) or by imposing time-out periods between drug injections
(Griffiths et al. 1981) as compared to ad libitum availability in
the continuous self-administration procedure. This latter procedure
tends to reduce the confounding effects of previous drug injections
upon operant behavior, and thus provides a more reliable measure of
the extent to which the "drug-seeking" performance is maintained by
the reinforcing properties of the drug per se.
Using the substitution procedure and cocaine (0.32 mg/kg/injection)
as a baseline drug (fixed ratio 160 schedule of reinforcement and a
3-hour time-out after each drug self-injection); Griffiths et al.
(1981) showed that the three barbiturates secobarbital.
pentobarbital, and amobarbital all maintained rates of responding
that were comparable to those maintained by cocaine. In addition,
numerous benzodiazepines (e.g., diazepam, clonazepam, chlorazepate,
flurazepam, and medazepam) sustained rates of responding that were
higher than vehicle control, but lower than those of cocaine.
iii) Intragastric, oral, and inhalation
self-administration
Yanagita and Takahashi (1973) reported that rhesus monkeys self-
administered pentobarbital and alcohol via an intragastric catheter,
though lever pressing rates were not as high as when the compounds
were given intravenously. In this same study, intragastrically
delivered diazepam maintained more robust self-administration than
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either chlordiazepoxide or oxazepam. Using a similar procedure
Altshuler et al. (1975) found that rhesus monkeys would self-
administer chlordiazepoxide intragastrically, but not diazepam.
Gotestam (1973) and Davis et al. (1978) reported that
intragastrically administered medazepam and chlordiazepoxide,
respectively, were reinforcing to rats while Walton and Deutsch
(1978) found no evidence for intragastric or oral self-
administration of diazepam.
The difficulty with intragastric self-administration studies appears
to reside in factors relating to drug delivery. Typically,
absorption from the stomach is relatively slow, and previous studies
by Stretch et al. (1976) have shown that response rates for cocaine
self-injection decrease when the delivery of the drug is delayed
after completing the operant task. Thus, the onset of drug effect
may in fact be anywhere from 5-30 minutes (depending on the drug)
after the injection. Controlled fasting prior to test sessions (to
maximize drug absorption) and appropriate stimuli associated with
drug delivery may 'facilitate intragastric self-administration, and
the use of second order schedules may prove helpful.
Because of taste and volume factors associated with drug solutions,
it has been difficult to conduct oral self-administration studies
(Wolf et al. 1978). Forced consumption of chlordiazepoxide in rats
has been accomplished by making the drug solution the only source of
fluid (Harris et al. 1968; Kamano and Arp 1965). This procedure,
however, has not been effective in inducing higher intake of
chlordiazepoxide during testing. An alternative procedure employs a
schedule in order to induce high fluid intake (Falk et al. 1972;
Sanger and Blackman 1978). This paradigm (schedule-induced
polydipsia) has been used to enhance chlordiazepoxide consumption in
rats (Sanger 1977) and ethanol (Henningfield et al. 1981) and
methohexital (Ator and Griffiths 1983) in primates.. During a 3-hour
session in which water was available via a drinking spout, the
entire daily ration of food biscuits was delivered at the end of the
first hour in the study by Ator and Griffiths (1983). This
procedure induced a large increase in drinking during the remaining
2 hours. Then, on subsequent days, increasing concentrations of
methohexital were substituted in place of the water. At a
methohexital concentration of 0.8 mg/ml, the volume consumed in the
first hour of the session (before food delivery) typically exceeded
30% of the session total and overt behavioral effects (e.g., ataxia)
were observed. Drinking and drug intake remained at high levels
after the food-inducing procedure was discontinued and food was made
available at the end of the session.
Administration of CNS depressants via inhalation as a means of
assessing abuse liability has been studied only in the rhesus monkey
(Yanagita et al. 1969). The subjects were fitted with an intranasal
catheter which provided a means by which lacquer thinner fumes could
be forced into the lungs by compressed air. The animals pressed a
lever, received a Z-minute exposure. to chloroform or ether, or 5
minutes of lacquer thinner. Goldstein (1972) has also used the
inhalation route to render mice tolerant and dependent upon ethyl
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alcohol, but the procedure has not, as yet, been employed routinely
as a self-administration paradigm.
iv) Reinforcing efficacy analysis
Extensions of the substitution procedure for evaluating relative
sedative/hypnotic abuse liability have involved the application of
numerous procedures including progressive ratio performance (Brady
et al. 1975; Yanagita 1976). response rate analysis (Griffiths et
al. 1981), concurrent or choice schedules (Findley et al. 1972), and
second order schedules (Kelleher 1975). Two basic findings have
evolved from these studies. First, barbiturates appear to maintain
higher levels of performance than benzodiazepines, though not enough
comparative data is available to rank-order depressants belonging to
other pharmacological classes. Secondly, compounds with short
durations of action appear to have a greater reinforcing efficacy
than their longer-acting analogues.
v) Tolerance and physical dependence
There is little or no data available on the effects of tolerance and
dependence on the reinforcing efficacy of CNS depressants,
hypnotics, or anxiolytics, nor on the effects of a prior history of
dependence in this regard. Griffiths et al. (1981) have reported,
however, that there was no difference in the benzodiazepine-
maintained self-administration performance of baboons before and
after barbiturate self-administration.
b. Drug Discrimination
Procedures for assessing the discriminative stimulus properties of
sedative/hypnotics have been described in pigeons (Herling et al.
1980), gerbils (Jarbe and Holmgren 1977), rats (Overton 1979). and
primates (Ator and Griffiths 1982; Winger and Herling 1982). The
most frequently used procedures in rodents have involved either a
T-maze (e.g., turn left if drugged; turn right if not drugged) or a
two-lever choice situation (e.g., left lever produces food or
terminates shock if drugged; right lever produces food or terminates
shock if not drugged).
The stimulus properties of benzodiazepines have been studied by
Overton (1982) with animals trained to discriminate a number of
benzodiazepines from saline (e.g., chlordiazepoxide, diazepam,
flurazepam, oxazepam). When compared under similar conditions,
training progresses more quickly with barbiturates than with
benzodiazepines. Compared to several other drug classes
(stimulants, hallucinogens, antipsychotics), however, the
benzodiazepines appear more discriminable. If, however, other drugs
are substituted in chlordiazepoxide-trained animals, generalization
(i.e., increased probability of drug-appropriate responses) is
observed for all other benzodiazepines, most other sedative/
hypnotics, but not for neuroleptics. indicating at least some
specificity of effect (Colpaert et al. 1976; Barry and Krinuner
1978).
56
Although pentobarbital- and ethanol-trained animals generalize to
benzodiazepines (but not to stimulants, opioids, or hallucinogens)
animals can be trained to discriminate chlordiazepoxide from
pentobarbital (Barry and Krimmer 1978). A certain asymmetry in
cross-generalization has been noted in that generalization from a
benzodiazepine to a barbiturate has not been demonstrated as
reliably as generalization from a barbiturate to a benzodiazepine.
For example, baboons trained to discriminate pentobarbital from drug
vehicle showed generalization to lorazepam, but not all baboons
trained to discriminate lorazepam showed generalization to
pentobarbital (Ator and Griffiths 1983). These same investigators
have reported that a specific benzodiazepine receptor antagonist, Ro
15-1788, completely blocked the discriminative stimulus effects of
lorazepam but not of pentobarbital. Similarly, Herling and Shannon
(1982) showed that Ro 15-1788 blocked the discriminative stimulus
effects of diazepam but not of pentobarbital.
c. Behavioral Toxicity
Procedures for assessing the acute effects of sedative/hypnotic
compounds on psychophysical processes (i.e., auditory and visual
thresholds and reaction times) have been developed over the past two
decades. Data provided to date suggests that only studies using
primates are sensitive enough to effectively and completely evaluate
the sensory-motor effects of psychotropic drugs. It has been
reported, for example, that barbiturates impair the processing and
interpretation of sensory input (Pragay and Mirsky 1973; Bartus and
Johnson 1977). Rhesus monkeys treated with pentobarbital show a
dose-dependent decrease in correct responding to tachistoscopically
presented stimuli as a function of systematic reductions in stimulus
exposure time. More recently, Hienz et al. (1981) demonstrated that
pentobarbital produces changes in absolute visual thresholds which
may account for the apparent impairment of information processing.
Baboons housed in individual cages and maintained on a 22-hour
restricted feeding schedule were trained to press a lever and hold
it depressed for varying intervals until presentation of a light
flash or tone burst. Correct responding (defined as release of the
lever within 1.5 seconds of stimulus presentation) was rewarded with
a banana flavored food pellet. A l-second intertrial interval (ITI)
was then imposed during which no stimuli were presented and
additional lever presses reinstated the ITI. Experimental sessions
were conducted daily over a 2-3 hour period.
Auditory and visual thresholds were determined by randomly varying
the intensity of the test stimuli from trial to trial and examining
the number of correct lever releases. Using this procedure, 4 to 5
separate measures of threshold and reaction times were obtained,
each of which was based upon 140 trials. In this manner, the time
course of drug effects was also measured. Pentobarbital produced
consistent, dose-related increases in visual thresholds with a
corresponding increase in both visual and auditory reaction time
(Hienz et al. 1981). Over the same dose range, however, no effects
were observed for auditory thresholds, suggesting a specificity in
pentobarbital's psychophysical profile. In contrast,
benzodiazepines such as diazepam produced increases in both auditory
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and visual thresholds which, unlike the effects of pentobarbital,
persisted for several days after injection. This procedure has also
been used to assess the effects of long-term administration of
benzodiazepines to determine whether tolerance develops to these
effects, and whether terminating extended benzodiazepine treatment
affects sensory-motor processes.
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D. Procedures for Assessing CNS Stimulants: Anorectics, Local
Anesthetics, and Antidepressants
1. Characterization of CNS Stimulant Effects
a. Acute Drug Effects
i) Spontaneous locomotor activity
The administration of CNS stimulants in relatively low doses
generally results in an alerting response accompanied by an increase
in locomotor activity and associated behaviors (e.g.. exploration,
grooming, and rearing). This effect is dose dependent in the low
dose range. After higher doses a different spectrum of effects
emerges; stereotypic head-bobbing, gnawing, sniffing, and licking
prevail with little or no increase in locomotion.
The procedures described in the general methods section above are
most commonly used to assess the pharmacological activity of these
compounds. Although the precise mechanisms underlying these actions
may differ for various CNS stimulants, all presumably have the
common effect of increasing activity of neuronal catecholaminergic
systems. Present evidence indicates that the increased locomotor
activity is mediated by both noradrenergic and dopaminergic systems,
while stereotypy is mediated by dopaminergic systems only (Lewander
1977).
ii) Electroencephalographic (EEG) activity
Using the procedures outlined in the general methods section above,
CNS stimulants have been shown to induce characteristic changes in
the EEG. These effects have been studied using two basic
procedures: acute EEG effects, and sleep-awake profiles.
Relatively large doses of amphetamine cause cortical EEG desynchrony
in conscious cats (Bradley and Elkes 1957) correlated with an alert
and excitable behavioral state. Similar results were reported in
the dog (Schallek and Walz 1953). A variant of this acute procedure
involves the use of amphetamine to alter (e.g., reverse) the EEG
effects of CNS depressant. Using this approach, Schallek et al.
(1967) demonstrated that d-amphetamine abolished the pentobarbital-
induced peak in the 8-14 Hz band and reduced the amplitude.
The assessment of changes in the EEG sleep-awake cycle requires a
much slower recording speed and, usually, a concurrent measure of
muscle activity in order to identify the various states of alert,
resting, drowsy, slow-wave sleep, and rapid-eye-movement (REM)
sleep. Nicotine's transient alerting effects have been documented
in the cat (Domino 1979) using this approach.
iii) Behavioral performance
Numerous operant paradigms have been employed to study the effects
of CNS stimulants. These include performance maintained
appetitively on ratio and interval schedules as well as aversively
maintained shock avoidance responses. One of the general
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principles which has emerged from this research is that the effect
of CNS stimulants on operant performance is dependent upon the
ongoing rate of responding. Under a wide variety of experimental
conditions, it has been demonstrated that CNS stimulants increase
low baseline response rates and decrease high baseline response
rates (Sanger and Blackman 1976). The rate dependency analysis of
the actions of CNS stimulant drugs has recently been extended to
behaviors other than schedule-controlled operants (Dews and Wenger
1977), demonstrating that this principle has wide applicability
across a variety of conditioned and unconditioned behaviors in a
variety of species.
iv) Anorexia
While numerous procedures have been employed to assess the appetite-
suppressive effects of drugs, the method of Randall et al. (1960)
serves as the standard. Groups of six rats are fasted for 18 hours
but receive water ad libitum. Consumption of a weighed amount of
dry food is then measured over any desired time period (e.g., 4
hours) following injection of saline or of various doses of the test
compound. The potency of the test compound is expressed as the
anorexic dose 50% (AD50) which reduces food consumption by 50%.
Alternatively, anorexic effects can be measured by monitoring an
animal's free feeding behavior using operant techniques. With
nonfasted baboons controlling their food consumption by depressing a
lever for delivery of a 1 g pellet, the relative potency of various
amphetamine analogues has been compared on the basis of the degree
of suppression of the lever-pressing response (Griffiths et al.
1979).
v) Intracranial electrical self-stimulation
Rats are surgically implanted with electrodes in discrete brain
regions (e.g., lateral hypothalamus, medial forebrain bundle) and
then subsequently allowed to depress a lever which delivers constant
current stimulation in 0.5 second trains of a 60 Hz sine wave after
each response. Once stable intermediate response rates are achieved
by adjusting the electrical stimulation parameters, the effects of
various drugs are studied. Drugs are given via an intravenous
catheter during the experiment or via i.p., s.c., or i.m. injection
just prior to session onset. Typically, CNS stimulants such as
amphetamine increase the rate of self-stimulation, presumably by
facilitating the effects of stimulation-induced release of
norepinephrine (Ritter and Stein 1973), though recent experiments
employing discrete brain lesions cast doubt on norepinephrine's role
(Phillips et al. 1977) and suggest that dopamine may be more
important (Hollister et al. 1974).
2. CNS Stimulant Physical Dependence Potential
a. Tolerance to Drug Effects
Tolerance develops to some of the physiological and behavioral
actions of CNS stimulant drugs. For example, tolerance develops to
the anorexigenic actions of these drugs and cross-tolerance between
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certain members of this class has been demonstrated (Woolverton et
al. 1978). Acute tolerance or tachyphylaxis is prevalent with
indirect-acting stimulants (e.g., those that cause the release of
endogenous catecholamines - such as amphetamine), but direct-acting
agents usually are not subject to this phenomenon. The general
methods described in previous sections apply to the assessment of
tolerance to CNS stimulants as well. Tolerance does not seem to
develop to the reinforcing effects of CNS stimulants, however, thus
playing little or no role in the assessment of the abuse liability
of CNS stimulants.
b. Withdrawal from Chronic Drug Administration
A number of investigators have reported the occurrence of withdrawal
effects when repeated administration of amphetamine is abruptly
terminated. The withdrawal profile consists primarily of
non-specific sedation or reduced motor activity (Lewander 1977).
The occurrence of such withdrawal signs has not been used as a
defining characteristic of dependence potential with CNS stimulants
primarily because of a lack of systematic and valid evaluation
procedures. Furthermore, no procedures have been developed to
classify drugs on the basis of their ability to substitute for
amphetamines and prevent the occurrence of the abstinence syndrome.
3. CNS Stimulant Abuse Liability
a. Drug Self-Administration
Procedures for assessing self-administration of CNS stimulants have
been described using rats (Pickens and Thompson 1968; Gotestam and
Andersson 1975), cats (Balster et al. 1976), dogs (Risner and Jones
1976). and primates (Deneau et al. 1969; Balster and Schuster 1973;
Griffiths et al. 1976; Johanson et al. 1976). Though the
intravenous route has been most commonly used, self-administration
has been reported to occur via the intragastric (Altshuler and
Phillips 1977), oral (Magour et al.
al. 1976) routes.
1976), and inhalation (Siegel et
i) Continuous self-administration
Procedures for continuous self-administration have been described in
detail elsewhere, in the general methods section above. Because
animals generally fail to titrate their intake of CNS stimulants
resulting in toxic overdoses (Johanson et al. 1976), continuous
self-administration techniques are generally employed within the
context of time- or dose-limited paradigms (e.g., Gotestam and
Andersson 1975; Risner and Jones 1976).
ii) Substitution
Procedures for the assessment of the abuse liability of CNS
stimulants using the substitution/limited access method have been
described in the general methods section above. Cocaine has most
often served as the baseline drug,
been used.
although amphetamine has also
Using cocaine as the baseline drug and a 3-hour timeout
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period after each ingestion, Griffiths et al. (1976) compared the
selfiadministration of eight phenylethylamines in the baboon. A
cyclic pattern of self-administration emerged over the 15-day
substitution period in which 2-4 consecutive days of high intake
were followed by 2-3 days of low intake.
iii) Reinforcing efficacy analysis
Extensions of the limited access and substitution procedures for
evaluating relative CNS stimulant abuse liability have involved the
application of numerous procedures including progressive ratio
performance (Griffiths et al 1978; Risner and Silcox 1981), bioassay
(Risner and Jones 1975, 1980), rates of response (Balster and
Schuster 1973). and discrete-trial choice (Brady and Griffiths 1977;
Johanson and Schuster 1975). In general, the results have confirmed
the sensitivity of these methods to detect differences between the
various CNS stimulants with respect to their reinforcing efficacy,
with cocaine—revealed as one of the most potent, efficacious
reinforcers —serving as the standard for comparison.
b. Drug Discrimination
Procedures for assessing the discriminative stimulus properties of
CNS stimulants have been established in a number of animal species
(Schuster and Balster 1977; La1 1977). Rats learned to discriminate
between injection of d,l-amphetamine and saline, and in addition,
generalization was obtained with methylphenidate but not with
atropine (Harris and Balster 1971). In a subsequent study,
d-amphetamine-trained rats generalized to l-amphetamine, but not to
nicotine, mescaline, fenfluramine, or LSD (Schechter and Rosecrans
1973). Additional evidence for the specificity of these procedures
has been provided by Overton and collegues (Overton 1966; Overton
and Lebman 1973), who demonstrated that animals trained to respond to
sedative/hypnotics responded to amphetamine as if it were saline
(i.e., no cross-generalization between drug classes was observed).
Similarly, generalization between d-amphetamine and cocaine has been
demonstrated in the rhesus monkey (Ando and Yanagita 1978).
c. Behavioral toxicity
Procedures for assessing the behavioral toxicity of CNS stimulants
have been refined for use in squirrel and rhesus monkeys, baboons,
and pigeons. Methamphetamine impairs pigeon's performance in visual
discrimination tasks (Dews 1955), while d-amphetamine decreases the
accuracy of visual stimulus duration discriminations in this same
species (Stubbs and Thomas 1974). In both rhesus monkeys (Brown and
Bass 1967) and baboons (Hienz and Brady 1981) d-amphetamine
decreases reaction times to visual and auditory stimuli. This
effect is dose-dependent, however, with increases in reaction time
predominating after higher doses. The decreased reaction times
following d-amphetamine occur in the absence of changes in size
discrimination thresholds (Brown and Bass 1967) or brightness
discrimination (Thurmond 1965) in the monkey. In the squirrel
monkey, however, d-amphetamine and methylphenidate produce modest
increases in masked auditory thresholds (Delay et al. 1979).
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E. Procedures for Assessing Cannabinoids
1. Characterization of Cannabinoid Effects
a. Acute Drug Effects
i) Spontaneous locomotor activity
In general, administration of cannabinoids results in decreased
motor activity over a wide dosage range. Most studies have been
conducted in rats and have used the interruption of photoelectric
beams (Kubena and Barry 1970; Brown 1972). the time to leave a
platform (Cohn et al. 1972), exploration of a shuttle box
(Hendrikson and Jarbe 1971), or merely gross observation (Phillips
et al. 1972) as measures of activity. Mice (Holtzman et al. 1969),
gerbils (Grunfeld and Edery 1969), chickens (Abel et al. 1972). and
dogs (Grunfeld and Edery 1969) have also been the subjects of
studies on the motor effects of cannabinoids.
Davis et al. (1972) demonstrated a biphasic effect of
delta-9-THC in rats over a ten-day period of dosing. Both
excitation (on first two days) and depression (third through the
tenth days) were observed using the photoelectric method of
monitoring locomotor activity. In a study by Hardman et al. (1971)
using dogs and monkeys as subjects, a number of THC analogues were
studied and two were found to decrease activity at low doses (e.g.,
0.1-0.2 mg/kg, i.m.). But high doses induced a biphasic response
characterized by initial CNS stimulation followed by prolonged
depression.
al. (1968).
This finding was confirmed for monkeys by Scheckel et
ii) Analgesic activity
Several laboratories have studied the antinociceptive effects of
cannabinoids using a number of different methods and in a variety of
species. Many pre-1974 studies used rats or mice in the tail-flick
or hot-plate procedures to demonstrate the analgesic activity of
delta-9-THC (Buxbaum 1972; Gallager et al. 1972; Bicher and
Mechoulam 1968). but Harris (1971) and Domino et al. (1971) obtained
inconsistent results. Hill et al. (1974) demonstrated that the
doses required for analgesia in these methods cause decrements in
motor activity. Thus, a retardation in the animal's physical
capacity to respond may partially explain the inconsistent finding
in earlier studies. Other studies using electrical tooth pulp
stimulation with dogs (Kaymakcalan et al. 1974) and shock titration
(Scheckel et al. 1968) have shown that delta-9-THC possesses
analgesic activity. Wilson and May (1975) have shown, however, that
the analgesic activity of delta-&and delta-9-THC is mainly due to
the 11-hydroxy metabolite.
iii) "Hallucinatory" behavior
While no systematic objective procedures have been developed to
assess whether animals experience hallucinations following drug
injection, numerous aberrant behaviors have been observed in higher
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mammals. For example, Joachimoglu (1965) observed dogs that had
received hashish to be trying to "grab an apparition in the air" and
to direct their eyes toward nonexistent objects in the air. Similar
accounts of abnormal behaviors have been reported to occur in
monkeys (Scheckel et al. 1968), with emphasis on apparent visual
"hallucinations."
iv) Dog ataxia test
Delta-9-THC and other cannabinoids with psychoactive effects in man
have particularly unusual effects on the overt behavior of dogs. A
rating scale for the effects has been developed to allow
quantitation (Dewey et al. 1972; Martin et al. 1975). Test drugs
are given i.v. At low doses a slight reduction in activity can be
seen, but at modest doses a distinctive "prance-like" walk with
exaggerated responses to stimulation is produced. At higher doses,
behaviorally active cannabinoids produce a static ataxia. The dogs
remain standing in one place but sway from side to side. The test
can be used to screen for THC-like activity as well as to estimate
potency differences among cannabinoids.
v) Schedule-controlled behavior
A recent review of the THC effects upon schedule-controlled behavior
has been provided by McMillan (1977). The use of such operant
techniques has been most effective in elucidating numerous
characteristics of the THC pharmacologic profile including their
effectiveness via various routes of administration, the time course
and degree of tolerance development, the long-term or irreversible
cumulative effects after cessation of exposure, and the cumulative
effects after repeated administration (Ferraro 1976).
vi) Electroencephalographic (EEG) activity
As described in the general methods section, two basic procedures
are employed to assess the EEG effects of the cannabinoids: acute
changes in the frequency and voltage characteristics, and
alterations in the sleep-awake cycle. In the former, the data are
quantified using visual inspection, voltage integration, frequency
analysis, or power spectral analysis. Animals prepared with chronic
cerebrocortical or depth electrodes are given acute injections of
either the active constituents of marijuana (e.g., delta-9-THC) or
crude marijuana extract. The resulting EEG effects are then
characterized with respect to the voltage content or predominant
frequency of various bands such as delta (O-4 Hz), theta (4-8 Hz),
alpha (8-13 Hz), or beta (13-25 Hz). Measurements are obtained at
specific time points after injection (e.g., 30 minutes, 1 hour, 2
hours, etc.). Power spectral analysis has been utilizied to more
precisely quantify the voltage and frequency components of the EEG
of rats given delta-9-THC (Buonamici et al. 1982). The EEG voltage
was reduced by 50% of control 1 hour after i.p. administration of 10
mg/kg of delta-9-THC. Return to control levels occurred over the
course of 8 hours. During this period prominent EEG bursts of 6 Hz
appeared to override the continuous EEG training. Similar findings
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were reported for delta-9-THC administration in the rabbit
(Willinsky et al. 1975).
Characterization of the effects of cannabinoids on sleep-awake
activity has been studied in the rat (Masur and Khazan 1970; Moreton
and Davis 1973). Changes in the distribution of the various phases
of sleep (as measured using the method of van Twyver 1969) have
suggested that time spent in slow-wave sleep is decreased and
wakefulness is increased (Moreton and Davis 1973). In addition,
this study compared REM-sleep-deprived with non-REM-sleep-deprived
rats and found that they differed in the degree of dissociation of
REM sleep phasic and tonic events, and with respect to the profile
of REM sleep rebound.
Both of these techniques provide excellent baselines upon which to
study tolerance development. Rats (Moreton and Davis 1973; Pirch et
al. 1973), pigeons (McMillan et al. 1972), dogs (Dewey et al. 1972),
and monkeys (Stadnicki et al. 1974) all show tolerance to
delta-9-THC or crude marijuana. Two reports, however, have failed
to find EEG tolerance to delta-9-THC in the cat (Lipparini et al.
1969; Barratt and Adams 1973).
2. Cannabinoid Physical Dependence Potential
a. Tolerance to Drug Effects
Tolerance to the analgesic effects of cannabis has been reported to
last up to 64 days after a single injection in the rat (Kaymakcalan
1973). Similar persistence of tolerance to the behavioral
depressant effects of delta-9-THC has been reported in the dog
(Dewey et al. 1972). This prolonged duration of tolerance coupled
with the fact that tolerance to the sedative and ataxic effects
develop slowly relative to other effects suggests that results
obtained with procedures which depend upon locomotor activity to
assess cannabinoid effects must be interpreted with extreme caution.
Such procedures should incorporate 1) controls for ataxia and/or
sedation, 2) standardized dosing and testing schedules, 3) multiple
test doses, and 4) appropriately long "wash-out" periods before
subsequent dosing. Wikler (1976) has reviewed the literature in
this area.
b. Withdrawal from Chronic Drug Administration
Procedures for assessing the abstinence syndrome in chronic
cannabinoid-treated subjects have not been as well standardized as
those for assessing opioids and CNS depressants. Such studies using
rats or mice have reported definite abstinence signs in some cases
(Cutler et al. 1975; Karler and Turkanis 1976), while others using
convulsive thresholds as an indicator (Chesher and Jackson 1974;
Leite and Carlini 1974) failed to demonstrate withdrawal. The most
conclusive evidence for a dependence potential of cannabinoids has
been provided by numerous studies with monkeys, using intravenous
(Kaymakcalan 1972), oral (Stadnicki et al. 1974; Snyder et al.
1975)) and inhalation (Heath 1976) routes of administration to
maximize exposure to the delta-9-THC. Behavioral signs of
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withdrawal from chronic delta-9-THC administration appear after
about 12 hours and continue for about 5 days. They include yawning,
anorexia, piloerection, hyperirritability, aggressiveness,
scratching, biting and licking fingers, pulling hair, tremors,
twitches, penile erection and masturbation, eating feces and
staring, and grasping at invisible objects (Kaymakcalan 1973).
Similar increased aggressiveness was observed by Stadnicki et al.
(1974) with the addition of EEG desynchrony and "hallucinations."
Snyder et al. (1975) reported a disruption of operant performance
for liquid reinforcement upon termination of delta-9-THC.
Precipitated withdrawal procedures have involved two different
strategies. Since the spontaneous withdrawal signs from delta-9-THC
resemble opioid withdrawal signs (Kaymakcalan 1973) and delta-9-THC
alleviates morphine withdrawal signs (Bhargava 1978), naloxone has
been used to precipitate withdrawal in delta-9-THC-maintained rats
(Hirschhorn and Rosecrans 1974; Kaymakcalan et al. 1977). Secondly,
observations suggesting that serotonergic mechanisms may be involved
in the action of delta-9-THC (Sofia et al. 1971) prompted Taylor and
Fennessy (1978) to administer the potent serotonin uptake inhibitor,
clomipramine, in order to precipitate withdrawal signs in
delta-9-THC-treated rats. Withdrawal signs were similar to those
reported to occur in spontaneously withdrawn animals, though Taylor
and Fennessy (1978) failed to observe spontaneous abstinence signs
when delta-9-THC was discontinued.
3. Cannabinoid Abuse Liability
a. Drug Self-Administration
Procedures for assessing self-administration of cannabinoids have
been described using rats (van Ree et al. 1978; Takahashi and Singer
1979) and rhesus monkeys (Kaymakcalan 1972; Pickens et al. 1973;
Harris et al. 1974). Both intravenous and inhalation (Pickens et
al. 1973) routes have been used.
i) Continuous self-administration
Studies using this procedure have failed to show that delta-9-THC
reliably maintains self-injection performance in drug-naive animals,
though subjects previously administered the compound passively do
self-inject (Kaymakcalan 1972; Harris et al. 1974; van Ree et al.
1978). Takahashi and Singer (1979) have also reported that food-
deprived rats self-administered more delta-9-THC than non-food-
deprived rats. Regardless of the procedure used, however, animals
self-administering delta-9-THC show lower response rates than those
reported for opioid, CNS depressant, or stimulant self-
administration.
ii) Substitution
Using cocaine (Kaymakcalan 1972) or phencyclidine (Pickens et al.
1973) as baseline drugs, substituted THC has been reported to
maintain self-injection behavior; however, other substitution
studies with delta-9-THC and other behaviorally active cannabinoids
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fail to find evidence for reinforcing properties (Harris et al.
1974; Carney et al. 1977; Young et al. 1981). No studies have as
yet been conducted to directly compare the relative reinforcing
efficacy of delta-9-THC and related cannabinoids.
b. Drug Discrimination
Procedures for assessing the discriminative stimulus properties of
cannabinoids have been reported with rats, gerbils, pigeons, and
rhesus monkeys. Using "T" maze performance in rats, it has been
demonstrated that delta-9-THC, delta-8-THC, and hashish' were all
capable of acting as discriminative stimuli resulting in better than
75% correct responses by the 10th trial (Jarbe and Henriksson 1974).
Generalization gradients for various doses of delta-9-THC have been
shown to correlate very well using a number of procedures including
rat two-lever discrimination (Balster and Ford 1978)) T-maze (Jarbe
and Henricksson 1974)) conflict (Barry and Kubena 1972). and
shock-escape maze (Jarbe et al. 1976).
An extension of these procedures provides information relating to
the degree of cross generalization from delta-9-THC to other
cannabinoids. Barry and Krimmer (1975) showed that crude marijuana
extract generalized to delta-9-THC in a two-lever discrimination
task in rats. Further, it has been shown that numerous metabolites
of delta-9-THC generalize to the parent compound. The 11-hydroxy
delta-8- and delta-9-THC compounds both generalize to delta-9-THC at
relatively low doses (Balster and Ford 1978). Cannabinol and
cannabidiol did not generalize to delta-9-THC (Barry and Kubena
1972; Jarbe and Henricksson 1974).
Finally, the discriminative stimulus properties of delta-9-THC are
fairly specific in that many psychoactive compounds do not
generalize to it. Pentobarbital, alcohol, chlordiazepoxide,
chlorpromazine, morphine, methamphetamine, cocaine, atropine, LSD,
mescaline, and phencylidine are among those' tested that fail to
generalize to delta-9-THC (Barry and Kubena 1972; Jarbe and
Henricksson 1974; Jarbe et al. 1975; Barry and Krimmer 1975.
c. Behavioral Toxicity
Procedures for assessing the effects of cannabinoids on sensory-
motor performance have encompassed a number of specific techniques
and animal species. Elsmore (1972) demonstrated that delta-9-THC
impairs auditory discrimination in the monkey, while Ferraro and
Grilly (1973) reported that delta-9-THC produced dose-related
changes in response speed on visual matching-to-sample performance
in the chimpanzee. The acute and chronic effects of marijuana on
complex operant performance have been quantified in the squirrel
monkey (Adams and Barratt 1974); In addition, delta-9-THC appears
todisrupt learning differentially, depending on the paradigm used in
rodents (Robichaud et al. 1973). This finding has been expanding to
include both cannabis extract and delta-9-THC. Stiglick and Kalant
(1982, 1983) showed that when these compounds are given chronically
by gavage to rats, impairment of learning on radial-arm maze, DRL
food-reinforced performance, and habituation in an open field
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develops and persists for long periods of time after drug
administration has ceased. While a number of studies have
characterized the behavioral toxicologic profile of delta-9-THC, no
studies to date have attempted to compare these effects with those
produced by other cannabinoids.
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F. Procedures for Assessing Hallucinogens and Anticholinergics
1. Characterization of Hallucinogen and Anticholinergic
Effects
a. Acute Drug Effects
i) Abnormal behaviors
Numerous animal species including mice, rabbits, and cats exhibit
characteristic abnormal postures or behaviors after receiving acute
injections of lysergide-like hallucinogens. Head twitching in mice
and hyperthermia in rabbits have been noted, but these observations
have not evolved into' a standardized testing procedure. The cat
limb-flick model of Jacobs et al. (1977) has received attention as a
more refined procedure for assessing hallucinogenic activity.
Moreover, this abnormal behavior has been shown to be associated
with a decreased firing of serotonin-sensitive neurons in the raphe
nucleus. The success of methods for recording single unit activity
in freely moving animals has been responsible for obtaining these
electrophysiological correlates of behaviors. Cats are given an
acute injection of the test compound and then observed in an open-
field environment. The limb-flick is seen in control, non-treated
cats only in response to the presence of a foreign substance on the
paw. In LSD-treated cats, the paw is raised from the ground and
then rapidly shaken or flicked away from the body. The number of
limb-flicks per unit time is then tabulated and used as an index of
a test drug's LSD-like activity.
Another approach to studying psychotomimetics has focused on the
complex relationships within social colonies of non-human primates.
On a test day, only one of 5-10 monkeys is treated and the entire
colony is observed for abnormal or "emergent" behaviors. Each
animal is treated on separate days, and the direct effects on the
treated animal are tabulated,as is the behavior of the untreated
monkeys. Behavioral checklists are used by "blind" observers;
Heinze et al. (1980) utilized this procedure to study the effects of
5-methoxytryptamine in Stumptail macaques. Schlemmer and Davis
(1983) have reviewed the literature comparing various models of
psychotomimetic-induced behaviors.
ii) Spinal dog preparation
This technique (which is described in detail in the opioid section)
has been used to characterize compounds with respect to their LSD-
like activity (Nozaki et al. 1977). In general, LSD and related
compounds produce a spectrum of effects including whining, eye
tracking movements, increased respiratory rate, hyperthermia,
increased latency to skin twitch, and facilitation of the flexor
reflex. Thus, it is the entire profile of effects in this procedure
that is utilized to determine a test compound's LSD-like activity.
An extension of this technique involves the use of specific
pharmacologic antagonists (e.g., cyproheptadine, phenoxybenzamine,
chlorpromazine) in order to further differentiate these compounds
with respect to their LSD- vs. amphetamine-like profiles.
8 1
iii) Schedule-controlled behavior
The basic procedures for assessing the effects of hallucinogens on
operant performance are similar to those described under general
methods above. LSD and congeners differentially affect positive
reinforced behavior depending upon the prevailing response rate and
schedule (Appel 1968; Dews and Wenger 1977). These techniques have
been most useful in providing information on relative potencies of
hallucinogens (Appel and Freedman 1965), demonstrating that -LSD is
about 10 times more potent than both psilocybin and d-amphetamine
and 100 times more potent than mescaline. The available data
indicate that the use of aversive control procedures does not
provide information that can be interpreted as unique to this class
of compounds (Appel et al. 1967).
iv) Electroencephalographic (EEG) activity
Procedures for assessing the EEG effects of LSD and related
compounds have been developed for the mouse (Morley and Bradley
1977)) rat (Depoortere and Loew 1971), rabbit (Long 1962; Khazan
and McCash 1965), cat (Killam and Killam 1956)) and monkey (Walter
et al. 1971). Most of these studies have focused on acute effects
described in terms of bursts of spikes, spindling. and
desynchronization. Increased wakefulness and delayed onset and
decreased duration of REM sleep have also been reported (Depoortere
and Loew 1971).
Attempts to quantify the EEG effects of hallucinogens with respect
to frequency and voltage components have been successful in both
mice and cats. Mescaline, dimethoxy-amphetamine (DMA), and related
ring-substituted phenylisopropylamines produce hypersynchronous
slow-wave activity associated with abnormal stereotypic behaviors in
the cat (Fairchild et al. 1967). These effects contrast with
amphetamine which produces desynchrony concomitant with behavioral
alerting and hyperactivity. These data provide a framework within
which relative potencies of test compounds for hallucinogenic
activity can be determined. Winters and Wallach (1970) demonstrated
that cats treated with hallucinogens exhibit hypersynchronous EEG
peaks in the 2.5-3.0 Hz range. Morley and Bradley (1977) have used
power spectral analysis to quantify the EEG effects of N,N-
dimethyltryptamine in mice. A dose-dependent hypersynchrony at
2.5-4.5 Hz was observed to persist for up to 60 minutes after
injection. In addition, anticholinergics produce slow wave
hypersynchrony associated with alteration in behavior consistent
with models of hallucinosis.
v) Binding assays
Stereospecific 3H-LSD high affinity binding was demonstrated in the
mid 1970s (Bennett and Aghajanian 1974; Bennett and Snyder 1975) and
has since provided a basis for associating serotonin and LSD with
specific neuronal structures. The physiologic significance of
binding potencies has not been identified because of the poor
correlation of lC50 values and hallucinogenic activity (Freedman and
Boggan 1982). Greater success has been achieved when correlations
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are made between changes in binding following in vivo treatment with
compounds that produce known functional changes in receptors (e.g.,
5,7-dihydroxytryptamine). Increases in LSD binding in specific
brain areas have been demonstrated in reserpine or para-
chloroamphetamine-treated rats (Bennett and Snyder 1976).
2. Hallucinogen and Anticholinergic Physical Dependence
Potential
a. Tolerance to Drug Effects
Tolerance appears to develop fairly rapidly to many of the effects
of LSD and related compounds. Most notable have been studies that
employ behavioral procedures (Freedman et al. 1958; Appel and
Freedman 1968). EEG activity (Wallach et al. 1972). and measures of
cardiovascular reflexes in the spinal dog preparation (Martin and
Eades 1972). Because the degree of tolerance developed to almost
all hallucinogens is so complete and occurs so rapidly, these
procedures are not particularly useful in quantifying the dependence
potential per se. Because marked cross-tolerance between compounds
of similar chemical structure is widespread (Martin and Eades 1972;
Vaupel and Nozaki 1975), however, screening for LSD-like activity
using this procedure may be useful.
b. Withdrawal from Chronic Drug Effects
To date no studies have demonstrated that the termination of chronic
administration of hallucinogens results in an abstinence syndrome
(McIsaac et al. 1970).
3. Hallucinogen and Anticholinergic Abuse Liability
a. Drug Self-Administration
i) Continuous self-administration
Deneau et al. (1969) demonstrated that rhesus monkeys would not
initiate self-administration of mescaline either spontaneously or
after 1 month of programmed administration. LSD may, in fact,
possess aversive properties, since Hoffmeister (1975) has
demonstrated that rhesus monkeys will respond in order to terminate
stimuli associated with the delivery of this compound.
ii) Substitution
Using cocaine as the baseline drug, Griffiths et al. (1979)
demonstrated that four hallucinogenic amphetamine-like compounds
(DOET, DOM, mescaline, and PMA) do not maintain self-administration
in baboons.
b. Drug Discrimination
Procedures for assessing discriminative stimulus properties are
perhaps the most well developed of those currently available for
assessing compounds for hallucinogenic activity. The discriminative
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stimulus properties of LSD, mescaline, and related compounds are
apparent after relatively small doses (Cameron and Appel 1973;
Hirschhorn and Winter 1971). In addition, the number of trials to
criterion is relatively small, suggesting that these compounds
generate strong interoceptive stimulation. Appel et al. (1978) have
investigated the conditions under which such performances occur and
report generalization gradients for doses other than the training
dose as well as for other stimuli (e.g., tones, lights, etc.).
There is good generalization or cross-transfer between the
discriminative effects of LSD, mescaline, psilocybin, and quipazine
(Appel et al. 1978). These procedures thus provide useful
information for classifying these and other compounds with respect
to pharmacologic class (Kuhn et al. 1977).
c. Behavioral Toxicity
Procedures for assessing the degree of behavioral toxicity of the
hallucinogens have been, for the most part, directed at quantifying
the sensory-motor performance of animals. Blough (1956, 1957)
demonstrated that LSD could improve pigeon's accuracy on a complex
visual discrimination task while elevating the absolute visual
threshold. Species differences are apparent, since LSD impairs
auditory frequency discrimination in the cat (Key 1961) but not the
rat (Dykstra and Appel 1974). Auditory generalization gradients
were unaffected by LSD in pigeons (Dykstra and Appel 1972).
Finally, Brown and Bass (1967) showed that LSD increases the visual
reaction time in rhesus monkeys while increased visual thresholds in
this species were reported by Ando and Takada (1979).
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G. Procedures for Assessing Dissociative Anesthetics
1. Characterization of Dissociative Anesthetic Effects
a. Acute Drug Effects
i) Spontaneous locomotor activity
Using an actophotometer, Chen (1959) demonstrated that the
predominant response of rodents to PCP was that of excitant
hyperactivity. This effect, however, was dose and species specific
in that higher doses induced stereotypic and depressed behavior, and
primates were only sedated after PCP administration.
ii) Forced motor activity
Using the rotorod assay described under general methods above, Kalir
et al. (1978) and Vincent et al. (1979) have demonstrated that PCP
and some of its analogues disrupt forced motor activity in a
dose-related manner. In addition, the relative potency for this
effect has been found to be positively correlated with the relative
potency for binding to a neuronal receptor.
iii) Electroencephalographic (EEG) activity
The EEG profile of PCP was first characterized in animals by Domino
(1964). In a comparative study, Gehrmann and Killam (1976)
demonstrated that of all the CNS depressants tested, PCP and
ketamine produced the greatest increase in EEG voltage in all
frequencies of the primate. More recently, Mattia and Moreton
(1981, 1982) have also characterized the EEG profile of PCP and
ketamine using power spectral analysis. Lower doses of PCP produced
increased voltage in the theta band while larger doses produced two
distinct peaks of activity (one at O-5 Hz and the other at 7-8 Hz).
Ketamine demonstrated a similar profile, but was about 10 times less
potent that PCP.
iv) Behavioral performance
Because of the complex nature of PCP's pharmacology, multiple
schedules seem to be the most appropriate paradigms to assess the
effects of PCP on operant performance. This is especially true
since the finding that the effects of psychoactive agents on operant
performance are related to the schedule employed (Dews and De Weese
1977; McKearney and Barrett 1978). In this regard, rodent (Murray
1978; Woolverton and Balster 1979) and primate (Chait and Balster
1978; Brady et al. 1980) data have shown that low doses of PCP
increase low rates of responding (e.g., fixed interval) and decrease
high rates of responding (e.g., fixed ratio). Three analogues, PCE,
TCP, and ketamine, have been shown to produce qualitatively similar
effects on operant performance; the only differences observed were
in the relative potencies of these compounds.
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v) Binding assays
Using techniques similar to those used to demonstrate the existence
of opiate receptors, a component in brain membrane has been shown to
3bind [ H] PCP with a high degree of specificity and with a fairly
high affinity (Vincent et al. 1979; Zukin and Zukin 1979). In
addition, PCP and 3 of its analogues have been shown to displace
C3H]quinuclidinyl benzylate (muscarinic receptor) and
[3H]dihydromorphine (opiate receptor) with a respectable degree of
specificity (Vincent et al. 1979; Su et al. 1980). The "PCP
receptor" appears to be most concentrated in the synaptic, fraction
of cerebral cortex and corpus striatum, while significant, but
somewhat lower, degrees of binding were found in hippocampus and
thalamus.
While there has been some early controversy regarding the specific
binding of PCP to glass wool fibers, the more recent studies have
demonstrated significant correlations between the relative potency
of PCP and its analogues in the rotorod test and binding affinities
(Vincent et al. 1979; Zukin and Zukin 1979). The ultimate impact of
the presence of PCP receptor may reside not in the advancement of
our understanding of PCP's mechanism of action, but in its possible
usefulness in rapid screening of drugs for PCP-like activity and in
the search for a PCP antagonist which would provide a valuable addi-
tion to the current strategy of treating PCP intoxication.
2. Dissociative Anesthetic Physical Dependence Potential
a. Tolerance to Drug Effects
Repeated administration of PCP to monkeys and rats results in a
decreased disruption (2-4-fold change) of operant performance
(Balster and Chait 1976; Chait and Balster 1978; Woolverton and
Balster 1979; Woolverton et al. 1980). Various behavioral paradigms
were used including a chain schedule procedure for food
reinforcement and a fixed interval schedule procedure for milk.
Similar degrees of tolerance were observed regardless of whether PCP
was administered before or after the test session. First dose
behavioral tolerance of PCP has also been reported to occur in the
rat (Ruffing and Domino 1980). This phenomenon was found to be
dose related; however, the duration of complete suppression of
lever-pressing activity was used as the dependent variable and not
response rate as reported in the earlier studies. Regardless of the
technique employed, it appears that marked tolerance develops to at
least some of the effects of PCP.
b. Withdrawal from Chronic Drug Administration
Using a continuous access self-administration paradigm, rhesus
monkeys were observed to readily initiate self-injections of PCP
(0.1 mg/kg/inj) and increase their drug intake over the course of 20
days (Balster and Woolverton 1980). Daily intakes of up to 7.4
mg/kg were achieved, and previously depressed food intake had
returned to baseline (indicative of tolerance development). The
animals maintained a state of continuous intoxication which was
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sustained when the dose was increased to 0.5 mg/kg. Substitution of
saline after 58 days of exposure resulted in the appearance of
numerous abstinence signs and symptoms including increased
vocalizations, bruxism, oculomotor hyperactivity, diarrhea, refusal
of preferred food, piloerection, and tremors. Less common signs
included ear and facial twitches, priapism, abdominal contractions,
emesis, and convulsions. The time course of withdrawal was
characterized by an initial recovery from , the PCP-induced
intoxication at about 4 hours after saline substitution. Onset of
hyperresponsive behaviors became evident at 8-12 hours, with the
maximum number of symptoms occurring 12-15 hours post-substitution.
The syndrome dissipated over 24 hours, however, and all withdrawal
signs were immediately reversed by PCP (0.25 g/kg, i.v.). This
study also showed that PCP blood levels were in the 105-280 mg/ml
range during self-administration, and declined to O-12 mg/ml with
saline substitution.
3. Dissociative Anesthetic Abuse Liability
a. Drug Self-Administration
The rhesus monkey has been shown to self-administer PCP
intravenously (Pickens et al. 1973; Balster et al. 1973; Balster and
Woolverton 1980) and orally (Carroll and Meisch 1980; Carroll 1982).
In the primate studies, not only did PCP maintain self-injection
performance when substituted for cocaine, but animals with no prior
history readily initiated self-injections of PCP (Balster et al.
1973). The self-administration profile of PCP was (like many other
drugs of abuse) characterized by an inverted U dose-response curve
and while the number of self-injections decreased as the dose was
increased, the total intake per day increased. When the fixed ratio
for delivery of an injection was increased from 1 to 5, the number
of self-injections also decreased.
Finally, self-administration studies with PCP analogues such as
ketamine (Moreton et al. 1977) and numerous N-substituted analogues
(Risner 1982) have shown that all of these compounds maintain
self-injection performance similar to that of PCP. The only
differences observed thus far were those of relative potency. Using
a bioassay procedure that predicts relative potencies, parallelism
of curves, and relative maximal effects, Risner (1982) demonstrated
that eight structurally related analogues of PCP were
self-administered by the dog. The thienyl-substituted analogue was
the most potent, followed by PCP, y-substituted alkyl analogues,
monohydroxylated metabolites, and ketamine.
b. Drug Discrimination
Procedures for assessing the discriminative stimulus properties of
phencyclidine and related compounds have been developed and refined
for both the rat and the squirrel monkey. Overton (1975) initially
demonstrated that PCP and ketamine shared similar discriminable
effects which were dissociable from the stimulus effects of
pentobarbital. Similar stimulus generalization curves were observed
for PCP, cyclohexamine, and ketamine, while ditran did not
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generalize to the PCP cue (Jarbe et al. 1975). These procedures
have been used by two laboratories to evaluate a series of PCP
analogues with respect to similar stimulus properties using food
reward in the squirrel monkey (Brady and Balster 1981) and shock
avoidance in the rat (Shannon 1981). Both studies demonstrated that
N-substituted phenylcyclohexylpiperidines generalize to the PCP cue
and, in addition, provided a basis for rank ordering the compounds
by relative potencies. Shannon (1981) studied 17 analogues of PCP
and found that neither the 4-hydroxycyclohexane metabolite nor three
carbonitrile analogues generalized to PCP.
c. Behavioral Toxicity
Procedures for comparing the sensory and motor effects of
dissociative anesthetics have been limited to a single report (Lukas
et al. 1980) showing that both PCP and ketamine disrupt auditory and
visual thresholds and reaction times in unrestrained baboons. The
data demonstrated a definitive difference in time course with PCP
markedly disrupting reaction-time performance throughout the two-to-
three hour test session, while recovery from ketamine's effects were
evident after one hour.
Three studies, however, have assessed PCP effects on size
discrimination in rhesus monkeys (Brown and Bass 1967)) matching-to-
sample task in pigeons (McMillan 1980), and acquisition and
performance of conditional visual discriminations in Patas monkeys
(Thompson and Moerschbaecher 1982). In general, PCP produced dose
related increases in reaction times and percent errors.
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VI. Human Testing Procedures
A. General Methods
1. Procedures for Characterization of Druq Effects
a. Acute Drug Effects
i) Analgesia
Procedures for the evaluation of the pain-relieving properties of
drugs in humans have developed along essentially two distinct lines
of investigation based on the origin of pain. In one, the empiric
drug trial, the studies are carried out in patients being treated
for clinical pain, usually, though not invariably, in a hospital
setting. In the other, the psychophysiological approach, the
studies are usually of experimentally induced pain and carried out
in normal volunteers or ambulatory chronic pain patients, most often
in a laboratory setting. Although the measurement of pain is common
to both methodologies, there are fundamental differences in concept,
applicability, and results of the two approaches.
In clinical pain, the strength of the stimulus is an unknown, and
inferred only from the medical history, physical examination,
ancillary clinical laboratory data, and the physician's past
experience. In a clinical drug trial meeting the basic requirements
for a well-designed study, the patient's report of pain is accepted
at face value and the effectiveness of any drug in relieving pain is
considered to be meaningful only in relative terms - that is,
relative to an appropriate standard drug or control medication. By
contrast, in psychophysiological experiments in which pain is
experimentally induced, the external stimulus is measurable and
controlled by the investigator or subject whose subjective responses
can be scaled in terms of the strength of the stimulus. Psycho-
physiological methods more often measure the effects of drugs on one
or more components of the pain complex and express the results in
absolute terms - that is, in terms of the criterion itself.
It has been long recognized that pain is a highly complex,
multifaceted experience with strong affective and motivational
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components (Beecher 1959; Sternbach 1968; Melzack and Torgerson
1971), and great strides have been made in the development of
laboratory methods for parceling out and measuring these elusive
variables (Clark 1974; Tursky 1975; Gracely 1980; Price et al.
1983). Early psychophysical tests concentrated on the pain
threshold and the dol scale of pain intensity (Wolff et al. 1941;
Hardy et al. 1947, 1952). A wide variety of measurable external
stimuli have been employed, including radiant heat and other forms of
thermal stimulation, electrical shocks, a variety of pressure and
physical devices, chemical methods, and arterial occlusion (Beecher
1957; Stevens et al. 1958; Smith et al. 1966; Yanaura et al. 1977;
Lim et al. 1967; Procacci et al. 1979). But the ability of methods
based solely on measurements of pain threshold to predict the
efficacy of an analgesic in the clinical setting has been
disappointing (Kutscher and Kutscher 1957; Beecher 1959; FDA
Guidelines 1979). 
The results of experimental procedures to measure pain tolerance
have been more concordant with the clinical experience but have
raised ethical issues and, like clinical pain, they are
unidimensional - measuring only pain intensity. More recent
developments of psychophysical measurement procedures have, however,
made it feasible to evaluate some of the qualitative as well as the
quantitative aspects of the pain experience. Most of these
approaches are based on signal detection theory (Green and Swets
1966), magnitude estimation and ratio stimulus scaling (Stevens
1975), or cross-modality matching techniques (Tursky 1975). These
methods have provided means of estimating the contributions of
discrimination sensitivity and response criterion shifts in
evaluating placebo effects and in the diagnostic evaluation of
individual and group expressions of pain, particularly in patients
with chronic benign pain. Measures based on signal detection theory
have also been employed to distinguish analgesics from psychotropic
drugs (Chapman 1977; Wolff et al. 1976; Yang et al. 1979). For
reliable results, however, psychophysical metholds generally require
that the subject submit to large numbers of painful stimuli under
conditions which limit use in seriously ill patients with either
acute or severe pain due to trauma or disease. Thus, in spite of
the more rigorous controls which can be applied in the laboratory,
the well-designed controlled clinical drug study is still regarded
as the crucial test of a drug's analgesic properties (FDA Guidelines
1979).
Psychophysical measurements of pain also include multidimensional
pain descriptor scales and attempts to generate independent
magnitude estimates for each of the pain descriptor categories. The
McGill Pain Questionnaire (Melzack 1975) has been used chiefly to
characterize clinical pain although, more recently, it has also been
used to measure the efficacy of analgesics (Heidrich et al. 1983).
This questionnaire consists of sets of words designed to quantify
three dimensions of the pain experience in terms of the intensity
ratings and number of descriptors chosen by the patient with pain.
Other recent studies employing magnitude estimation, ratio stimulus
scaling, and cross-modality matching procedures have shown that
verbal meanings to an individual may be appropriately quantified
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either by the individual or a similar group of individuals (Gracely
et al. 1978). These techniques have proven effective in
distinguishing the sensory from the hedonic effects of narcotics and
anxiolytics (Gracely and Dubner 1981). The advantages of these
methods lie in their potential for characterizing how drugs act,
rather than as a means of evaluating the analgesic efficacy or
potency of new drugs.
Scientifically acceptable principles for the conduct of clinical
analgesic drug trials were pioneered and elucidated over 25 years
ago by Beecher (1957). He emphasized that while reliance must be
placed on the verbal report of the patient with "pathological pain,"
reliability and validity can be achieved by appropriate experimental
designs and controls including the double- blind technique,
randomization of treatments, appropriate active drug standards and
placebo controls, and statistical verification of the significance
of the results. On this foundation, a number of different drug
testing models have been developed using either single or repeated,
fixed or graded, doses of the test drug and reference standard, with
or without placebo controls, and administered by one or more of
several different routes to patients with acute or chronic pains of
diverse etiologies (Keats 1956; Houde et al. 1960; Lasagna 1960;
Bellville et al. 1968; Sunshine 1980). In addition, a well-designed
study should include an internal control - a means of demonstrating
within each study that the sample population and the experimental
procedure are capable of discriminating between a.known active drug
standard and a placebo, or between graded doses of the standard - in
terms of the analgesic data generated (Modell and Houde 1958; Houde
et al 1965). There are many factors, however, which enter into the
choice of the appropriate experimental design, standards and
controls, and methods of collecting and analyzing the data. Among
them are the general pharmacological profile based upon laboratory
animal and preclinical data, and the expected role the drug will
fill in medical practice (FDA Guidelines 1979). Pharmacokinetic
characteristics of the test and reference drugs will also influence
the choice of single or repeated doses, and crossover or non-
crossover experimental designs, the timing of drug administration
and data collection, and the manner in which the results are
analyzed. Decisions are commonly based on whether a drug 1) is
morphine-like, 2) has associated narcotic antagonist properties, 3)
is aspirin-like or, 4) does not fit any of these stereotypes (FDA
Guidelines 1979).
Because of the great variety of clinical pains for which analgesics
with potential for abuse are employed, there is no single
experimental design or method of conducting a clinical analgesic
drug assay which is appropriate for all situations. The procedure
followed most frequently is to employ fulltime trained observers,
usually registered nurses, who administer the study medication for
complaints of moderate or severe pain. Observations are generally
made prior to and at frequent regular intervals for 4 to 6 hours
after medication or until pain is reported to have returned to its
premedication intensity. For pain which is short-lived, such as
postpartum pain (Bloomfield et al. 1970) and that following many
types of surgery including the extraction of impacted molars (Cooper
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and Beaver 1976), the patient receives only one treatment or test
medication, and comparisons of the drugs are made in parallel
patient groups. Studies carried out in situations in which the pain
is expected to be more long-lasting, such as in patients undergoing
more formidable surgical procedures, and patients with pain due to
cancer, some form of crossover design may be employed in which each
patient receives single doses of each test drug on separate days
(Houde et al. 1965). The objectives of most of these studies are
not only to test for analgesic efficacy but also to provide an
estimate of the potency of the test drug relative to a known or
established standard analgesic. The methodology for chronic or
repeated dose administration of new drugs has not been as well
characterized, but some. procedures incorporating many of the
features of the single dose studies have been reported (Wang et al.
1981; Ouellette 1982). These methods allow for comparisons of the
effects of the initial doses of drugs with those at proximate
steady-state levels. This can be of considerable importance in
evaluating drugs which are cleared from the body more slowly or have
active metabolites.
Virtually all of the methods of evaluating pain in clinical settings
rely on the patient's own report. While a number of objective
methods - including the measurement of a variety of autonomic signs
(Beecher 1957) and biochemical correlates of pain (Terenius 1978),
of recordings of evoked brain potentials (Chapman et al. 1979)) and
of observations of behavior (Fordyce 1976) - have been employed in a
variety of clinical settings, these methods have had limited
applicability and have been of questionable reliability in
predicting the efficacy of an analgesic (Houde 1982). Most clinical
methods employ some form of categorical or ordinal scale for rating
pain severity. Typically, analgesia is measured indirectly in terms
of changes in pain intensity levels on a 4-5 point scale at
intervals after administration of the test medication in comparison
with the levels of pain before administration. Analgesia is also
measured directly in terms of pain relief estimates. Comparison of
analgesic drugs is generally made in terms of the cusum of
observational period scores and commonly expressed as SPID [sum of
pain intensity differences] or TOTPAR [total pain relief] (Forrest
et al. 1963). Quanta1 measures of pain relief or comfort have also
been employed successfully, often together with the graded rating
1975).
scales, but they tend to be less sensitive (Wallenstein and Houde
Visual analogue scales (VAS) are also being used to measure pain
intensity, pain relief, and mood effects. The VAS is usually
presented in the form of a 100 mm horizontal line with no other
markings except at their ends which are identified as "no pain" and
"worst possible pain, " "complete pain relief" and "no pain relief,"
or "best mood" and "worst mood." The patient places a mark between
these extremes to indicate his subjective impressions. The VAS has
also been presented in the form of a dial, pain thermometer, and
vertical line, but none of these variations provide any advantages
(Huskisson 1974; Littlejohns and Vere 1981). Good agreement has
been found between the ordinal pain scales and the VAS, but the
latter tend to be more sensitive (Ohnhaus and Adler 1975;
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Wallenstein et al. 1980). Despite some debatable assumptions of the
mathematical properties of the ordinal scales employed (Littlejohns
and Vere 1981), the results of clinical relative analgesic potency
assays by most investigators have, in general, been consistent
whether analyzed by standard parametric tests or by non-parametric
tests (Fucella et al. 1977).
In summary, there are basic differences in the approach to measuring
pain when the objective is the evaluation of an analgesic and when
the objective is the evaluation of the nature of pain. The latter
is recognized as a complex process whose multidimensional features
can best be delineated in a controlled laboratory setting using a
variety of psychophysiological methods. By contrast, the assessment
of analgesic potency and efficacy of a drug is judged in terms of a
unidimensional scale of pain intensity and compared with an
established standard analgesic in a clinical setting. The two
approaches to measuring pain complement eash other, but the
psychophysical techniques are limited in their ability to detect the
effects of simple analgesics and by their often not being applicable
to studies of analgesics in patients with acute pain.
ii) Electroencephalographic (EEG) activity and
sleep
The EEG recorded from multiple scalp electrodes has been utilized in
two basic modes to assess 1) acute effects of a compound on the
electrical activity of the brain and 2) effects of a compound on the
sleep-awake cycle. While the basic equipment is similar, these two
types of studies involve procedural differences that relate to
recording session length, methods of analysis, and in some cases,
recording montage and method of electrode attachment (Fink 1968).
The acute effects of a compound are usually evaluated during a
relatively short (e.g., 3-5 hour) recording session (Itil 1972)
employing an abbreviated method of attaching the scalp electrodes.
Electrodes are usually placed according to the l0-20 system (Jasper
1958) but not all 21 possible electrodes are utilized. Recording
montages are usually selected on the basis of special interest or
because the experiment is designed to study the drug-induced changes
in certain neuronal structures immediately below the electrodes.
Before administering the drug, a sufficiently long period is
customarily devoted to obtaining control, awake recordings under
various conditions, (e.g., eyes closed and relaxed, eyes open and
relaxed, and eyes open and concentrating). These sessions serve as
the basis for assessing drug-induced changes (Longo 1977). The EEG
effects can also be correlated with subjective ratings of euphoria
and other physiological responses (Volavka et al. 1973).
Quantitation of the EEG effects is either by visual inspection,
integrated voltage, period analysis, or power spectral analysis.
The study of effects of drugs on the sleep-awake cycle necessitates
some procedural refinements. Recording sessions typically last 6-8
hours and the EEG train is described by visual inspection in terms
of frequency and amplitude components. These procedures have
provided standardized characteristics that define the various phases
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of sleep (Rechtshaffen and Kales 1968; Niedermeyer 1982). The sleep
profile has identifiable onset and duration characteristics
involving the various sleep stages I-IV and REM sleep, as well as
amplitude and frequency characteristics involving the clinically
relevant band widths of delta (O-4Hz), theta (4-8 Hz), alpha (8-13
Hz), and beta (13-25 Hz).
Sleep stages have been characterized by their EEG profiles and
rarely by simply observing the subject (Harvey 1980). During stage
0 or awake, beta activity predominates while the eyes are open and
alpha activity while the eyes are closed. Stage I or the decending/
dozing stage is characterized by theta, alpha, and beta activity
with occasional bursts of eye movement. The onset of sleep during
stage II is heralded by the appearance of sleep spindles and K
complexes and the disappearance of alpha and beta activity; theta
waves, however, remain. Stage III or deep sleep transition is
differentiated from Stage II by the appearance of slow delta waves
along with the other waveforms. Deep sleep or Stage IV occurs when
only delta activity prevails with little or no eye movement. Rapid-
eye-movement or REM sleep is a stage that typically follows IV. It
is characterized by many different frequencies, but no spindles or K
complexes are seen. There is a corresponding increase in the amount
of eye movement. Most dreaming occurs during this stage.
Quantification of the EEG activity has been, accomplished by
integrating the amplitude (Goldstein et al. 1963) using a pulse
generator. Temporal frequency changes have also been identified
using period analysis (Burch et al. 1964), by measuring the time
interval between two successive baseline crossings of the EEG
waveforms. EEG power spectral analysis is based upon the
analog-to-digital conversion of the EEG activity which is then
mathematically fitted to a sine/cosine signal. The Fast Fourier
Transform (Grass and Gibbs 1938; Walter 1963), when applied to such
data, results in a fingerprint-like array that characterizes the
amplitude and frequency components simultaneously.
2. Procedures for Assessing Physical Dependence Potential
a. Tolerance to Drug Effects
The development of tolerance to a drug effect is reflected by an
attenuation of the original response with continued exposure to the
drug. The extent of tolerance is determined by the specific drug,
the parameter being assessed, and the dose and duration of
treatment. Thus, once the acute effects of a compound are
characterized, the development of tolerance can be tracked during
treatment.
The assessment of tolerance to a drug's effect must take into
account numerous factors (Martin and Sloan 1977). First, with
chronic administration, the drug's pharmacologic profile may change
due to differential tolerance development to some of the effects and
not others. This complicates subsequent reassessment of the drug's
effects. Secondly, an appropriate baseline of effects must be
established. The time interval from the last dose to the initiation
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of the procedures for assessing tolerance must be carefully
determined, since certain acute effects may be confounded with the
appearance of early abstinence signs. Thirdly, appropriate dose-
response relationships should be demonstrated before chronic
exposure is begun. Thus, a "tolerance index" can be used to compare
different drugs (Martin and Fraser 1961).
b. Withdrawal from Chronic Drug Administration- -
The assessment of the dependence potential of a class of drugs
generally focuses upon procedures far identification and
quantification of the behavioral and physiological changes following
cessation of chronic drug exposure. Characteristically, such
effects depend primarily on the drug being studied, the maintenance
dose, and the duration of treatment. Two different techniques are
employed to assess the consequences of withdrawal from chronic drug
exposure. Direct or primary dependence assessment involves using a
drug-free (but not necessarily a drug-naive) subject given
increasing doses of a test compound for a predetermined length of
time (Fraser et al. 1957). Upon withdrawing the drug, the subjects
are assessed at regular intervals for changes in physiological
processes, vital signs, and subjective or "mood" changes. These
signs and symptoms are rank-ordered with respect to their degree of
severity and then used as the basis for describing the syndrome as
either mild, moderate, or severe (Martin and Gorodetzky 1965;
Jasinski et al. (1971b).
The substitution procedure uses subjects currently receiving a
compound on a chronic basis. The test compound is then substituted
for a predetermined length of time, usually on a double-blind basis
(Jasinski 1977). The signs and symptoms are recorded and tabulated,
with the presence or absence of signs reflecting the degree of
similarity between the test drug and the standard drug.
3. Procedures for Assessing Abuse Liability
a. Drug Self-Administration
Drug self-administration procedures have evolved over the past 18
years and at present have been refined by the introduction of more
standardized techniques and an adherence to certain basic guidelines
(Bigelow et al. 1976). Assessments of true drug-seeking behavior
must satisfy the following criteria: 1) ingestion or injection of
the drug must be optional (Mello and Mendelson 1965), 2) the
behavior must be observed during a number of experimental
manipulations (Nathan et al. 1970). and 3) the drug self-
administration patterns must be established over an appropriately
long time interval (Cohen et al. 1971).
In general, two basic subject populations have been studied. Normal
volunteers reporting to the lab for only a few hours each day have
been used for short-term determinations of reinforcing efficacy
(Johanson and Uhlenhuth 1978), while residential ward settings have
been used with drug-experienced subjects (Bigelow et al. 1975; Mello
and Mendelson 1978; Fischman and Schuster 1982). In the short-term
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studies, subjects receive a physical examination and are given drug
or placebo either orally or by injection. Typically, double-blind
conditions are observed. At various time intervals, the subjects
are asked to evaluate their feelings while physiological responses
are monitored. This procedure provides baseline data against which
choice procedures (i.e., between two different drugs) can be
evaluated.
In residential ward settings, subjects usually are given control of
access to drug. In addition, they are required to work (e.g., ride
an exercise bicycle for 15 minutes) in order to obtain drug
(Griffiths et al. 1979). This procedure tends to reduce variability
and increase sensitivity by restricting the drug availability. The
residential ward setting also provides a built-in control for
environmental factors such as social interactions (Bigelow et al.
1974). This procedure is also conducive to studying the patterns of
drug self-administration over time as a basis for the assessment of
tolerance and dependence.
Prior to the initiation of studies with a volunteer participant, an
extensive drug history should be obtained. In addition, the
subjects should be evaluated for current tolerance and/or dependence
to certain drug classes either by giving a test dose or by requiring
a controlled observation period to determine whether withdrawal
signs appear.
b. Self-Report of Drug Effects
Procedures for assessing changes in subjective feelings have been
developed to aid in the identification of drug-induced effects
superimposed on the subject's baseline mood state. The most widely
utilized test, the Addiction Research Center Inventory or ARC1 (Hill
et al. 1963) is a series of 550 questions that are answered "yes" or
"no. " The content of the items reflects a broad range of physical,
emotional, and generally subjective effects of drugs. Additionally,
certain questions are designed to provide some measure of
personality and psychiatric stability (Haertzen et al. 1963). In
some circumstances, an additional 50 questions are asked which
provide information on the sociologic profile of the subject. The
most useful information obtained when applying this test is the
average scores on the 38 recommended scales (see Haertzen 1974),
since these averages can serve as a standard for comparison in the
classification of subjects or groups. Essentially, validation of
the ARCI has resulted in the identification of six psychiatric
groupings and ten drug conditions. The six psychiatric groupings
are: normal, mentally ill, alcoholics, criminals, opiate addicts,
and simulated mental illness. The ten experimental drug conditions
are: no-drug, morphine, cyclazocine and nalorphine, pentobarbital,
chlorpromazine, LSD, benzedrine, alcohol, opiate withdrawal, and
chronic opiate maintained.
Many pharmacological studies have used short forms or single scales
of the ARCI. These forms can be quickly administered and are
especially useful in demonstrating whether a drug effect is present,
its potency, and its duration of action. Three scales in particular
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have been used to identify sedative-(PCAG), euphoric-(MBG), and
psychotomimetic-(LSD) effects (Martin 1967; Jasinski et al. 1971a).
Morphine and morphine-like drugs elevate MBG scores but not PCAG or
LSD, while nalorphine and nalorphine-like drugs elevate LSD and PCAG
scores but not MBG scores. Central nervous system depressants
elevate PCAG scores and not LSD or MBG scores. The utility and
validity of these short forms have been individually substantiated
by the good correlations of relative potencies and time-action
curves for the resultant assessment of subjective effects and other
physiological responses such as pupillary diameter and nystagmus
(Martin 1967; Jasinski et al. 1971a).
The method of classification of subjective effects inherent in the
ARCI is based on discriminant function procedures described by Rao
(1952). The advantage of this procedure is that it provides a
mechanism that corrects for individual differences and variability.
Full details of the correcting procedures are provided by Haertzen
(1974).
Various studies have shown that ARCI scales may have a factor
analytic or structural significance that is constant in going from
one group to another or in testing from one condition to another.
When individuals are tested under different conditions, however,
different individuals may be placed in the same category. The
successful implementation of the ARCI and resultant predictive power
of the scales are also dependent on the specific test-taking
instructions given, and as such, should be standardized (Haertzen
1974).
c. Behavioral Toxicity
Procedures for assessing drug-induced changes in human performance
have been developed and refined for psychomotor and reaction time
procedures. Little consistent data are available on more complex
behaviors and functions, however (Johnson and Chernik 1982). The
role of such behavioral toxicology assessment has become
increasingly important because substances with little or no
disruptive behavioral or pharmacological effects are not regarded as
having significant abuse liability. In contrast, compounds that are
used even sparingly which produce marked disruptive changes are
considered to have high abuse liability. Since drugs may fall
anywhere on the continuum defined by these parameters, relative
abuse liability is most effectively determined by a comprehensive
assessment of these interactive dimensions.
A relevant issue that must be addressed when conducting these
studies is whether the procedure distinguishes between drug-induced
sensory. decrements (or improvements) on the one hand, and motor
impairment on the other. While it is quite clear that relatively
large doses of CNS depressants will sedate a subject so that he is
incapable of performing, these types of studies do not provide a
complete profile of the drugs being assessed. Rather, the
determination of the threshold dose for performance decrement and
the duration of such decrement more appropriately characterize the
behavioral toxicity of a compound. Recently, performance decrements
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that occur the day after a hypnotic is used ("hangover effect") have
been studied more closely (Johnson and Chernik 1982; Hindmarch 1980;
Wittenborn 1979). These studies have been generated primarily in
response to the Institute of Medicine's report dealing with the
issues surrounding the relationship of short- versus long-acting
hypnotics and performance decrements (Solomon 1979).
The assessment of performance is also useful in the evaluation of
subjects on chronic methadone maintenance (Rothenberg et al. 1977)
and the enhancement of performance after caffeine and amphetamine
(Weiss and Laties 1962). Basic changes in auditory and visual
thresholds following marijuana administration have also been
documented (Caldwell et al. 1969).
Acute studies are conducted over the course of a few hours with
appropriate collection of pre-drug control performance before
administration. Depending on the procedure employed, the evaluation
is conducted continuously, or in discrete sessions separated by
standard time-out periods until the drug effect has peaked and
waned. In studies designed to assess the "hangover effect," the
subject first undergoes an assessment of performance during the day,
and then receives the drug either later in the day or at bedtime.
Performance is again assessed at various times the following day.
Procedures typically employed include visual tracking (Borland and
Nicholson 1974), auditory vigilance (Jones et al. 1978), and tests
such as continuous arithmetic (Epstein and Lasagna 1968). time
estimation (Pfaff 1968), free recall (Murdock 1962), and digit
symbol substitution (Wechsler.1944). In addition, some procedures
are designed to mimic real life situations such as automobile
driving (Biehl 1979; Hindmarch et al. 1977), while one study has
actually employed real-life driving in downtown traffic (Klonoff
1974).
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B. Procedures for Assessing Opioids
1. Characterization of Opioid Drug Effects
a. Acute Drug Effects
i) Analgesia
Methods of assessing the analgesic efficacy and potency of opioids
are greatly influenced by the singular pharmacological properties of
this class of drugs - which includes not only the opiates and their
semisynthetic and synthetic derivatives with both morphine-like and
morphine antagonist properties, but also a large and growing number
of chemically unrelated compounds with similar disparate attributes
- linked together in that they are believed to act upon the same
family of CNS receptors, though with different affinities and
intrinsic activities. Among their most distinctive features are
that they include some of the most potent and universally
efficacious drugs for the control of clinical pain and that their
analgesic properties are greatly influenced by their repeated use
and by prior exposure to drugs of the same class. These factors are
important determinants not only of the setting and subject/patient
population in which opioids are evaluated, but also of how opioids
are evaluated for their analgesic efficacy.
The analgesic properties of most opioids are readily demonstrated in
double-blind, controlled clinical trials employing categorical or
visual analogue scales of pain intensity or pain relief. Moreover,
in clinical assays of graded doses of opioids in patients with
either postoperative or cancer pain, the analgesic response
[measured in terms of pain intensity reduction or pain relief ] has
been observed to be linearly related to the logarithm of the dose
(Houde et al. 1965). Relative analgesic potency assays comparing
graded doses of parenteral morphine to those of other opioids have
shown remarkably consistent results in terms of the cusum scores of
these parameters of pain relief (SPID, TOTPAR) in studies of
patients with postoperative and cancer pain (Wallenstein and Houde,
1975).
Unlike many nonopioid analgesics, the opioid's can be administered by
several parenteral or enteral routes. However, their potencies are
substantially influenced by the route of administration (Beaver et
al. 1977). Flexibility in dose and route of administration provides
an opportunity to evaluate the opioids in a wide variety of pain
models, but, since many have substantial abuse liability, they are
generally tested in hospitalized patients with severe or acute pain.
Graded parenteral doses are usually the most efficient and often the
only feasible method of administering these drugs in this setting.
The most frequently employed pain model used for assaying patient
opioid analgesics is postoperative pain, although analgesic assays
have also been carried out in patients with cancer, biliary or renal
colic, myocardial infarctions, severe or extensive burns, and women
in labor (Lasagna 1960).
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Although the effects of various opioids can be demonstrated in a
variety of laboratory models employing experimentally induced pain,
these techniques have not consistently and accurately predicted the
clinical efficacy of new analgesics (FDA Guidelines, 1979).
However, some of the psychophysical scaling techniques which were
developed using normal volunteers have been applied to the clinical
setting and have been useful in distinguishing the sensory and
hedonic actions of morphine from those of diazepam (Gracely et al.
1978). Psychophysical procedures which assess pain in its different
dimensions have also provided useful guides to the appropriateness
and usefulness of opioids
(Sternbach 1978).
in certain chronic pain syndromes
The design of a clinical analgesic study of a new opioid will
primarily be determined by the role it is expected to fill - or the
opioid that it is expected to replace - in the therapeutic
armamentarium. Drugs that are expected to substitute for codeine
are commonly tested orally against codeine or propoxyphene, either
alone or in combination with aspirin, acetaminophen or one of the
newer non-steroidal antiinflammatory drugs. These studies are most
frequently carried out in patients with postpartum pain, oral
surgery pain, headaches, or rheumatic and orthopedic pains (Beaver,
1966). A variety of acceptable experimental designs are employed
including single fixed dose comparisons of the test drug with a
known analgesic standard and placebo control, parallel line assays
of graded doses of the test drug and standard, with or without a
placebo control. Factorial studies have also been carried out of
fixed doses of the test drug, standard drug, combined test and
standard drugs, and a placebo control (Houde et al. 1960). Ordinal
and visual analogue scales are most frequently employed, and the
results analyzed using standard parametric and nonparametric
statistical tests (Fucella et al. 1977; Quiding et al. 1981).
Relative oral/parenteral analgesic assays can also be carried out
using graded doses of the two forms of the drug and a double placebo
technique in which each study medication consists of both a capsule
(or tablet) and an injection, one containing the active drug and the
other a placebo (Beaver et al. 1967).
Opioids that are being considered as analgesic substitutes for
morphine or its surrogates are frequently tested first in
parenteral, graded dose, relative to analgesic potency assays with
morphine as the reference standard. The relative potency comparison
allows for an assessment of acute side effects or adverse effects at
equianalgesic doses of the test drug and standard. These assays
have been carried out as non-crossover, twin crossover (incomplete
block) or complete crossover designed studies in hospitalized
patients with moderate to severe pain following major surgery and in
patients with advanced cancer (Wallenstein and Houde 1975).
Categorical and VAS measures of pain intensity are customarily
employed and standard parametric and non-parametric statistical
analyses are carried out on the peak and total (SPIC, TOTPAR)
scores. Multivariate analyses can be performed on the data using
computer programs. Concomitant assessment of the patient's
emotional status can also be carried out using the McGill
Questionnaire (Heidrich et al. 1983), as well as by adjective check
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lists and visual analogue measures of mood (Kaiko et al. 1981a). In
addition, differential effects on mood can be demonstrated between
morphine and some of the newer nonsteroidal antiinflammatory drugs
in doses which are equianalgesic in terms of measures of pain
intensity (Wallenstein 1981a,b). In similar analgesic assays,
equianalgesic doses of morphine and heroin produced almost identical
changes in mood (Kaiko et al. 1981a,b).
Since the empirical clinical analgesic assay is meaningful only in
terms of comparison between a test drug and a reference standard,
differences between the test and standard drugs in cross-tolerance
to a prior opioid will influence the estimate of their relative
potency. That effect appears to be minimal in most studies of
postoperative and postpartum pain, and even in cancer pain when the
test and standard drugs are different from the prior medication, and
when prior opioid exposure has not been excessive in dose,
frequency, or duration. However, when assaying agonist/antagonist
analgesics this can be a problem because sensitivity to the
antagonist actions is directly proportional to the degree of
physical dependence, and this effect can override both the agonist
actions of the test drug and the diminished efficacy of the standard
drug as a consequence of cross-tolerance (Houde 1979).
Assessment of analgesic potency based on chronic administration of
opioids has been limited and tends to be confounded by a large
number of uncontrollable variables which can develop in the course
of the analgesic assay. Nevertheless, short-term repeated dose
comparisons of fixed doses of opioids have been carried out in a
noncrossover design. In these studies, the patients received the
test or standard drug for periods of up to two to three days, on
request (prn), for moderate or severe pain. Ordinal scale
measurements of pain intensity and pain relief were made on the
first, second, and third days of the study prior to and at 1/2, 1,
2, 3, 4, 5, 6, 7, 8 hours following study medication, or until pain
returned to premeditation level (Wang et al, 1981; Ouellette, 1982).
These studies provide comparisons of the analgesic effects of the
test and standard drugs on the first day with those of the second
and third days. Proximate plateau plasma concentrations of the
drugs will be reached at that time if their terminal elimination
half lives are sufficiently short, as they would be with morphine,
the usual standard in these studies. Graded doses of at least the
standard drug are recommended as an internal control - or measure of
the sensitivity of the study - since placebo controls without rescue
medications would be inappropriate in a double-blind, repeated dose
study of this design.
ii) Electroencephalographic (EEG) activity and
sleep
As mentioned in the General Methods Section, the EEG is used to
measure both the acute effects of drugs and long-term effects on the
sleep-awake cycle. Almost all studies to date have used visual
inspection techniques to characterize the EEG profile of opioid
administration. In general,
to nontolerant,
morphine or heroin acutely administered
nondependent subjects produces a number of changes
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in the EEG consisting of: slowed alpha frequency, appearance of
delta activity, and an increase in theta activity (for review, see
Martin and Kay 1977). Fink et al. (1968), Zaks et al. (1969), and
Volavka et al. (1970) demonstrated that heroin-induced changes in
the EEG were time dependent and could be divided into an early
response (first 4 minutes) and a later response (5-32 minutes). The
most prominent effect was that the alpha activity was increased
early in the response and subsequently decreased in the late
response. Additionally, these studies showed that these EEG effects
of heroin could be reversed or blocked by naloxone. Similar
techniques have been applied to assess the acute effects of
methadone (Isbell et al. 1947) and cyclazocine (Fink et al. 1969).
The use of power spectral analysis to quantify the effects of
opioids has been relatively limited. Volavka et al. (1974)
demonstrated that the above-mentioned changes in EEG activity were
related to other physiologic measures such as respiratory rate and
heart rate, and the behavioral measures of subject's mood. Power
spectral analysis has also been used to monitor the EEG changes in
heroin addicts during induction and maintenance on methadone
(Feinstein and Hanley 1975). The EEG effects of heroin were
characterized by a prominent, sharply peaked narrow band (9-10 Hz)
of activity. When the subjects were started on methadone, this
alpha peak was substantially attenuated and the predominant
frequency was shifted to 11-12 Hz. In one subject who continued to
use heroin (verified by urinalysis), these shifts did not occur.
Studies on the effects of acute opioid administration on sleep-awake
patterns have been limited to only a few laboratories where such
extensive amounts of data can be gathered. Kay et al. (1979)
compared the effects of acute morphine, heroin, and methadone in
nondependent opioid abusers using double-blind, cross-over design.
Subjects were given single i.m. doses of drug or placebo at weekly
intervals. Each experiment consisted of one adaptation night
followed by an injection night. All three compounds produced
similar changes (as revealed by computer-derived bisector analysis)
in the EEG and muscle activity. These included increased time
awake, increased muscle activity, increased alpha activity, and
decreased theta activity and decreased spindling. Using standard
bioassay techniques (Finney 1964), heroin was about twice as potent
as morphine, which was found to be equipotent with methadone. Other
physiologic measures such as ocular activity and respiration
correlated very well with the EEG sleep stages.
iii) Gastrointestinal motility
The opioids are the most effective antidiarrheal drugs currently
available. Procedures for assessing the passage of intestinal
contents through the G.I. tract have been developed and incorporate
one of three basic designs: 1) monitor the appearance of an orally
ingested dye in the feces (Rothman and Katz 1964); 2) monitor the
progress of a barium-treated meal through the G.I. tract using X-ray
technology (Manousos et al. 1967); and 3) intubation (Hunt and
Spurrell 1951) for sampling gastric contents. The effects of acute
doses of various opioids can then be assessed by the percent of
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retarded progress of a meal through the G.I. tract. A continual
slow passage of markers through the G.I. tract is indicative of a
lack of tolerance to the constipating effects of opioids. Tolerance
to the effects of opiates on gastrointestinal motility develops only
extremely slowly. In man, tolerance to the constipating effects of
methadone may become apparent after as long as three years of
continual use (Kreek 1973; 1978).
iv) Cough
Procedures for assessing the antitussive effects of opioids have
relied mainly on the use of subjects with pathological cough (e.g.,
obstructive emphysema or chronic bronchitis) rather than
experimentally induced cough (e.g., inhalation of noxious vapors).
The significant developments in this regard relate mainly to methods
utilized to record the incidence and severity of coughs. Sevelius
and Colmore (1966) developed a method that uses a contact throat
microphone coupled to a voice-activated tape recorder via a long
flexible cord. This provided the subject essentially 'unrestrained
movement within the private room. Subjects reside in the room for
at least 6 consecutive days; the first 2 days are used to record
control cough levels. At a specified time (usually in the morning)
subjects receive either codeine, placebo, or a dose of test
substance. Cough rates are then calculated on an hourly basis until
the next morning. The number of coughs after medication is
represented as a percent of the number of coughs after placebo.
One method of experimental induction of cough utilizes citric acid
aerosal spray (Bicker-man 1956). Normal subjects are used, and after
receiving placebo or an antitussive, are exposed to the spray. The
frequency of coughs is recorded and used as an index for the degree
of cough suppression.
2. Opioid Physical Dependence Potential
a. Tolerance to Drug Effects
The nature and characteristics of the development of tolerance to
the effects of opioids in man have been extensively studied. The
basic premise behind the techniques employed to study tolerance
relates to obtaining accurate measures of dose-related drug effect
in the non-tolerant or opioid-free subject first. Then, once the
treatment regimen has been established, controlled reassessments of
the effects of single doses of the same opioid or a test compound
(cross-tolerance evaluation) can begin. This is most effectively
accomplished when multiple doses are studied. Thus, a ratio of the
effective doses in the nontolerant and tolerant state can be
calculated and becomes the "tolerance index" for that compound
(Martin and Fraser 1961).
Numerous problems exist when attempting to quantify the degree of
tolerance to opioids. First, because of different durations of
action, the time between the last maintenance dose and the
administration of the test dose for tolerance assessment can be
critical. Predetermined objective criteria must be established in
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order to maintain uniformity between test sessions. Another problem
is that with repeated administration of opioids, the profile of
effects changes. For example, non-tolerant subjects report feeling
euphoric and sedate while tolerant individuals report apathy,
anhedonia, and withdrawal from social interactions (Haertzen and
Hooks 1969; Martin et al. 1973).
b. Withdrawal from Chronic Drug Administration- -
Procedures for assessing the dependence potential of opioids in man
have focused upon three main areas: substitution, single dose
suppression, and primary dependence. Typically, individuals with a
history of opioid use are employed since the procedures necessitate
a chronic steady state preparation.
In the substitution procedure, subjects are maintained on morphine
at a dose of 240 mg/day, s.c., given in divided doses. This
treatment is continued for 30 days,after which test procedures can
be initiated. Under double-blind conditions and beginning with the
evening dose (e.g., 10 p.m.), a dose of a test substance, placebo,
or the usual morphine dose is administered. This substitution is
continued for 24 hours during which the subject is observed at 1-
hour intervals. Signs and symptoms such as restlessness, emesis,
fever, hyperpnea, blood pressure, and body weight are scored
according to the Himmelsbach procedure (Jasinski 1977). The
intensity of withdrawal (should these test substances fail to
substitute for morphine) is scored on the basis of the signs present
and include: Mild - yawning, lacrimation, rhinorrhea, perspiration;
Moderate - muscle tremor, dilated pupils, goose flesh, anorexia;
Marked hyperpnea, restlessness, insomnia, elevated blood pressure;
Severe - emesis, diarrhea, weight loss. The original technique as
proposed by Himmelsbach (1937a) was adapted to incorporate a point
system based upon the composite signs of abstinence (Himmelsbach
1937b; Kolb and Himnelsbach 1938)) updated by Fraser and Isbell
(1960), and was reviewed by Jasinski (1977). By systematically
varying the dose of the test substance, the relative degree of its
dependence potential can be determined.
The single dose substitution procedure (Himmelsbach and Andrews
1943) was based on the premise that a compound that possesses
morphine-like activity should be able to suppress abstinence signs
in morphine-dependent subjects. This relatively quick method of
assessing a drug's dependence potential is conducted in subjects
that are stabilized on morphine as described above. At a specific
time, the morphine injections are terminated and the time course of
withdrawal is recorded. At 30 hours after the last morpine
injection, a dose of the test compound, placebo, or the normal
morphine dose is given and the evaluations continued. The relative
dependence potential of a compound is thus defined by its capacity
to ameliorate the signs and symptoms of withdrawal. Morphine
dependence is then reestablished for 1 week, at which time another
experiment is performed.
The conduct of primary dependence studies on opioids has not been
utilized as extensively as the substitution techniques. This is
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mainly due to the paucity of suitable volunteer subjects and the
concern over the toxicity of the test compounds during long-term
administration. While the chronic administration of a compound is
considered to be the definitive test of its dependence potential,
this procedure is rarely performed first and usually is only
incorporated after the results of substitution or single dose
suppression studies are known. The procedure employs the use of
doses of the test compound that are equivalent to (i.e., similar
analgesia, suppression scores, degree of miosis, etc.) 240 mg of
morphine (Jasinski 1977). Care must be exercised to avoid the
accidental accumulation of drug or metabolites that result in toxic
reactions. Typically, the length of exposure is 18-20 days followed
by 10 days of placebo administration. Alternatively, naloxone can
be administered in order to precipitate withdrawal (Jasinski and
Nutt 1972), althougti this procedure is not widely used. Regardless
of the method used, the appearance of signs and symptoms of
abstinence is graded and the relative degree of dependence is
determined.
3. Opioid Abuse Liability
a. Drug Self-Administration
Because of numerous medical and ethical considerations, unresricted
self-administration of opioids such as morphine or heroin is not
possible. However, procedures that employ limited access have been
developed and provide ample opportunity to study the reinforcing
properties of opioids in human volunteers residing in an inpatient
ward (Mello et al. 1981, 1982). In these studies, heroin was
available every 6 or 8 hours and was self-injected (under
supervision by a physician) at a unit dose of 10 mg, i.v. The
contingency placed upon the subjects was that they work for points
that could then be used to "buy" the heroin dose. This was
accomplished using standard operant procedures that employed a fixed
ratio 300/fixed interval 1 second schedule of reinforcement. As an
added incentive for the subjects to remain on the research ward,
points could also be earned for money which would be paid upon
completion of the study.
Once stable response patterns are established, various manipulations
of the experimental conditions can be employed. To date, no studies
have been conducted that substitute unknown compounds for the
heroin. Rather, studies have been directed at pharmacological
interventions which include observing the changes in heroin
self-administration during chronic naltrexone (Mello et al. 1981) or
buprenorphine (Mello et al. 1982). Both naltrexone and
buprenorphine significantly decreased the number of heroin
self-ingections as compared to placebo conditions. Thus, these
studies satisfy the three criteria defined previously: optional drug
injections, various experimental manipulations were performed, and
the availability for heroin self-injection was over a 30-35 day
period.
An alternative procedure employs subjects that are receiving
methadone as a maintenance therapy for opioid dependence (Stitzer et
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al. 1979, 1983; McLeod et al. 1983). In the studies by Stitzer et
al. (1979), participating subjects were maintained on an outpatient
basis but were required to attend the clinic each day for their dose
of methadone. On two days of the week, immediately after consuming
their regular dose of methadone, subjects were offered a choice
between an additional dose of methadone (0, 1, 5, 10, 25 or 50 mg)
and money (either $1 or $5). The selected item was given
immediately. In addition, subjects completed a 60-item symptom
check-list four times a week in order to assess signs of opioid
withdrawal. Urines were also analyzed for illicit drugs. These
studies demonstrate that methadone serves as reinforcer in
methadone-maintained subjects and that the relative frequency of
choosing methadone over money increased. as the dose of methadone was
increased. Further, the number of choices for methadone was greater
when the alternative was $1 when compared with $5. This procedure
provides an excellent model of human abuse liability testing and can
be expanded to include the assessment of other opioids, drugs
belonging to different classes, and different alternative choices.
McLeod et al. (1983) utilized methadone-maintained subjects that
resided on a research ward. Subjects regulated their own methadone
dose by completing a fixed number of responses on an operant console
during a 6-hour interval. Both constant and progressive ratio
procedures were used. Non-contingent pretreatment with methadone
reduced methadone self-administration. Subjects who required an
increasing number of responses (i.e., progressive ratio) for a 4 mg
unit dose of methadone, were more likely to detoxify than those
whose response requirements remained constant.
b. Self-Report of Drug Effects
The present instrument used to measure the subjective effects of
acutely administered opioids is the single dose opioid questionnaire
originally developed by Fraser et al. (1961). It consists of four
questions, the first of which simply determines whether the subject
feels the drug or not. Question two asks the subject to identify
the drug by comparing it with prototypic drugs of various classes.
The various physiological sensations are assessed in question three
while question four asks the subject to rate his degree of "liking"
of the drug. Concomitant with this assessment, observers blind to
the experiment rate the subject using similar questions.
The Morphine-Benzedrine Group Scale (or MBG) of the Addiction
Research Center Inventory (ARCI) is a multiple scale questionnaire
that has been used to identify compounds that produce opioid-like
effects (Jasinski et al. 1971). Morphine-like compounds. will
elevate the scores on the MBG scale in a dose-related fashion, so
that bioassay statistics (Finney 1964) can be used to determine
relative potencies between a standard (e.g., morphine) and a test
compound. With the development of opioids that possess mixed
agonist/antagonist effects, the other two questionnaires,
Pentobarbital, Chlorpromazine, Alcohol Group Scale (PCAG), and the
Lysergic Acid Diethylamide Scale (LSD) must be used in order to
characterize the full profile of behavioral effects of a test
compound (Jasinski 1977).
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Such studies are usually conducted within a crossover design in
which each subject receives two or three doses of the standard drug
(e.g., morphine), an appropriate blank or placebo, and two or three
doses of the test drug. All drugs are given under double-blind
conditions. Double-dummy procedures are employed if the test drug
is given orally and is to be compared to parenterally administered
morphine. This entails giving the subject both an injection and a
liquid (or pill) to consume for each assessment. Thus, on placebo
days, the subject will receive a saline injection and drink a glass
of the liquid vehicle (usually orange-flavored Tang or equivalent).
Drugs are administered in random order with a minimum of 7 days
between sessions. Questionnaires are completed a number of times
after drug administration. The responses are quantified using a
standard scoring system, and dose response curves are constructed
using the mean responses for the standard test drug.
c. Behavioral Toxicity
Procedures for assessing the toxic effects of opioids on behavior
have been limited in scope. The two main studies in the literature
employed subjects currently enrolled in a methadone maintenance
program and compared them with matched non-dependent controls
(Gordon 1970; Rothenberg et al. 1977). Gordon (1970) assessed
single and choice reaction times to a visual stimulus. Subjects
were seated in front of a console that contained 6 neon lights in a
row on a display screen and 6 corresponding buttons on a panel
parallel to the table top. Lights were programmed to remain lit
until a response was made. Three basic conditions were studied:
simple reaction time, multiple-discrimination-multiple-response, and
multiple-discrimination-single-response. Waiting periods (from
completion of response to next stimulus presentation) were varied
randomly. The single reaction time required that the subjects
simply depress the button that corresponded to the illuminated
light. The multiple discrimination-multiple-response condition
required that the subject depress the buttons in the identical
sequence that the lights were illuminated. The multiple-
discrimination-single-response condition required that the subject
simply select one of the buttons in the sequence of up to 6 stimuli.
Methadone-maintained subjects achieved the shortest reaction times;
this trend was consistent across the different experimental
conditions.
Rothenberg et al. (1977) also used a visual discrimination task
except that the environment was much more rigorously controlled than
in the previous study. Between 1 l/2 and 2 1/2 hours after their
morning dose of methadone, subjects were placed in the apparatus
(head restraint and chin support) in order to minimize head
movement-induced artifacts. Four different tests were administered
including letter recognition (3 different letters), continuous
performance (interval between test stimuli was 10 msec), reaction
time (the letter X was flashed on the screen and subject's time to
depress a microswitch was recorded), and reaction time with money
incentive (same conditions as previous test except that subjects
were paid for each response that was faster than a predetermined
value). Non-opioid-dependent subjects were similarly tested under
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non-drug conditions and after receiving various doses of methadone.
Methadone-maintained subjects consistently performed faster than
controls, and money incentive reduced reaction times equally for both
groups. Acute doses of methadone produced dose-related increases in
reaction time.
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C. Procedures for Assessing CNS Depressants: Sedative/
Hypnotics, Anesthetics, Anxiolytics and Antihistamines.
1. Characterization of CNS Depressant Effects
a. Acute Drug Effects
i) Anxiolytic and Sedation
Objective measures of anxiety in human subjects are relatively
difficult to obtain. Muscle tension (which can be effectively
measured) is not a direct correlate of anxiety. Thus, almost all
procedures for assessing the effectiveness of these compounds in
reducing anxiety have employed verbal self-reports of a subject's
behavior (McReynolds 1968). One study by Kelly et al. (1969) has
attempted to incorporate concomitant measures of the clinical,
psychological, and physiological components of anxiety and the
effects of chlordiazepoxide on such measures. Chlordiazepoxide was
found to produce improvements in self-ratings and those of clinical
observers on anxiety and depression assessments, to decrease the
dizzy factor score on the Clyde Mood Scale, and to decrease resting
forearm blood flow.
While it is not clear whether the anxiolytic effect of these
compounds is distinctly different from their non-specific effects,
several procedures have been utilized to selectively parcel out the
sedative/hypnotic effects of these compounds as reflected in studies
evaluating sleep (Kay et al. 1976).
ii) Electroencephalographic (EEG) Activity and
Sleep
While procedures for assessing the direct effects of sedative/
hypnotics on human EEG are available, they have not, as yet, been
systematically applied to characterize these compounds. Most
studies have concentrated on subjective ratings of the relative
amounts of various EEG waveforms such as alpha, delta, theta, and
beta activity. In this regard Malpas et al. (1970) compared the EEG
effects of nitrazepam with those of amylobarbitone sodium. Using a
double-blind cross-over design, subjects received either 5 or 10 mg
of nitrazepam, 100 or 200 mg of amylobarbitone, or placebo.
Criteria for scoring EEG activity were established as follows.
0 - Epochs containing 50% or more alpha activity
1 - Epochs containing less than 50% of alpha but
no paroxysmal features of sleep
2 - Epochs containing one paroxysmal feature of sleep
3 - Epochs containing delta activity more than 50% of the
time.
The values were then tabulated as a function of time and then total
scores calculated to determine the sleep-awake profile. These
investigators also used subjective mood ratings and measured
psychomotor performance. Approximately 18 hours after a single
dose, mood and psychomotor performance had returned to normal, but
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EEG changes were found to persist after the highest dose of
nitrazepam. These effects were indicative of a drowsy state.
Procedures for assessing the effects of these compounds on sleep
have been relatively well developed, refined, and validated in the
clinic. In these types of studies, drugs are assessed with respect
to three major criteria: the effectiveness of inducing and
maintaining sleep, development of tolerance to the hypnotic effects,
and effects upon individual sleep stages manifested by clinical
signs and symptoms. Thus, by employing quantified EEG procedures,
it is possible to replace verbal reports of how well a subject slept
with an objective measure of the sleep stages during the night.
Recently, Kay et al. (1976) reviewed the pharmacology of sleep.
Barbiturates, benzodiazepines, nonbarbiturates, and alcohol have all
been studied extensively using a variety of techniques for their
effects on sleep. Few studies, however, have attempted to provide
comparative information among several compounds. Hartmann (1968)
compared the effects of pentobarbital, chlordiazepoxide, Ro 5-6901,
and amitriptyline on sleep patterns in normal volunteers. All drugs
except amitriptyline increased total sleep. REM sleep was markedly
suppressed by amitriptyline and marginally suppressed by
pentobarbital while chlordiazepoxide and Ro 5-6901 did not affect
REM sleep.
2. CNS Depressant Physical Dependence Potential
a. Tolerance to Drug Effects
Procedures for determining the degree to which tolerance develops to
the effects of these compounds have not been extensively utilized.
Essentially, only the hypnotic effects of the barbiturates,
benzodiazepines, and miscellaneous compounds have been the subject
of tolerance assessment. These techniques are inherent in the
procedures described in the previous section on electro-
encephalographic activity and sleep.
Tolerance to the hypnotic effects of barbiturates occurs very
rapidly; in fact, blood levels upon awakening from a single dose are
higher than when the subject originally fell asleep (Harvey 1980).
The extent to which tolerance develops to the barbiturates depends,
in part, upon the duration of action and frequency of use. Wikler
(1976) demonstrated that the degree of tolerance to secobarbital or
pentobarbital could be minimized by enforcing a once-a-day treatment
with clinically acceptable hypnotic doses. When such controls over
the subjects' behavior is absent, they may experience less
satisfying sleep (due to the drug's effect on specific sleep stages)
and as a result, increase their dosage. This practice may be
responsible for the rapid development of tolerance.
Thus, while no systematic procedures are currently in use to compare
the degrees of tolerance to the sedative effects of these compounds,
a few points should be followed. First, the doses of the compounds
to be compared should be optimized to produce qualitatively and
quantitatively similar degrees of sedation. This may require using
the pharmacokinetic profile of each drug in preparing the treatment
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regimen. Secondly, the duration of treatment should be comparable
to ensure similar degrees of exposure. And thirdly, objective
measures of drug effect (e.g., latency to sleep and various sleep
stages, duration of sleep, number of awakenings, etc.) should be
obtained on a regular basis during control and drug phases.
b. Withdrawal from Chronic Drug Administration- -
Procedures for assessing the dependence potential of sedative/
hypnotics in man have evolved over the past 30 years. The early
studies of Isbell et al. (1950, 1955) demonstrated that chronic
administration of intoxicating doses of barbiturates or alcohol
produced a pronounced abstinence syndrome when treatment was
discontinued. In addition, the withdrawal syndrome was
significantly different from that observed following withdrawal from
opiates.
While rating scales for opiate or opioid withdrawal are relatively
well established (Himmelsbach 1941), there is no such uniformity of
procedures for the evaluation of sedative/hypnotic dependence. The
first signs to appear after barbiturate withdrawal include:
anxiety, nervousness, tremors, weakness, anorexia, nausea, vomiting,
and insomnia. Acute weight loss also accompanies these- signs.
Unlike opiate withdrawal, the signs and symptoms of barbiturate
withdrawal may increase in intensity to the extent that grand ma1
convulsions, hallucinations (both auditory and visual), and frank
delirium occur. Hyperpyrexia followed by death has been reported
(Fraser et al. 1953).
The first use of the EEG as a measure of barbiturate withdrawal was
reported by Fraser et al. (1954, 1958). Abrupt termination of a
dose of 0.2 g of pentobarbital per day for as long as six months was
followed by no significant effects. About one third of the subjects
that received 0.4 g for 3 months experienced paroxysmal EEG changes
(e.g., random spikes, fast waves, slow waves) in lieu of other
significant clinical signs of withdrawal. Minor signs of withdrawal
and about 50% abnormal EEG's were characteristic of abrupt
withdrawal from pentobarbital at a dose of 0.6 g for 1 to 2 months.
Seizures, delirium, and all minor abstinence signs were evident in
subjects upon withdrawal from high doses (0.9 to 2.2. g/day X
several months) of pentobarbital.
Benzodiazepines have, for the most part, replaced barbiturates as
the treatment of choice for sedation and hypnosis. Consequently,
procedures for assessing their dependence potential have been
reported. Hollister et al. (1961, 1963) demonstrated that the
termination of high doses of chlordiazepoxide or diazepam in
schizophrenics resulted in signs of withdrawal that resembled the
barbiturate withdrawal syndrome. Studies demonstrating the relative
dependence potential of various barbiturates have been reviewed by
Woods et al. (1983). The lack of uniformity of experimental
procedures between the various studies has made it impossible to
distinguish between the various benzodiazepines, if indeed such a
distinction exists.
125
3. CNS Depressant Abuse Liability
a. Drug Self-Administration
Procedures for measuring the self-administration of sedative/
hypnotics by human subjects have been validated by experimental
manipulation of the conditions surrounding drug availability
including such factors as amount of work required to obtain drug and
unit dose size (Bigelow et al. 1976a, 1976b; Pickens et al. 1977)
and choice between different sedatives (Bigelow et al. 1976b;
Griffiths et al. 1979, 1980).
One study by Johanson and Uhlenhuth (1978) used a paired preference
procedure to assess the relative reinforcing efficacy of diazepam as
compared to saline in normal subjects with no history of sedative
abuse. Subjects did not choose any dose of diazepam over saline but
did choose amphetamine over diazepam.
While some studies have assessed self-administration of these
compounds in a treatment facility where patients merely ask for
medication (Rothstein et al. 1976; Kryspin-Exner and Demal 1975),
more recent reports were obtained in research settings employing
more rigorous control over the drug delivery process. These studies
typically use token economies (Bigelow et al. 1976a) in which
subjects are required to perform work for a specific length of time
in order to earn a specific number of tokens. These tokens can then
be exchanged for drug. Surplus tokens are not carried over to the
next day, but rather are cashed in for money to be paid to the
subject upon discharge from the unit.
Most studies have been conducted with subjects that have current or
past histories of sedative abuse. Bigelow et al. (1976b) studied
the effects of varying the number of tokens required to purchase a
single 30 mg dose of pentobarbital or a 10 mg dose of diazepam.
Subjects were required to ride a stationary exercise bicycle for two
minutes for each token. The number of tokens required to purchase
the dose (drugs were available for 7hr/day) was randomly varied
among 1, 3, 5, 8, and 10. Subjects generally worked for and
subsequently consumed all doses of both drugs when the number of
tokens required for purchase was 1 or 3. As the number of tokens
for each dose was increased, however, the amount of drug earned
correspondingly decreased. The results of this study provide a
basic framework upon which to build a more complete program for
assessing sedative self-administration by humans. In subsequent
studies (Griffiths et al. 1979, 1980), it has been shown that
subjects will generally prefer pentobarbital to diazepam over a
fairly wide dose range.
b. Self-Report of Drug Effects
Subjective rating scales remain the primary means of assessing the
effects of psychoactive compounds on mood and feeling states (Fraser
and Jasinski 1977). The PCAG scale scores (Haertzen 1966) are
particularly sensitive to feelings of lethargy, weakness, and loss of
energy that characterize sedative/hypnotics. In order to obtain an
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overall profile of drug effect, however, liking scores and the MBG
scale scores are also calculated. Using this method, Fraser and
Jasinksi (1977) demonstrated that pentobarbital and secobarbital
produced dose-related increases in the above scale scores.
Phenobarbital, while producing some increases in scores, was only
one-fifth to one-seventh as potent as pentobarbital and
secobarbital, and did not appreciably elevate MBG scale scores.
In a subsequent study, Jasinski et al (1981) compared the effects of
various doses of pentobarbital with diazepam and chlordiazepoxide.
In a double-blind crossover design, both diazepam and
chlordiazepoxide were found to produce pentobarbital-like effects
and euphoria. Diazepam was about ten times more potent than
pentobarbital.
Two other procedures that have been used to characterize the mood
effects are based upon a Mood Adjective Check List (MACL) for
self-report of mood originally introduced by Nowlis and Nowlis
(1956), and Magnitude Estimation (ME) introduced by Ekman (1967).
Svensson et al. (1980) compared the efficiency of these two measures
in evaluating the mood effects of diazepam and caffeine. The result
of both scales indicated that diazepam decreased feelings of
activation and extroversion and increased calmness. While the ME
scale provided slightly better validity, it was harder for the
subjects to complete.
c. Behavioral Toxicity
Numerous procedures for assessing the toxic effects of sedative/
hypnotics on behavior have been developed, refined and validated.
McNair (1973) reviewed the results of 101 studies that assessed the
effects of antianxiety drugs on human performance. He grouped the
43 types of tests into four categories from high to low sensitivity.
Among the highest were digit-symbol substitution test (DSST),
driving accuracy, visual thresholds, and auditory flutter fusion.
Among the low sensitivity tests were problem solving, visual and
auditory vigilance, arithmetic, and learning nonsense syllables.
Studies that compare the psychomotor performance effects of various
benzodiazepines and barbiturates have been reviewed recently by
Johnson and Chernik (1982) with an emphasis on procedures designed
to assess the "day-after" or hangover effect. Card sorting, tapping
rate, symbol copying, and DSST were found to be among the most
sensitive tests for assessing behavioral impairment after
benzodiazepine administration. These effects were dose related, but
inconsistencies with respect to plasma half-lives and duration of
impairment were found (Johnson and Chernik 1982).
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D. Procedures for Assessing CNS Stimulants:Anorectics, Local
Anesthetics, and Antidepressants
1. Characterization of CNS Stimulant Effects
a. Acute Drug Effects
i) Electroencephalographic (EEG) Activity and
Sleep
The direct effects of CNS stimulants on EEG activity have been shown
to be alerting or activating as determined by the qualitative
techniques of visual inspection. The desynchronized pattern of EEG
activity, characterized by a slight decrease in amplitude and an
increase in predominant frequency, has been quantified by the use of
voltage integration procedures (Goldstein et al. 1963). Although
the use of power spectral analysis has not been employed extensively
to assess the EEG effects of this class of compounds, a report by
Gibbs and Maltby (1943) did describe a shift in the spectrum to
higher frequencies following benzedrine.
ii) Appetite
Procedures for assessing the effects of stimulants on appetite have
been developed for short-term, single dose experiments. Hoebel et
al. (1975) utilized a procedure that tests a drug's effectiveness in
reducing intake of a diet liquid meal product. Volunteers report to
the laboratory having refrained from eating for 2 hours prior to
lunchtime (12 noon). Using a double-blind cross-over design,
subjects were given either placebo or 25 mg of phenylpropanolamine
30 minutes before lunch. Lunch consisted of a canned chocolate-
flavored drink which was dispensed via a long straw from a graduated
cylinder. The reservoir was hidden from the subject's view.
Subjects were instructed to drink as much as they wished.. Upon
completion of lunch they filled out questionnaires that related to
the taste of the lunch, the reason for stopping, the amount that
they consumed relative to the previous day, and the taste of the
lunch relative to the previous day.
2. CNS Stimulant Physical Dependence Potential
a. Tolerance to Drug Effects
The assessment of tolerance to the effects of the CNS stimulants has
been directed mainly at two of their pharmacologic effects:
anorexia and mood elevation. Tolerance to the appetite-suppressant
effects has been demonstrated to occur in numerous studies. It
appears; however, that obesity has many complex components, at least
one of which, the 'craving" for food, may interact with the
evaluation of tolerance effects (Wooley and Wooley 1981).
The currently accepted criterion for the appetite suppressant effect
is that weight is lost and not recovered. The fact that the rate of
weight loss rapidly decreases over the course of treatment is taken
as evidence of tolerance. Stunkard (1979) has suggested that these
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criteria are not valid for assessing tolerance, since a deceleration
in weight loss is common even in more drastic treatments of obesity
such as jejunoileal bypass surgery. Additionally, the metabolic
characteristics of the body change as a result of weight loss, and
these changes should be taken into account when assessing tolerance.
Food that has been ingested during a period of weight loss is more
efficiently metabolized than when the caloric balance is in steady
state (Keesey et al. 1976). A more appropriate determinant of
whether tolerance has developed or not may be the degree of weight
gain following cessation of drug treatment. Tolerance would be
shown by a return to normal weight despite continued administration
of the drug. Rebound hyperphagia and weight gain, upon withdrawal
of the drug, would constitute a withdrawal reaction.
Tolerance to the mood elevating effects of CNS stimulants has been
assessed and, in addition,
effects (Gunne 1977).
is distinct, from the appetite-suppressant
Tolerance to the euphoric effects of
amphetamine (as measured by a subjective questionnaire) was found to
develop rather quickly over 14 days of daily treatment (Rosenberg et
al. 1963). In addition, these authors demonstrated that there was
no cross-tolerance to LSD. To date, no studies have been conducted
to directly compare the degree of tolerance development to the
subjective effects of CNS stimulants.
b. Withdrawal from Chronic Drug Administration
Only limited data are available on withdrawal from chronic CNS
stimulant use, since experimental studies have rarely been
undertaken, and virtually all reported observations have been made
within the context of treatment programs. In addition., the
difficulty in obtaining valid patient histories complicates
determination of the exact profile of the CNS stimulant withdrawal
syndrome. Amphetamine withdrawal has been characterized, however,
by assessing affective states, sleep patterns, and MHPG excretion
(Watson et al. 1972). Suprisingly. patients do riot seem to "crave"
for amphetamine during this abstinence phase as patients withdrawing
from opiates do for morphine.
3. CNS Stimulant Abuse Liability
a. Drug Self-Administration
Procedures for assessing self-administration of' i.v. cocaine have
been reported by Fischman and Schuster (1982) with experienced
cocaine users prepared with two indwelling Angiocath Teflon
catheters, one for drug infusion and one for blood withdrawal.
Subjects were instructed that each of two buttons would be
associated with the same solution (drug or saline) throughout the
study. On the first day, subjects were exposed to each solution and
for the next 8 days were required to press the response button 10
times in order to receive an injection. Once a single response was
made on a given button, the other one was deactivated. A total of
10 injections could be taken during a l-hour session with blood
drawn prior to and after each injection followed by completion of
the POMS and ARC1 questionnaires. After initial sampling on the
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first day, subjects consistently chose cocaine over saline.
Subjective ratings of drug effect correlated with the self-injection
of cocaine. The most pronounced effects on subjective states, blood
pressure, heart rate, and cocaine levels occurred after this initial
injection.
b. Self-Report of Drug Effects
Studies assessing the subjective effects of CNS stimulants have been
conducted using subjects with drug abuse histories (Martin et al.
1971; Jasinski et al. 1974; Fischman et al. 1976) and normal
volunteers with no history of drug abuse (Johanson and Uhlenhuth
1980). In the former studies, subjects lived on the ward during
their participation in the study. Martin et al. (1971) compared the
subjective effects of several sympathomimetic amines with
physiologic and behavioral effects. Amphetamine, methamphetamine,
ephedrine, phenmetrazine, and methylphenidate were given under
double-blind conditions using a Latin square design. Subjects
completed questionnaires every hour for 6 hours after drug
administration. These scales consisted of the PCAG, MBG, BG, and a
new amphetamine (A) scale which was constructed from significant
items in the other scales. All compounds produced dose-related
increases in MBG, BG. and A scale, as well as subject and observer
liking. PCAG scale scores were also decreased, while the highest
dose of all drugs increased LSD scale scores. These subjective
responses correlated well with physiologic effects and allowed for
valid estimates of relative potency measures.
Johanson and Uhlenhuth (1980) employed a procedure in which the
subjects reported to the laboratory in the morning 3 times a week
for each session. Subjects filled out a POMS form prior to each
amphetamine or placebo ingestion and then again at 1, 3, and 6 hours
post drug. The authors have used this procedure as a basis upon
which to build a choice procedure for different drugs. Subjects
associated certain colored capsules with drug effects, and during the
latter part of the experiment they were allowed to request the
capsule they preferred.
c. Behavioral Toxicity
Studies assessing the effects of CNS stimulants on psychomotor
performance have used a number of strategies to detect increases or
decreases in speed, error rate, and efficiency. In general, most
CNS stimulants have been shown to enhance performance.
Early studies such as that by Seashore and Ivy (1953) and Somerville
(1946) studied the effects of caffeine, amphetamine. and placebo on
perception and motor skills in fatigued army soldiers. Performance
was generally enhanced, but the differences observed between drug
and placebo condition were small, probably because they used trained
individuals that were already performing at peak levels. More
recently Evans et al. (1976) studied the effects of various doses of
dextroamphetamine on quantitative measures of psychomotor
performance. Non-fatigued volunteers refrained from using any drugs
for 18 hours prior to testing. Three measures of psychomotor
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performance were used: the wobble board (Shipley and Harley 1971),
the pursuit meter (Evans et al. 1973), and delayed auditory feedback
(Hughes et al. 1963). There was some improvement in stability on
the wobble board during the eyes closed condition as well as slight
improvements in performance on the pursuit meter (but only at the 7
cycles/sec mode and not at 5 or 2 cycles/sec) that were dose
related. No change in delayed auditory feedback performance was
observed, however.
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E. Procedures for Assessing Cannabinoids
1. Characterization of Cannabinoid Effects
a. Acute Drug Effects
i) Analgesia
Clinical data on analgesic activity have generally been derived from
studies assessing the effects of delta-9-THC or smoked marijuana on
pain which have not yielded clear results. It appears, however,
that delta-9-THC (5-20 mg) is effective in relieving the pain
associated with' advanced stages of cancer (Noyes et al. 1976).
While higher doses were effective in relieving pain, they were
accompanied by significant side effects, including sedation and
verbal impairment. In contrast, Hill et al. (1974) using
experimental electrical stimulation were unable to detect analgesic
activity after 12 mg of delta-9-THC.
While several of the newer synthetic cannabinoids are currently
undergoing clinical evaluations as analgesics, it is clear that the
most difficult problems associated with such assessments continue to
involve the need for parceling out confounding side effects such as
sedation and impaired verbal performances.
ii) Electroencephalographic (EEG) Activity and
Sleep
Studies designed to assess the EEG effects of acute administration
of cannabinoids have been conducted almost exclusively with
delta-9-THC or marijuana via the oral or inhalation (smoked) route.
Most of the past work was performed prior to the widespread use of
computerized, power spectral analysis. In general, orally
administered marijuana or THC has been reported to increase alpha
activity and EEG synchronization (Hollister et al. 1970;
Deliyannakis et al. 1970; Volavka et al. 1971, 1973; Tassinari et
al. 1974). More recently, however, a study by Koukkou and Lehmann
(19.76) utilizing spectral techniques to more accurately quantify the
EEG effects of 200 mg/kg delta-9-THC showed that the predominant
alpha frequency was decreased by THC. but the magnitude of change
was related to the resting state and EEG baseline of each subject.
The effects of cannabis on sleep have been assessed using all-night
EEG recordings in a laboratory setting (Barrett et al. 1974).
Slow-wave sleep increases during the first four nights after smoking
marijuana, though the amount of slow-wave sleep progressively
decreased beyond that point until it was below normal levels. The
suppression of slow-wave sleep persisted well into the post-drug
period. These effects seem to be dose related in that higher doses
actually overstimulate the subjects such that they sleep less.
Pivik et al. (1972) compared the effects of delta-9-THC and synhexl
on sleep patterns in normal subjects. Both compounds selectively
increased stage 4 sleep while rapid-eye-movement or REM sleep was
depressed. When a sleep deprivation procedure was employed,
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however, subjects recovered from these effects much more rapidly
when treated with synhexl than with delta-9-THC.
2. Cannabinoid Physical Dependence Potential
a. Tolerance to Drug Effects
Tolerance to the subjective and physiological effects of
cannabis as compared to synhexyl was demonstrated by Williams et al.
(1946). In this study measures were collected daily over a 39-day
period, including rectal temperature, pulse, respiratory rate, blood
pressure, body weight, caloric intake, EEG, sleep, and mood states.
Pulse, caloric intake, and expressions of euphoria were all
initially increased, but decreased after a few days of marijuana. A
similar profile was noted for synhexyl. More recently, Fink et al.
(1976) demonstrated tolerance to marijuana produced increases in
pulse rate and alpha activity of the EEG as well as to the
decremental effects of the drug upon short-term memory and reaction
time. After low dose chronic administration of delta-9-THC, it is
difficult to observe tolerance to subjective effects even though
tolerance to the drug-induced tachycardia and dizziness is readily
demonstrated (Hollister and Tinkleberg 1973). Such tolerance
effects are clearly dose related, however, since they are most
apparent after prolonged exposure to high doses.
b. Withdrawal from Chronic Drug Administration- -
Only limited data are available on procedures for assessing the
signs and symptoms attendant upon cessation of chronic cannabinoid
administration. Jones and Benowitz (1976), for example, gave
subjects an oral 30 mg dose of delta-9-THC every 4 hours for 10 to
20 days. Autonomic signs of withdrawal included increased sweating,
salivation, and tremors of the extremities. Milder signs included
irritability, sleep disturbances, and anorexia, while nausea,
vomiting, and diarrhea occurred in some subjects.
3. Cannabinoid Abuse Liability
a. Drug Self-Administration
Procedures for studying self-administration of cannabinoids have
been established using basic operant procedures that employ
marijuana cigarettes as the reinforcer (Mendelson et al. 1974,
1976). Subjects lived on a research ward during all three phases of
the study: 5-day baseline, El-day marijuana smoking, 5-day post-
marijuana. During their stay, subjects earned points by pressing a
button on a hand-held portable manipulandum. Subjects could then
"buy" a marijuana cigarette for 1800 points (the equivalent of 30
minutes of sustained button pressing) or save the points until the
end of the study and exchange them for money (about 8.50 per 30
minutes). Once a subject decided to buy a marijuana cigarette, the
points were immediately deducted from his running total and the
cigarette was smoked at that time under staff supervision. Both
"heavy" and "casual" users were studied. All subjects avidly worked
for more points than were necessary to buy the number of cigarettes
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they used, and as a result they earned a substantial amount of money
as well. The procedure thus serves as' a basis for evaluation of
other constituents of cannabis with respect to the maintenance of
operant performance.
b. Self-Report of Drug Effects
Using the standardized ARCI, Isbell et al. (1967) demonstrated that
subjects could not distinguish between marijuana and delta-9-THC.
Jones and Benowitz (1976) administered the Profile of Mood States
(POMS) questionnaire to subjects participating in a 30-day chronic
marijuana study. Tolerance to the subjective effects (e.g.,
confusion, inertia, and vigor) of 210 mg/day of delta-9-THC was
clearly evident within 3 days. In addition, using the Nurses'
Observation Scale for Inpatient Evaluation (NOSIE-3O), tolerance to
the decrease in social competence was also apparent by the 6th day.
Hollister and colleagues have systematically evaluated many of the
constituents of marijuana, THC metabolites, and synthetic analogues
of THC. In a summary of this work, Hollister (1974) showed that
delta-8-THC differed from delta-9-THC in a quantitative fashion.
Differences in relative potency were obtained with substitutions on
the alkyl side chain. The metabolites 11-hydroxy-delta-9- and
11-hydroxy-delta-8-THC were both more potent than their respective
parent compounds.
c. Behavioral Toxicity
Procedures for assessing the toxic consequences of cannabinoid
administration have been developed for measures of both- verbal
performances (e.g., "attention," "memory") and sensory-motor
functions (e.g., reaction time, stimulus discrimination). Dornbush
and Kokkevi (1976) assessed the acute effects of various doses of
delta-9-THC or hashish (compared to placebo) upon digit spans,
serial sevens, star tracing, and time estimation. The simple task
(e.g., digit span) was unaffected by cannabinoid administration
while performance on the more complicated tasks was impaired.
Numerous models of human memory assessment have been described
(Delong and Levy 1974; Darley and Tinklenberg 1974) in which
cannabinoids were shown to interfere with attention and decrease
memory efficiency. Vachon and Sulkowski (1976) attempted to dissect
the effects of marijuana on attention, memory, and psychomotor speed
by means of numerous automated testing devices including the
Continuous Performance Test (CPT) developed by Rosvold et al. (1956)
and modified by Mirsky and Kornetsky (1964), and the Automated Digit
Symbol Substitution Test (ADSST). A single dose of delta-9-THC (25
mg in a smoked cigarette) significantly decreased performance scores
as a function of an increase in complex response times and the
emmission of fewer responses.
Finally, the assessment of motor performance using an aviation
instrument flight simulator involved subjects (licensed pilots)
instructed to "fly" through each of four prespecified (and
practiced) holding patterns (Blaine et al. 1976). Using
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double-blind conditions, marijuana (0.09 mg delta-9-THC per kg) or
placebo cigarettes were smoked during a lo-minute interval. Thirty
minutes later the subjects began the simulations. There was a
significant increase in the number of both major and minor errors,
and an increased average deviation from the assigned flight
sequence. This decrement in performance persisted for at least 2
hours after smoking and returned to control levels by 6 hours post
drug.
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F. Procedures for Assessing Hallucinogens
1. Characterization of Hallucinogen Effects
a. Acute Drug Effects
i) Electroencephalographic (EEG) Activity
In general, LSD has been shown to increase the alpha frequency in
patients with sensory defects (Korein and Musacchio 1968) and normal
individuals (Shagass 1967). Reduction in the overall amplitude of
the EEG has also been reported after LSD and mescaline (Monroe et
al. 1957) and LSD-25 (Rodin and Luby 1966; Shagass 1967), while both
frequency and power shifts have been quantified using spectral
analysis after ditran and LSD administration (Itil and Fink 1966).
In a study using integrative techniques, Goldstein et al. (1963)
demonstrated that a 1 microgram/kg dose of LSD decreased
electrogenesis of the EEG of normal male volunteers, but not in
chronic schizophrenic patients. The successive waves of the EEG
were full-wave rectified and an oscillator was used to generate a
train of pulses the frequency of which was directly proportional to
the area under the rectified EEG. Thus, pulses per unit time were
used to quantify the amount of energy contained in the corresponding
epoch of EEG activity. Recordings from the occipital area were
analyzed because of alpha rhythm prominence. After 10 minutes of
control recording, the subjects were allowed to rest for 20 minutes.
This cycle was repeated to obtain five lo-minute sessions at 10, 30,
60, 90, and 120 minutes. Drug or placebo was administered orally
after the first control session.
Doses of LSD (0.001-0.002 mg/kg) were administered intravenously
over a period of 5 minutes. Twenty-to 60-second epochs of EEG
activity were sampled and subjected to computer analysis. Samples
were taken before injection and 15 to 25 and 40 to 50 minutes
post injection. LSD caused an increase in all frequencies, a
decrease of slow activity, and an increase in beta activity.
2. Hallucinogen Physical Dependence Potential
a. Tolerance to Drug Effects
Physiologic measures of pupil diameter, patellar reflexes, blood
pressure, heart rate, and body temperature are typically used for
assessing the development of tolerance to the hallucinogens.
Subjective effects are assessed using the 70 item LSD questionnaire
(Isbell et al. 1956) and a clinical ordinal scale sensitive to
expressions of anxiety at the low end, and perceptual distortions
as well as hallucinations at the high end.
have been found,
While some exceptions
chronic treatment with LSD leads to a rapidly
developing tolerance to these effects (Isbell et al. 1956).
Cross-tolerance in LSD-treated subjects to the acute effects of
N,N-dimethyltryptamine (DMT) has also been found to occur for the
above physiologic effects as well as subjective reports after drug
administration (Rosenberg et al. 1964).
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Wolbach et al. (1962) studied the effects of chronically
administered mescaline and found tolerance to both the subjective
effects and the mydriasis. In addition, marked cross-tolerance to
the effects of LSD on subjective response, pupillary diameter, and
blood pressure were found. The reverse situation was also observed
(i.e., subjects tolerant to the effects of LSD were cross-tolerant
to mescaline).
b. Withdrawal from Chronic Drug Administration- -
While the degree of tolerance that develops to the effects of these
compounds is quite extensive, no signs of abstinence have been
reported in subjects treated chronically with LSD.
3. Hallucinogen Abuse Liability
a. Drug Self-Administration
To date, no systematic studies have been undertaken to characterize
the profile of hallucinogen self-administration in man. There are
obvious difficulties in conducting such studies, which require
rigorous control of t h e subject's environment during
self-administration, including lighting conditions and visual and
auditory stimuli as well as social contacts.
b. Self-Report of Drug Effects
Procedures for assessing the subjective effects of the hallucinogens
have centered around the use of questionnaires that are completed at
regular intervals after drug administration. Using the MMPI,
Belleville (1956) found that LSD elevated the Psychasthenia,
Schizophrenia, Paranoia, and Taylor Anxiety scales. Klee et al.
(1961) found that the clinical grades of LSD reaction were dose
related. These were found to range from expressions of anxiety and
nervousness to perceptual distortion or hallucinations without
recognition of the drug-related nature of these effects.
The LSD Significant Scale of the ARCI (Hill et al. 1963a) contains
items that are related to expressions of euphoria and sedation,
anxiety, restlessness and dysphoria, disruption of thought
processes, paresthesia, perceptual changes, changes in self-image,
and autonomic changes. The specific questions that relate to the
above effects are outlined by Martin and Sloan (1977). Lower doses
of LSD were found to produce expressions of euphoria, while higher
doses were associated with nervousness and anxiety (Hill et al.
1963b).
Snyder et al. (1974) studied the stereospecific actions of DOET in
man using the Lon Outpatient Mood Scale, Outpatient Symptom Check
List, Hildreth Current Reaction Scales, and the Block Design and
Digit Span subtests of the Wechsler Adult Intelligence Scale.
Subjects were also evaluated using a modified clinical grade scale.
All drugs and placebo were administered under double-blind
conditions while the subjects resided in a quiet comfortable room.
A variety of art objects as well as records were available. The (-)
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or "R" isomer was found to be four times more potent than the (+) or
"S" isomer. This study represents a novel approach to confirming
the active chemical conformation of a hallucinogen at its receptor
site.
C. Behavioral Toxicity
Procedures for assessing the effects of hallucinogens on psychomotor
performance have mainly measured visual acuity and reaction time.
Edwards and Cohen (1961) studied the effects of LSD on visual
illusion, tactile sensibility, and reaction time in normal
volunteers. Subjects were tested for their ability to detect colors
while seated 10 feet from a translucent light filter (12.5 cm
diameter) surrounded by a black panel. By randomly presenting
different colors at various intensities using the Method of Constant
Stimuli, the threshold for detection of- each color could be
obtained. LSD had no effect on color detection, but size constancy
(assessed by maneuvering two triangles until they appeared to be the
same size) was affected, with the subjects becoming more susceptible
to illusions of similar sizes. LSD also significantly elevated the
difference threshold in a warmth detection discriminator procedure
and increased visually determined reaction times. When a buzzer was
used instead of light for reaction time determinations, no
significant drug effects were observed.
Hartman and Hollister (1963) compared three hallucinogens
(mescaline, LSD, psilocybin) for their effect on color perception
using the Farnsworth-Munsell hue discriminator which consists of 85
colored buttons arranged in four banks of graded hues. The buttons
are mixed thoroughly and the subjects are required to replace them
in the correct sequence of graded hue. After-images were also
determined by having the subjects look at a bright light for 5
seconds, close their eyes, and then name and pick out the colors that
they perceived. All three compounds impaired the subjects' ability
to distinguish the colors. LSD produced more disruptive effects in
the red-yellow and yellow-orange range, while mescaline increased
errors throughout a wider range. Psilocybin increased errors in all
areas except green-blue. LSD and mescaline caused more colors to be
evoked by flicker, but only psilocybin significantly increased the
duration of after-image. Thus, the results of this study indicate
that tests requiring subjective reports of color evoked artificially
are more sensitive to hallucinogens than tests of color perception
based upon hue discrimination procedures.
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6. Procedures for Assessing Dissociative Anesthetics-
1. Characterization of Dissociative Anesthetic Effects
a. Acute Drug Effects
i) Anesthesia
The characteristics of the various stages of anesthesia following
both inhalation and intravenous administration of dissociative
anesthetics have been defined by Gillespie (1943) and remain in use
today. Four stages are delineated in the progression from loss of
consciousness through delirium and surgical anesthesia, to medullary
depression and cardiovascular collapse. While early clinical
studies showed that phencyclidine (PCP) readily induced and
maintained anesthesia, the incidence of delirium, hallucinations,
and disruptive reactions discouraged further use in surgical
procedures (Johnstone et al. 1959; Luby et al. 1959; Domino 1968).
Some of these effects are also seen with ketamine, but the incidence
and severity are lower.
Stella et al. (1979) determined the relative potencies of ketamine
with respect to a number of other anesthetics using standardized
probit analysis. Drugs were administered via a large antecubital
vein 20 seconds after releasing a sphygmomanometer cuff. A 10 ml
volume was injected over a 15-second interval during which the
subjects were asked to count out loud. When they stopped counting and
did not respond to a request to open their eyes, they were considered
sleeping. Using a total of 450 subjects, dose-respose relationships
were obtained by considering the percentage of positive responses
(i.e., asleep) in groups of subjects given different doses of each
agent. In this manner, the UD30, UD50, and UD80 (unconscious dose
30%, 50%. and 80%, respectively) were determined. Ketamine was
found to be about 4.4 times more potent than thiopentone and about
equipotent with diazepam. The UD95 of each drug was calculated and
is considered to be the clinically relevant dose.
ii) Analgesia
Sadove et al. (1971) determined the analgesic effects of ketamine
both by an experimentally induced pain technique and by questioning
individuals during recovery from surgery. Painful stimuli were
produced using an earlobe algesimeter (Siker et al. 1966). While
the earlobe contains undifferentiated bare nerve endings, subjects
have easily distinguished between heat, cold prick, and touch
(Sinclair et al. 1952). The current delivered to the earlobe is
adjusted from 8 to 30 microamperes and after 3 determinations of
control responses (time to release button), separate measures of
pain threshold were obtained at 15-minute intervals after drug
injection. Ketamine was compared with meperidine and saline and was
found to increase the pain threshold to a level higher than
meperidine, but its duration was shorter (about 75 minutes vs. 120
minutes for ketamine and meperidine, respectively). In the clinical
double-blind study of post-operative pain, subjects were asked to
rate their pain on a 0 to 3 scale ("none," "mild," "moderate," and
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"severe"). Beginning with a pain scale score of 2, they were
re-evaluated at 5-and lO-minute intervals after receiving 0.44 mg/kg
of ketamine, i.m., or placebo. Ketamine significantly reduced the
pain scores, but the duration of this analgesic effect was limited
to 1 hour.
iii) Electroencephalographic (EEG) Activity
Procedures for assessing the EEG effects of dissociative anesthetics
in man using visual inspection techniques have shown that doses of
2-3 mg of PCP produce slowing of the EEG that is most pronounced in
the theta band. Higher doses produce more diffuse, slow activity
mostly in the occipital, temporal, and parietal areas (Greifenstein
et al. 1958). The EEG effects of ketamine have been shown to be
similar in nature to PCP (Schwartz et al. 1974) using conventional
EEG tracings and a single-channel cerebral function monitor (CFM)
(Sully and Scott 1972) which graphs the mean amplitude of the EEG
over a 2-50 Hz band on slowly moving paper. The CFM consistently
detected changes 1O-15 seconds before the direct EEG when injections
were given over both a 15-and 60-second interval. The differences
in onset of effect were less for the second ketamine injection (same
dose) given 10 minutes after the first.
Most recently, power spectral analysis has been used to quantify the
frequency and voltage components of the EEG after PCP intoxication
in one patient (Stockard et al. 1976). A prominent theta peak (5.75
Hz) persisted during the period when the patient was unconscious and
unresponsive to stimulation. Intravenous administration of diazepam
produced a shift to a lower predominant frequency accompanied by a
return of spontaneous movements, though normal alpha frequencies
(i.e., 8.5 Hz) were recovered only after 72 hours.
2. Dissociative Anesthetic Physical Dependence Potential
a. Tolerance to Drug Effects
Numerous case reports of tolerance to the anesthetic and analgesic
doses of ketamine, particularly in pediatric medicine, have appeared
stating the approximate percent increase in dose required to
maintain adequate anesthesia (Cronin et al. 1972; Stevens and Hain
1981). No attempts to control for duration between treatments in
these studies were reported, however, and no systematic quantitative
studies of tolerance are available.
b. Withdrawal from Chronic Drug Administration
While drug-seeking behavior has been noted to occur, no signs of
withdrawal were noted in individuals who reported smoking 100 mg or
more of PCP daily for several months (Burns and Lerner 1981). To
date, however, no quantitative methodology has been applied to
determine the nature and extent of the abstinence syndrome following
withdrawal from chronic administration of dissociative anesthetics.
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3. Dissociative Anesthetic Abuse Liability
a. Drug Self-Administration
There are currently no accepted procedures for assessing the ability
of PCP or its analogues to maintain self-injection performance in
humans.
b. Self-Report of Drug Effects
Numerous studies of PCP have described verbal reports of subjective
effects involving impairments of thought processes, changes in body
image and sensory perception, and depersonalization concomitant
with impaired attention and concentration (Burns and Lerner 1981).
Occasionally delusions and hallucinations have been reported, as
after-effects usually associated with the recovery following drug
withdrawal. No reports are available describing the use of
standardized psychological testing procedures (e.g., MMPI, ARCI).
c. Behavioral Toxicity
Morgenstern et al. (1962) administered a battery of seven tests to
normal volunteers in order to study the effects of PCP on sensory
processes. After swallowing a 7.5 mg tablet, the battery of tests
(which took 10-12 minutes to complete) was repeated every 15 minutes
for 2 hours. Phencyclidine produced a general impairment in sensory
function as evidenced by the elevated thresholds on all seven tests.
Two-point discrimination, aesthesiometry, and perimetry thresholds
showed the greatest increase, while taste was the least affected. In
addition, the PCP-induced sensory disturbances always occurred
before any verbal reports of subjective changes in feelings or mood.
PCP's effects on reaction time, rotary pursuit, and weight
discrimination have also been compared with LSD-25 and amobarbital
sodium in normal volunteers (Rosenbaum et al. 1959). PCP and
amobarbital were given i.v., while LSD was given orally. The tests
were administered imediately after PCP and amobarbital, and 3 hours
after LSD. A marked increase in reaction time was observed after
PCP with a lesser increase observed after amobarbital. LSD did not
affect reaction time. The ability to trace a rotating disc was also
impaired by PCP, though amobarbital had little or no effect, while
LSD actually improved performance on this task. PCP significantly
disrupted performance on the weight discrimination tasks as well,
though amobarbital and LSD had no such effect.
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Szara, M.D., D.Sc.. and Jacqueline P. Ludford, M.S., eds.
GPO Stock #017-024-01108-B $5 NTIS PB #B2-139106 $18.95
34 PROBLEMS OF DRUG DEPENDENCE, 1980: PROCEEDINGS OF THE 42ND
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis 5. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01061-B $8 NTIS PB #81-194847 $36.95
35 DEMOGRAPHIC TRENDS AND DRUG ABUSE, 1980-1995. Louise G.
Richards, Ph.D., ed. NCDAI out of stock
GPO out of stock NTIS PB #82-103417 $18.95
36 NEW APPROACHES TO TREATMENT OF CHRONIC PAIN: A REVIEW OF
MULTIDISCIPLINARY PAIN CLINICS AND PAIN CENTERS. Lorenz K.Y.
Ng. M.D.. ed.
GPO out of stock NTIS PB #81-240913 $24.95
37 BEHAVIORAL PHARMACOLOGY OF HUMAN DRUG DEPENDENCE. Travis
Thompson, Ph.D., and Chris E. Johanson, Ph.D., eds.
NCDAI out of stock
GPO Stock #017-024-01109-6 $7 NTIS PB #82-136961 $30.95
38 DRUG ABUSE AND THE AMERICAN ADOLESCENT. Dan J. Lettieri, Ph.D..
and Jacqueline P. Ludford, M.S., eds. A RAUS Review Report.
GPO Stock #017-024-01107-O $4.50 NCDAI out of stock
NTIS PB #82-148198 $18.95
39 YOUNG MEN AND DRUGS IN MANHATTAN: A CAUSAL ANALYSIS.
Richard R. Clayton, Ph.D., and Harwin L. Voss, Ph.D.
GPO Stock #017-024-01097-9 $5.50 NCDAI out of stock
NTIS PB #82-147372 $24.95
40 ADOLESCENT MARIJUANA ABUSERS AND THEIR FAMILIES. Herbert
Hendin. M.D., Ann Pollinger, Ph.D., Richard Ulman, Ph.D., and
Arthur Carr, Ph.D. NCDAI out of stock
GPO out of stock NTIS PB #82-133117 $18.95
41 PROBLEMS OF DRUG DEPENDENCE, 1981: PROCEEDINGS OF THE 43RD
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D.. ed. NCDAI out of stock
Not avallable from GPO NTIS PB #82-190760 $42.95
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42 THE ANALYSIS OF CANNABINOIDS IN BIOLOGICAL FLUIDS. Richard L.
Hawks, Ph.D., ed.
GPO Stock #017-024-01151-7 $5 NTIS PB #83-136044 $18.95
43 PROBLEMS OF DRUG DEPENDENCE, 1982: PROCEEDINGS OF THE 44TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris. Ph.D., ed. NCDAI out of stock
GPO out of stock NTIS PB #83-252-692lAS $42.95
44 MARIJUANA EFFECTS ON THE ENDOCRINE AND REPRODUCTIVE SYSTEMS.
Monique C. Braude, Ph.D., and Jacqueline P. Ludford. M.S., eds. A
RAUS Review Report. NCDAI out of stock
GPO Stock #017-024-01202-5 $4 NTIS PB #85-150563/AS $18.95
45 CONTEMPORARY RESEARCH IN PAIN AND ANALGESIA, 1983. Roger M.
Brown, Ph.D.; Theodore M. Pinkert. M.'D., J.D.; and Jacqueline P.
Ludford, M.S., eds. A RAUS Review Report. NCDAI out of stock
GPO Stock #017-024-01191-6 $2.75 NTIS PB #84-184670/AS $13.95
46 BEHAVIORAL INTERVENTION TECHNIQUES IN DRUG ABUSE TREATMENT. John
Grabowski, Ph.D.; Maxine L. Stitzer, Ph.D., and Jack E.
Henningfield. Ph.D., eds.
GPO Stock #017-024-01192-4 $4.25 NTIS PB #84-184688/AS $18.95
47 PREVENTING ADOLESCENT DRUG ABUSE: INTERVENTION STRATEGIES.
Thomas J. Glynn, Ph.D .; Carl G. Leukefeld, D.S.W.; and
Jacqueline P. Ludford, M.S., eds. A RAUS Review Report.
GPO Stock #017-024-01180-l $5.50 NTIS PB #85-159663/AS $24.95
48 MEASUREMENT IN THE ANALYSIS AND TREATMENT OF SMOKING BEHAVIOR.
John Grabowski, Ph.D., and Catherine S. Bell, M.S., eds.
GPO Stock #017-024-01181-9 $4.50 NCDAI out of stock
NTIS PB 84-145-184 $18.95
49 PROBLEMS OF DRUG DEPENDENCE, 1983: PROCEEDINGS OF THE 45TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01198-3 $12 NTIS PB 85-151553/AS $36.95
50 COCAINE: PHARMACOLOGY, EFFECTS, AND TREATMENT OF ABUSE. John
Grabowski, Ph.D., ed.
GPO Stock #017-024-01214-g $4.50 NTIS PB 85-150381/AS $18.95
51 DRUG ABUSE TREATMENT EVALUATION: STRATEGIES, PROGRESS, AND
PROSPECTS. Frank M. Tims, Ph.D., ed.
GPO Stock #017-024-01218-l $4.50 NTIS PB 85-150365/AS $18.95
52 TESTING DRUGS FOR PHYSICAL DEPENDENCE POTENTIAL AND ABUSE
LIABILITY. Joseph V. Brady, Ph.D., and Scott E. Lukas, Ph.D., eds.
GPO Stock #017-024-01204-l $4.25 NTIS PB 85-150373/AS $18.95
53 PHARMACOLOGICAL ADJUNCTS IN SMOKING CESSATION. John Grabowski,
Ph.D., and Sharon M. Hall, Ph.D., eds.
GPO Stock #017-024-01266-l $3.50 NCDAI out of stock
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54 MECHANISMS OF TOLERANCE AND DEPENDENCE. Charles Wm. Sharp,
Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01213-l $8.50
55 PROBLEMS OF DRUG DEPENDENCE, 1984. PROCEEDINGS OF THE 46TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01242-4 $9.50
56 ETIOLOGY OF DRUG ABUSE: IMPLICATIONS FOR PREVENTION. Coryl LaRue
Jones, Ph.D., and Robert J. Battjes. D.S.W., eds.
GPO Stock #017-024-01250-5 $6.50
57 SELF-REPORT METHODS OF ESTIMATING DRUG USE: MEETING CURRENT
CHALLENGES TO VALIDITY. Beatrice A. Rouse, Ph.D., Nicholas J.
Kozel, M.S., and Louise G. Richards, Ph.D., eds.
GPO Stock #017-024-01246-7 $4.25 NCDAI out of stock
58 PROGRESS IN THE DEVELOPMENT OF COST-EFFECTIVE TREATMENT FOR DRUG
ABUSERS. Rebecca S. Ashery, D.S.W.. ed.
GPO Stock #017-024-01247-5 $4.25 NCDAI out of stock
59 CURRENT RESEARCH ON THE CONSEQUENCES OF MATERNAL DRUG ABUSE.
Theodore M. Pinkert, M.D., J.D., ed.
GPO Stock #017-024-01249-l $2.50
60 PRENATAL DRUG EXPOSURE: KINETICS AND DYNAMICS. C. Nora Chiang,
Ph.D., and Charles C. Lee, Ph.D.. eds.
GPO Stock #017-024-01257-2 $3.50
61 COCAINE USE IN AMERICA: EPIDEMIOLOGIC AND CLINICAL PERSPECTIVES.
Nicholas J. Kozel, M.S., and Edgar H. Adams, M.S.. eds.
GPO Stock #017-024-01258-l $5
62 NEUROSCIENCE METHODS IN DRUG ABUSE RESEARCH. Roger M. Brown,
Ph.D., and David P. Friedman, Ph.D., eds.
GPO Stock #017-024-01260-2 $3.50
63 PREVENTION RESEARCH: DETERRING DRUG ABUSE AMONG CHILDREN AND
ADOLESCENTS. Catherine S. Bell, M.S., and Robert Battjes,
D.S.W., eds.
GPO Stock #017-024-01263-7 $5.50
64 PHENCYCLIDINE: AN UPDATE. Doris H. Clouet, Ph.D., ed.
GPO Stock #017-024-01281-5 $6.50
65 WOMEN AND DRUGS: A NEW ERA FOR RESEARCH. Barbara A. Ray, Ph.D.,
and Monique C. Braude, Ph.D., eds.
GPO Stock #017-024-01283-l $3.25
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66 GENETIC AND BIOLOGICAL MARKERS IN DRUG ABUSE AND ALCOHOLISM.
Monique C. Braude, Ph.D., and Helen M. Chao, Ph.D. eds.
GPO Stock #017-024-01291-2 $3.50 NCDAI out of stock
67 PROBLEMS OF DRUG DEPENDENCE, 1985. PROCEEDINGS OF THE 47TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01292-l $18
68 STRATEGIES FOR RESEARCH ON THE INTERACTIONS OF DRUGS OF ABUSE.
Monique C. Braude, Ph.D., and Harold M Ginzburg, M.D.,J.D.M.P.H.,
eds.
GPO Stock #017-024-01296-3 $6.50 NCDAI out of stock
69 OPIOID PEPTIDES: MEDICINAL CHEMISTRY. Rao S. Rapaka. Ph.D.;
Gene Barnett, Ph.D.; and Richard L. Hawks, Ph.D., eds.
GPO Stock #017-024-1297-l $11
70 OPIOID PEPTIDES: MOLECULAR PHARMACOLOGY, BIOSYNTHESIS, AND
ANALYSIS. Rao S. Rapaka, Ph.D., and Richard L. Hawks, Ph.D., eds.
GPO Stock #017-024-1298-0 $12
71 OPIATE RECEPTOR SUBTYPES AND BRAIN FUNCTION. Roger M. Brown,
Ph.D.; Doris H. Clouet. Ph.D.; and David P. Friedman, Ph.D., eds.
GPO Stock #017-024-01303-O $6
72 RELAPSE AND RECOVERY IN DRUG ABUSE. Frank M. Tims, Ph.D., and
Carl G. Leukefeld, D.S.W., eds.
GPO Stock #017-024-01302-l $6
73 URINE TESTING FOR DRUGS OF ABUSE. Richard L. Hawks, Ph.D., and
C. Nora Chiang, Ph.D., eds.
GPO Stock #017-024-1313-7 $3.75
74 NEUROBIOLOGY OF BEHAVIORAL CONTROL IN DRUG ABUSE. Stephen I.
Szara. M.D., D.Sc., ed.
GPO Stock #017-024-1314-5 $3.75
75 PROGRESS IN OPIOID RESEARCH. PROCEEDINGS OF THE 1986 INTER-
NATIONAL NARCOTICS RESEARCH CONFERENCE. John W. Holaday. Ph.D.;
Ping-Yee Law. Ph.D.; and Albert Herz, M.D., eds.
GPO Stock #017-024-01315-3 $21
76 PROBLEMS OF DRUG DEPENDENCE, 1986. PROCEEDINGS OF THE 48TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed.
GPO Stock #017-024-1316-l $16
IN PRESS
77 ADOLESCENT DRUG ABUSE: ANALYSES OF TREATMENT RESEARCH.
Elizabeth R. Rahdert, Ph.D. and John Grabowski, Ph.D., eds.
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